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Abstract 
Dipeptidyl peptidase 9 (DPP9) is an atypical post-proline serine protease of the DPP4 
enzyme family which has ubiquitous expression and DPP4-like enzymatic activity. It is 
localised intracellularly and has roles in antigen processing and epidermal growth 
factor signalling. It interacts with H-Ras and small ubiquitin-like modifier-1 and 
influences cellular interactions with extracellular matrix. Our lab made the first DDP9 
gene knock-in (gki) mouse with a DPP9 active site (S729A) mutation which results in a 
lack of DPP9 enzymatic activity. This thesis investigated the biological properties of 
DPP9 using this genetically modified mouse model. 
 
Mice lacking DPP9 proteolytic activity die in the early neonatal stage. This study 
validated that the DPP9 protein, while present in the gki mouse, is enzyme-inactive 
and the DPP9-S729A protein and wild-type DPP9 have similar subcellular localisation.  
A range of investigations were undertaken to determine if obvious histological and/or 
physiological differences exist between early neonate DPP9S729A/S729A homozygotes 
from their heterozygous and wild-type littermates and involved analysis of organ 
morphology, histology and function and investigation of autophagy. The novel findings 
of this study show that DPP9 enzymatic activity is essential for early neonatal survival 
in mice and suggest that there is dysregulated autophagy in the DPP9-enzyme-activity-
deficient neonatal mice that may contribute to the lethal phenotype. 
 
Other members of the DPP4 protein family are implicated in wound healing with 
xxvi 
 
fibroblast activation protein expressed in the granulation tissue of healing wounds and 
DPP4-positive T cells involved in regulation of granulation tissue formation. As there is 
a heterozygous effect on survival to weaning and DPP9 immunoreactivity was shown in 
the skin of both WT and DPP9S729A/S729A neonates, the skin of adult mice was studied 
using a model of cutaneous wound healing. This involved analysis of wound closure 
rates, tensile strength and collagen levels of both wounded and steady state tissue in 
adult DPP9wt/S729A mice and their wild-type littermates. It was found that adult 
heterozygous DPP9-GKI mice display reduced skin collagen levels compared to their 
WT littermates, but that the rate of skin wound healing appeared unaffected. 
 
DPP9 has in vivo expression in normal immunological tissues and major lymphocyte 
populations that alters with chronic liver injury, suggesting a role in immune function. 
To investigate the importance of DPP9 in immune regeneration and function, primary 
and secondary mixed chimeric mice were created using DPP9S729A/S729A and WT fetal 
liver cells and adult bone marrow, respectively, injected into irradiated recipients. The 
process of regeneration of the immune system in these mice was assessed at several 
time-points and the immune cells present in the regenerated immune systems were 
compared between DPP9S729A/S729A -origin and WT-origin chimeras. These chimeric 
mice were then subjected to an immune challenge by influenza virus infection. The 
novel findings of this study suggest that DPP9-enzyme-activity-deficient secondary 
chimeric mice may have an enhanced ability to recover from an immune challenge 
with influenza virus. Therefore, DPP9 appears to influence immune function in that 
viral infection. 
xxvii 
 
 
Together, these studies underline the biological significance of DPP9 in vivo in both 
neonatal and adult mice. These data contribute to the expanding knowledge of the 
role of DPP9, building upon recent discoveries in vitro of its involvement in multiple 
biological processes. By providing physiologically relevant results, this study has 
enhanced the knowledge of DPP9 enzyme function and the overall biological roles of 
DPP9. 
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1 Introduction 
 
1.1 The Dipeptidyl Peptidase 4 (DPP4) Family 
 
Proteases are important regulatory and modifying molecules which are responsible for 
the dynamic upkeep of many cellular physiological processes. The DPP4 family of 
enzymes are serine proteases of the S9b protease subfamily which are ubiquitously 
expressed and contain a conserved catalytic triad of serine, aspartate and histidine 
(Gorrell and Yu, 2005). They possess a rare ability to cleave a post-proline peptide 
bond near the N-terminus of a protein (Abbott et al., 2000a, Ajami et al., 2004, Qi et 
al., 2003).  The presence of a proline near the N-terminus of a peptide (Figure 1.1) 
confers resistance against protease degradation and occurs in many different 
biologically active peptides, including chemokines, incretins and neuropeptides. Thus,  
Figure 1.1: Cleavage of a post-proline bond.  
A tri-peptide containing a proline at position two creating a bend in the peptide chain. 
Dipeptidyl peptidase cleavage occurs C-terminal to the proline residue. 
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the specialised ability of dipeptidyl peptidases to cleave these bonds is useful for 
processing and degradation of such peptides (Cunningham and O'Connor, 1997). 
The DPP4 protein family consists of six members: four enzymatic members and two 
non-enzymatic members. DPP4, DPP8, DPP9 and fibroblast activation protein (FAP) 
have dipeptidyl peptidase activity while FAP is also an endopeptidase. The two non-
enzymatic members are dipeptidyl peptidase like protein (DPL)-1 and DPL-2. (Figure 
1.2)  
 
 
Figure 1.2.: Cellular localisation of the six members of the DPP4 family. DPP4 and FAP are 
membrane-bound cell surface proteases and also exist in soluble forms both inside and 
outside the cell. DPP8 and DPP9 are intracellular proteases. DPL1- and DPL-2 are membrane-
bound, non-enzymatic proteins. Adapted from (Kirby et al., 2010) 
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1.1.1 DPP4 
 
DPP4 is the prototypical and most well characterised member of the family. It displays 
enzymatic activity in both the dimeric cell-surface membrane-bound form and in the 
soluble circulating form (Gorrell, 2005). In the bound form, DPP4 is expressed by 
epithelial cells in the liver, gut, uterus and kidney; by capillary endothelium of all 
organs examined; by acinar cells of mucous, salivary glands and pancreas and by 
immune organs (Gorrell et al., 2001). The soluble form is present in serum, seminal 
fluid, saliva, kidney, liver and bile (Keane et al., 2012, Keane et al., 2014).  
Functionally, DPP4 is involved in numerous processes throughout the body, including 
immunological, endocrine, haematological and metabolic (Yu et al., 2010). These 
include the ability to participate in chemokine inactivation and also to have a role in 
apoptosis, lymphocyte activation and cell migration, along with the capacity to cleave a 
wide range of small bioactive proteins (Keane et al., 2012, Waumans Y et al., 2015). 
Most noted of these is the ability of DPP4 to rapidly inactivate the incretins glucagon-
like peptide-1 (GLP-1) and glucose insulinotropic peptide (GIP) (Mentlein et al., 1993) 
leading to the inhibition of DPP4 as a successful type 2 diabetes therapy. DPP4 
inhibitors are now implicated in a wide range of physiological and metabolic benefits 
and potential benefits including improved cardiac health, improved glucose uptake, 
improved energy metabolism and less fat accumulation (Keane et al., 2012). DPP4 is 
also known as CD26 and, as such, has roles in the immune system in T cell activation 
and proliferation and T helper 1 responses to foreign antigens. Cell surface expression 
on T cells greatly increases following stimulation with antigen or mitogens (Gorrell et 
al., 1991, Gorrell et al., 2001, Chowdhury et al., 2013). 
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1.1.2 FAP  
 
FAP, which is also known as seprase, also displays enzymatic activity as a 
transmembrane protein or a soluble protease. Although DPP4 and FAP share 52% 
amino acid sequence identity, these proteins differ in their enzyme activities and 
expression profiles. FAP possesses both dipeptidyl peptidase and endopeptidase 
activites, which enables it to cleave a prolyl bond two or more amino acids from the N-
terminus of a protein (Figure 1.3) (Aertgeerts et al., 2005).  
 
 
Figure 1.3: Enzyme activity of FAP  
A Dipeptidyl peptidase activity involves the cleavage of two amino acids off the N-
terminus of a protein following a proline residue.  
B Endopeptidase activity involves the cleavage of a post-proline bond that is more 
than two amino acids from the N-terminus of a protein. 
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While DPP4 is abundant in most tissues, FAP is at very low levels (Keane et al., 2014) 
with high level expression being limited to sites of tissue remodelling and areas of 
stromal activation, such as in wound healing, tissue damage and inflammation (Garin-
Chesa et al., 1990), during mouse embryogenesis (Niedermeyer et al., 2001) and in 
activated hepatic stellate cells in cirrhotic liver (Levy et al., 1997, Wang et al., 2005). 
FAP has, however, also been isolated in a truncated form from human plasma (Lee et 
al., 2006b) and bovine serum (Collins et al., 2004). FAP activity levels in normal and 
diseased tissue from humans, mice and baboons, has been extensively analysed by our 
group using the novel FAP-specific substrate, 3144-AMC. In mice, uterus, pancreas, 
submaxillary gland and skin showed the highest levels of FAP activity (Keane et al., 
2014). 
While FAP has been shown to cleave some DPP4 substrates in vitro (Keane et al., 
2011), until recently there were no known physiological substrates of FAP’s dipeptidyl 
peptidase activity. This lab carried out the first study to characterize the physiological 
DPP substrate repertoire of endogenous FAP in mammalian plasma, thereby revealing 
a potential function of FAP in neuropeptide signaling within liver and cancer biology 
(Wong et al., 2016). In addition to its dipeptidyl peptidase activity, FAP also has 
endopeptidase activity cleaving known substrates α2-antiplasmin (Lee et al., 2006b) 
and denatured type I collagen (Park et al., 1999). The gelatinase activity of FAP most 
likely contributes to extracellular matrix degradation.  
Because of its pattern of expression on activated stromal fibroblasts in many cancers, 
FAP has been studied as a therapeutic target in tumours. This role in cancer biology 
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has been reviewed previously (Sulda et al., 2010, Hamson et al., 2014). Strategies for 
targeting FAP for cancer therapy include the use of inhibitors, antibodies, prodrugs and 
T-cell immunotherapy however, as the role of FAP seems to be highly contextual, the 
expression pattern of FAP requires greater definition to better predict the effects of 
targeting this protease. 
 
1.1.3 DPL-1 and DPL-2  
 
DPL-1 (DPP6) and DPL-2 (DPP10) have 53% amino acid similarity with each other and 
are highly homologous to DPP4 with sequence identities of 33% and 32% respectively 
(Qi et al., 2003, Chen et al., 2005). While they both have dimeric forms, they lack the 
catalytic serine and a nearby tryptophan that are essential for enzymatic activity. DPL-1 
has a wide tissue distribution but DPL-2, in contrast, has expression limited to human 
brain, adrenal gland and pancreas (Abbott and Gorrell, 2002, Qi et al., 2003, Chen et 
al., 2005). The functional effects of these proteins appear to be through binding 
interactions and there is evidence of an association between DPL-1 and DPL-2 and 
neuronal diseases (Chen et al., 2008) and asthma (Cronin et al., 2008) with DPL-2 being 
indicated in a possible role in excitability of neurons in the lung airway (Ren et al., 
2005). 
 
1.1.4 DPP8 and DPP9 
 
DPP8 and its closest relative DPP9 are the most recently discovered members of the 
DPP4 gene family (Abbott et al., 2000b, Olsen and Wagtmann, 2002, Qi et al., 2003, 
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Ajami et al., 2004). As DPP4, DPP8 and DPP9 all have DPP4-like enzymatic activity and 
ubiquitous expression, the discovery of DPP8 and DPP9 has called for the 
reinterpretation of previous DPP4 data (Abbott et al., 2000b, Ajami et al., 2004). This 
was necessary to determine which functions had been attributed to DPP4 which may 
instead be accounted for by DPP8 and DPP9.  
Unlike DPP4, DPP8 and DPP9 are intracellular proteins and are therefore likely to have 
different biological roles. As there are currently no substrates or inhibitors that 
distinguish DPP8 from DPP9, their characteristics are usually outlined together. DPP8 
and DPP9 are currently under study in many fields including cell biology, immune-
biology and tumour biology (Zhang et al., 2013). 
 
1.1.4.1 Structure of DPP8 and DPP9 
 
DPP8 and DPP9 are located on human chromosome 15q22 and 19p13.3 (Abbott et al., 
2000b, Olsen and Wagtmann, 2002) and mouse chromosome 9 and 17 respectively. In 
DPP4 and FAP, the sequence adjacent to the active-site serine is encoded by two exons 
while the homologous region in DPP8 and DPP9 is encoded by a single exon which 
suggests that the DPP8 and DPP9 genes arose at an earlier evolutionary stage.  
Although located on different chromosomes the resultant proteins have a closely 
related sequence, sharing 58% overall identity to each other and 72% in the catalytic 
region (Ajami et al., 2004) suggesting that they may have arisen by gene duplication 
(Olsen and Wagtmann, 2002). There is a high homology between the amino acid 
sequences of human and mouse DPP8 and DPP9, with 95% and 92% identity 
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respectively (Olsen and Wagtmann, 2002, Ajami et al., 2004). Currently, no crystal 
structures of DPP8 or DPP9 exist but homology models have been built using the 
known structures of DPP4, DPL-1 and FAP (Park et al., 2008, Rummey and Metz, 2007). 
In these models, DPP8/9 is depicted with an α/β-hydrolase domain containing a Ser-
Asp-His catalytic triad and an 8-blade β-propeller domain containing two glutamic 
Figure 1.4: A putative model of DPP9 protein structure.  
DPP9 residues 51 to 863 are depicted in ribbon representation of the monomer. The α/β-
hydrolase domain is in red and the 8-blade β-propeller domain in green. The catalytic triad 
(Ser-Asp-His) is shown as blue spheres in the hydrolase domain and the 2 glutamates 
essential for catalysis as yellow spheres in the propeller domain. An extended arm 
(285VEVIHVPSPALEERKTDSYR304) in the propeller surface of DPP9 that is critical in SUMO1–
DPP9 interaction is colored pink.  Modified from (Zhang et al., 2013) 
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acids essential to functionality of the catalytic pocket (Figure 1.4).  
While structurally similar to DPP4 and FAP, DPP8 and DPP9 lack a transmembrane 
domain and are translated as intracellular proteins (Abbott et al., 2000b, Ajami et al., 
2004). Another structural difference between DPP4 and DPP8 and 9 is that selective 
point mutations in the C-terminal loop of both proteases can result in their inactivation 
but the integrity of their dimeric structure is maintained (Tang et al., 2009). This 
confirms the importance of the C-terminal loop for DPP8 and DPP9 enzymatic function. 
Finally, since DPP8 has been shown to have a larger substrate pocket than DPP4 
(Pitman et al., 2010), there is some suggestion that DPP8 and DPP9 might have a larger 
β-propeller domain and/or contain a separate element of tertiary structure at the N-
terminus of the protein. 
 
1.1.4.2 Expression profiles and tissue distribution of DPP8 and DPP9 
 
DPP8 and DPP9 are cytoplasmic enzymes that are ubiquitously expressed in tissues at 
both the mRNA (Olsen and Wagtmann, 2002, Bjelke et al., 2006, Qi et al., 2003) and 
protein levels (Yu et al., 2009) and both DPP8 and DPP9 occur in different isoforms.  
Human DPP8 has several mRNA transcripts identified, one is abundant in testis, 
prostate and muscle (Abbott et al., 2000b, Qi et al., 2003) while another longer 
transcript variant has intense signals in adult testis (Zhu et al., 2005). Bioinformatics 
analysis of NCBI database sequences has identified at least two other isoforms (Abbott 
and Gorrell, 2013). 
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DPP9 cDNA was cloned in two forms with the short form encoding 863 amino acids 
(Olsen and Wagtmann, 2002, Ajami et al., 2004) and the longer full-length form 
encoding 971 amino acids (Ajami et al., 2004). The short form is ubiquitously expressed 
including high levels in liver, heart and skeletal muscle, while the long form is much 
less abundant and is predominantly expressed in skeletal muscle. It has been recently 
shown that the N-terminal extension of the long form of DPP9 contains a nuclear 
localisation signal (NLS) allowing it to preferentially localise to the nucleus (Justa-
Schuch et al., 2014).  
In canine and porcine small intestine, lung, kidney and pancreas, differential relative 
abundance of DPP8 and DPP9 has been measured by RT-PCR analysis with DPP9 having 
the greater expression (Wagner et al., 2006b). In adult mice, greater numbers of DPP9 
transcripts are in brain, skin, colon and thymus compared with DPP4 (Helmuth et al., 
2006, Ansorge et al., 2009, Wagner et al., 2006a).  
DPP8 mRNA is in human testes and upregulated in adult testis compared to fetal testis 
(Zhu et al., 2005). DPP8 and DPP9 is also present in the male reproductive tissue of 
different mammals with bovine and rat testis showing DPP8/9 localised in 
spermatozoids embedded in the epithelium of the seminiferous tubules (Dubois et al., 
2009). DPP9 has been purified from bovine testes and identified and characterised as 
the short form isoform (Dubois et al., 2010). Taken together, these studies suggest a 
role for DPP8 and DPP9 in spermatogenesis and male fertility.  
Using in situ hybridisation, immunohistochemistry and enzyme assays on baboon and 
human tissues, the ubiquitous expression and distribution of DPP8 and DPP9 has been 
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validated in lymphocytes and epithelial cells in the brain, muscle, gastrointestinal tract, 
liver, lung, spleen, lymph node and skin, as well as in pancreatic acinar cells, adrenal 
gland, spermatogonia and spermatids of testis and Purkinje cells and the granular layer 
of the cerebellum (Yu et al., 2009). These findings are in agreement with related 
studies (Stremenova et al., 2007, Schade et al., 2008, Dubois et al., 2009).  
More recently, data on mRNA and protein levels in Sprague-Dawley rat and 
cynomolgus monkey showed similar ubiquitous expression and tissue distribution 
correlation with specific enzymatic activity in those species (Harstad et al., 2013). DPP8 
and DPP9 have been shown to be in rat primary endothelial cells of aortic, endocardial 
and cardiac microvascular origin (Matheeussen et al., 2011) with a greater abundance 
of DPP8 protein over DPP9. However, in human carotid artery endothelial cells, DPP9 is 
the only DPP4-like enzyme detected using immunohistochemistry suggesting a 
regulated expression of DPPs in endothelial cells.  
Both DPP8 and DPP9 expression has been shown to be present in tumour tissues 
(Ajami et al., 2004, Yu et al., 2009), hepatocytes (Yu et al., 2009, Yao et al., 2011, 
Chowdhury et al., 2013) and lymphocytes (Maes et al., 2007, Yu et al., 2009, 
Chowdhury et al., 2013) but absent from activated stellate cells (Yu et al., 2009). 
Recent reviews provide more detailed information regarding the expression and 
distribution of DPP8 and/or DPP9 (Yu et al., 2010, Wilson and Abbott, 2012b, Zhang et 
al., 2013, Waumans Y et al., 2015). 
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1.1.4.3 Enzymatic activity and substrate specificity of DPP8 and DPP9 
Although originally identified as monomers, both DPP8 and DPP9 are now known to be 
catalytically active as dimers in their dominant conformation (Bjelke et al., 2006, Lee et 
al., 2006a, Tang et al., 2009). Both DPP8 and DPP9 have optimum activity at neutral to 
basic pH of 7.0 – 8.5 (Abbott et al., 2000b, Qi et al., 2003, Tang et al., 2009) which is 
consistent with cytoplasmic localisation. DPP8 and DPP9 have reversible variation in 
Figure 1.5: DPP8/DPP9 enzyme activity in mouse organs.  
The approximate intensity of DPP8 and DPP9 enzyme activity was measured by Yu and 
colleagues (Yu et al., 2009) from mouse organs in DPP4-gene knockout mice with/without 
the addition of N-ethylmaleimide (NEM), which modifies thiols and inhibits DPP8/9. NEM-
inhibited activity was subtracted from total DPP activity to estimate the activity derived from 
DPP8 and DPP9. From (Zhang et al., 2013) 
 
                                                                                                                  Chapter 1: Introduction 
15 
 
enzymatic activity dependent on the redox state of their cysteine moieties with activity 
decreased by oxidation and increased by reduction (Park et al., 2008, Geiss-Friedlander 
et al., 2009). DPP9 is also allosterically activated by SUMO1 (Pilla et al., 2012), however 
the small peptide region of SUMO1 which interacts with DPP9 was also shown to act as 
a non-competitive inhibitor of DPP9 activity with inhibition dependent on the residues 
in the DPP9 arm motif (Figure 1.4) (Pilla et al., 2013).  
Both enzymes have similar substrate specificity, preferring a proline in the penultimate 
P1 position and small or basic amino acid residues at the P2 position of synthetic 
substrates (Lee et al., 2006a, Geiss-Friedlander et al., 2009, Tang et al., 2009). This was 
confirmed by an in vivo substrate study which showed DPP8 and DPP9 favoured 
natural substrates with a P1 proline preceeded by an alanine in the P2 position (Wilson 
et al., 2013). Ala-Pro- and Gly-Pro-containing fluorogenic and chromogenic substrates 
have been routinely used to determine DPP8/9 enzymatic activity derived from DPP8 
and DPP9 (Figure 1.5), but Arg-Pro is also hydrolysed (Ajami et al., 2004, Yu et al., 
2009). 
DPP8 and/or DPP9 are able to cleave a number of naturally occurring peptides and 
chemokines in vitro but with reduced rates of hydrolysis compared to DPP4 (Ajami et 
al., 2008). Whether these predominantly extracellular substrates have physiological 
relevance, however, when considering the intracellular location of DPP8 and DPP9, is 
unclear. It has previously been shown that neuropeptide Y (NPY) can be cleaved by 
DPP4, DPP8, DPP9 and FAP (Mentlein, 1999, Bjelke et al., 2006, Frerker et al., 2007, 
Keane et al., 2011). NPY extracted from rat brain can be cleaved in the presence of a 
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DPP4 inhibitor, suggesting that DPP8 and DPP9 can cleave NPY in vivo (Frerker et al., 
2007). A later study of dipeptidyl peptidases in tumour cells showed that NPY could act 
as a substrate for DPP8 and DPP9 in intact cells, not just cell extracts. Cleavage of 
releasable NPY by DPP4, DPP8 and DPP9, but not FAP, regulates Ewing Sarcoma family 
tumour cells (ESFT) by reducing NPY-induced cell death (Lu et al., 2011). 
A role of DPP9 in antigen presentation and peptide turnover was shown by the 
identification of the antigenic peptide RU134-42 as its first natural substrate. This 
peptide is degraded in vitro by both DPP8 and DPP9, however, silencing of DPP8 and 
DPP9 using siRNA resulted in increased RU1 presentation only in DPP9-silenced cells, 
which indicated that the RU134-42 antigen is a substrate of DPP9 (Geiss-Friedlander et 
al., 2009). DPP9 substrates have been sought using a degradomic approach and 
resulted in the identification and validation in vitro of adenylate kinase 2 and 
calreticulin as DPP8 and DPP9 substrates. That  study suggested a role for DPP8 and 
DPP9 in cellular metabolism and homeostasis (Wilson et al., 2013).  
By targeting the DPP9 protein active site with a serine to alanine point mutation, we 
were able to create a DPP9 gene knock-in mouse (DPP9-GKI) that lacks DPP9 enzymatic 
activity while maintaining normal DPP9 protein structure. This mouse exhibits neonate 
lethality suggesting that DPP9 enzymatic activity is essential for early neonatal survival 
in mice (Gall et al., 2013)(Chapter 3 of this thesis).  Further studies using neonatal liver 
and gut from DPP9-GKI mice compared to WT have shown that DPP9 enzymatic 
activity influences the expression of neonatal metabolic genes. Differential gene 
expression patterns of genes involved in cell growth, innate immunity, lipid 
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metabolism and gluconeogenesis were found suggesting a role for DPP9 enzymatic 
activity in regulation of metabolic pathways in the neonate (Chen et al., 2016). 
Most recently, two-dimensional differential in-gel electrophoresis (DIGE) was used in 
vitro on cells lacking endogenous DPP9 activity to identify novel DPP9 substrates 
(Zhang et al., 2015b), with nine being confirmed as substrates by MALDI-TOF or 
immunoblotting. This study also identified a DPP9-specific consensus site for cleavage 
(Val-Ala) that was not recognised by DPP8, suggesting that these two proteases have 
different in vivo roles. 
 
1.1.4.4 Non-enzymatic functions of DPP8 and DPP9 
 
Early investigations showed potential roles for DPP8 and DPP9 in apoptosis, wound 
healing and cell migration. In-vitro over-expression of DPP8 and DPP9 resulted in 
impaired cell adhesion, migration and monolayer wound healing for DPP9 and 
impaired migration and wound healing for DPP8, suggesting that those outcomes may 
result from direct protein-protein interactions or via altered expression of other 
proteins involved in cell adhesion and migration (Yu et al., 2006b). Both DPP8 and 
DPP9 also enhanced apoptosis. Using enzyme-negative mutants of each protein, in 
which enzyme activity was absent, the role of DPP8 and DPP9 in apoptosis appeared to 
be independent of enzymatic activity. 
Recent work supported the finding of the previous study (Yu et al., 2006b) that 
apoptosis and cell death were unaffected by DPP9 knockdown or enzyme inhibition, 
but has provided contrary data on cell adhesion and migration compared to the part of 
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that earlier work that examined protein over-expression in 293T cells (Zhang et al., 
2015b). Inhibition or silencing of DPP9 in Huh7 cells resulted in less cell mobility and 
adhesion compared to control cells (Zhang et al., 2015a), indicating that DPP9 
enzymatic function is important for these processes. The mechanistic roles of DPP8 
and DPP9 require further study. 
 
1.1.4.5 Inhibition of DPP8 and DPP9 
 
Many early DPP4 inhibitors were later found to also inhibit DPP8 and DPP9, raising the 
question of which functions attributed to DPP4 activity, should be attributed to DPP8 
and/or DPP9. This has led to the development of many inhibitors that are selective for 
DPP8 and DPP9 over DPP4 and FAP (Lankas et al., 2005, Wu et al., 2009, Jiaang et al., 
2005, Van der Veken et al., 2008, Van Goethem et al., 2011) but are not selective for 
DPP8 or DPP9 alone. While some isoindoline inhibitors were originally thought to 
inhibit DPP8 alone (Jiaang et al., 2005, Van der Veken et al., 2007), these were later 
shown to inhibit both DPP8 and DPP9 (Wu et al., 2009).  
The safety of targetting DPP8/9 activity for therapeutic use has been controversial with 
toxic effects reported in rats with the use of the DPP8/9 selective inhibitor, 
UAMC00132 (Lankas et al., 2005), while a later study on rats and mice using 
vildagliptin at high doses showed no toxicity or mortality of animals (Burkey et al., 
2008). Using the compound 1G244, Wu et al did not discover any pathological 
symptoms of inhibiting DPP8 and DPP9 (Wu et al., 2009). With the recent design of 
two analogues of 1G244 which have shown a 10-fold selectivity for DPP8 over DPP9 
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(Van Goethem et al., 2011), there is good progress towards selectively differentiating 
between these two enzymes by inhibition of either DPP8 or DPP9, rather than both. 
An alternative approach to chemical inhibitors has been studied in other DPPs, namely 
DPP4 and FAP. As these proteases also have non-enzymatic functions, there have been 
attempts to treat disease by blocking protein-binding interactions using 
immunotherapy, with several studies undertaken to demonstrate the efficacy of 
immunotargetting DPP4 (Ohnuma et al., 2002, Ho et al., 2001, Inamoto et al., 2006, 
Inamoto et al., 2007). Another study involved the use of a non-substrate nonapeptide, 
the HIV-1 Tat protein, which was identified as the first natural inhibitor of DPP4, as an 
immunosuppressor (Wrenger et al., 2008). However, whether these nonapeptides can 
enter the cell and act on DPP8 and DPP9 was not shown.  
More recently, it was found that, while the small ubiquitin-like protein modifier 
SUMO1 interacts with DPP9 leading to allosteric activation of the peptide (Pilla et al., 
2012),   the E67-interacting loop peptide acts as a non-competitive inhibitor (Pilla et 
al., 2013). This highlights the potential modulation of enzyme activity by peptides that 
mimic interaction surfaces. Development of therapeutics which target the non-
enzymatic activities of DPP8 and DPP9 as a therapeutic approach will require further 
research aimed at identifying protein-binding partners.  
 
1.1.4.6 Biological functions of DPP8 and DPP9 
 
Knowledge of the precise physiological functions of DPP8 and DPP9 is emerging with 
further research into their roles in normal homeostasis and pathophysiological 
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conditions. Data on enzymatic activity, substrate specificity and cell and tissue 
distribution of these proteases provide some clues to their biological functions, such as 
cell survival and cell biology, disease and inflammation and both cell-mediated and 
humoral immunity. 
1.1.4.6.1 DPP8 and DPP9 in immunity 
1.1.4.6.1.1 DPP8 and DPP9 in innate immunity 
The innate immune system consists of cells and proteins that are always present and 
ready to activate and attack when exposed to alien elements. The non-specific defence 
mechanisms which initiate after exposure to foreign substances can include physical 
barriers, such as skin, blood-borne chemicals and immune cells, such as phagocytic 
leukocytes, dendritic cells and natural killer (NK) cells. DPP8 and DPP9 have been 
shown to have extensive in vivo expression in epithelial cells of the gut and skin and 
normal immunological tissues (Yu et al., 2009) and also are expressed by all major 
lymphocyte populations (Abbott et al., 2000b, Chowdhury et al., 2013).  
Natural killer (NK) cells play a major role in host-rejection of both tumours and virally 
infected cells in the innate immune system. An early study showed that inhibition of 
DPP4 enzyme activity resulted in the suppression of certain stimulatory cytokines 
causing a reduction of DNA synthesis and cell cycle progression (Buhling et al., 1994). 
However, the inhibitors used in that study were later shown to also inhibit DPP8/9 
activity (Lankas et al., 2005), therefore those effects were possibly DPP8/9 mediated. 
Further support for that conclusion derives from the finding that the presence or 
absence of DPP4 on the cell surface of NK cells does not influence the natural 
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cytotoxicity of these cells (Madueno et al., 1993). Interestingly, in a lung metastasis 
model using DPP4-deficient rats, NK cytolytic function against tumour cells is lessened 
(Shingu et al., 2003). 
1.1.4.6.1.2 DPP8 and DPP9 in adaptive immunity 
 The antigen-specific adaptive immune response is more complex and includes a 
“memory” that improves the efficiency of future responses and depends upon antigen 
presentation and recognition. DPP9 has been shown to be involved in the degradation 
in vitro of the antigenic peptide RU134-42 and, hence, down-regulation of DPP9 results 
in increased presentation of this antigen (Geiss-Friedlander et al., 2009).  
DPP8 and DPP9 have also been shown to be up-regulated upon B or T cell activation 
(Chowdhury et al., 2013). Several T cell leukemia cell lines highly expressed DPP8 and 
DPDP9 mRNA transcripts (Tadje et al., 2008), while CD3+ T cells isolated from healthy 
human donors showed up-regulation of DPP9 mRNA after T cell activation (Heimburg 
et al., 2008).   
DPP8/9 enzyme activity has been found in human lymphocytes, monocytes and also in 
human and mouse primary leukocytes and monocytes, B and T cell lines (Abbott et al., 
2000b, Lankas et al., 2005, Maes et al., 2007, Bank et al., 2011). While thought to be 
only located intracellularly, one study suggested that DPP8 and DPP9 may also be 
present on the surface of immune cells under certain conditions (Bank et al., 2011), 
although they indicated that there was uncertainty whether this externalisation of 
DPP8 and DPP9 was undertaken actively by viable cells or passively by stressed, 
apoptotic or necrotic cells. In a rat model of cerebral ischemia, an association was 
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found between DPP8 and active microglia and macrophages (Röhnert et al., 2012) and 
a study of atherosclerosis showed an abundance of DPP8 and DPP9 in the 
macrophage-rich regions of atherosclerotic plaques (Matheeussen et al., 2013). 
While mouse-spleen derived B lymphocytes express little DPP4 mRNA, DPP8 and DPP9 
mRNA are expressed at greater levels and stimulation with pokeweed mitogen and 
lipopolysaccharide of mouse splenocytes, Jurkat T- and Raji B-cell lines up-regulates 
both proteins (Chowdhury et al., 2013).  DPP8 and DPP9 mRNA are down-regulated 
after dithiothreitol (DTT) treatment and up-regulated upon mitomycin c treatment in 
Raji cells. Contrary to this, Jurkat cells or peripheral blood mononuclear cells 
stimulated with phytohaemagglutinin does not change DPP8 or DPP9 expression levels 
(Tang et al., 2009). 
DPP8 and DPP9 has been detected by in-situ hybridisation in lymphocytes in the 
mantle and paracortical zones of human lymph node and baboon spleen and DPP8/9 
activity was detected in interfollicular T-cells of baboon spleen and Jurkat cells (Yu et 
al., 2009).  Activation and proliferation of immune cells appears to be affected by DPP8 
and DPP9 enzymatic activity and selective DPP8/9 inhibition can reduce cytokine 
production due to the induction of TGF-β secretion, as well as DNA synthesis and T cell 
proliferation (Lankas et al., 2005, Reinhold et al., 2009).  This is suggestive of DPP8/9 
enzyme activity having important roles in the regulation of immune function. 
1.1.4.6.2 DPP8 and DPP9 in cell biology and cell survival 
In an early study, both DPP8 and DPP9 were involved in cell-extracellular matrix 
interactions and influenced apoptosis but DPP8 did not influence cell adhesion and 
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only DPP9 was a primary trigger of apoptosis (Yu et al., 2006b). Overexpression of 
DPP8 and DPP9 in HEK293T epithelial cells showed impaired cell adhesion, migration 
and monolayer wound healing in vitro which appeared to be independent of enzyme 
activity. While DPP8 and DPP9 are very similar intracellular enzymes and both 
ubiquitously expressed, DPP9, as suggested by the literature, appears to have a more 
pronounced role in cell biology. 
DPP9 mRNA expression is up-regulated after activation in human T-cells, in contrast to 
DPP8 (Heimburg et al., 2008, Tadje et al., 2008) and DPP9 mRNA was also elevated in 
cartilage from osteoarthritis patients (Milner et al., 2008). A study of normal and 
keloid-derived skin fibroblasts in vitro showed that inhibitors of DPP8 and DPP9 could 
suppress proliferation, decrease fibrogenic cytokine transforming growth factor-β1 and 
secretion of procollagen type 1, which is seen as a major therapeutic goal in the 
treatment of fibrotic skin disorders and keloids (Thielitz et al., 2008). 
In sarcoma cell lines, NPY-driven tumour cell death, mediated by the nuclear protein 
modifying enzyme poly(ADP-ribose) polymerase (PARP-1) and apoptosis-inducing 
factor, can be abolished by the overexpression of DPP8 and DPP9 and enhanced by 
their own down-regulation (Lu et al., 2011).  In contrast, overexpression of DPP9 in 
epithelial tumour cell lines is anti-proliferative and enhances intrinsic apoptosis (Yu et 
al., 2006a, Yao et al., 2011). DPP9 overexpression was also shown to result in 
significantly less epidermal growth factor(EGF)-mediated Akt pathway activation in 
HepG2 cells but not observed in cells stimulated with other growth factors, suggesting 
that this activation was growth factor dependent (Yao et al., 2011). Since experiments 
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in which DPP9 is overexpressed, gene-silenced or inhibited have resulted in conflicting 
data, the pro- or anti-apoptotic activity of this enzyme may depend on its in vitro 
culture environment and/or the cell type in which the experiment is undertaken. 
While studying the antileukemic activity of the chemotherapy drug, parthenolide, and 
using a high-throughput screen, it has been found that the DPP inhibitor vildagliptin 
synergistically enhances parthenolide’s action in leukemia, lymphoma and primary 
human acute myeloid leukemia cell lines (Spagnuolo et al., 2013). This synergy is due 
to the inhibition of DPP8 and DPP9 rather than DPP4 suggesting that this inhibition 
might be used as a chemosensitising strategy for leukemia cells. 
Primary endothelial cells from aortic, endocardial and cardiac microvascular regions of 
the rat heart contain DPP8/9 enzymatic activity, with DPP8 protein more abundant 
than DPP9 (Matheeussen et al., 2011). In that study, the localisation of DPP8 and DPP9 
showed spatial heterogeneity, with DPP8 more abundant in the cardiac microvascular 
endothelium and DPP9 predominant in human carotid artery endothelial cells.  
More recently, that research group focussed on the expression of DPPs in human 
atherosclerotic plaques by using the monocyte cell line U937 differentiated into either 
M1 or M2 macrophages, and showed that DPP8 and DPP9 are abundant in the 
macrophage-rich regions of plaques (Matheeussen et al., 2013). Another study used 
the mouse macrophage cell line J774, as well as monocytes and macrophages derived 
from mouse bone marrow, to show that the inhibition of DPP8/9 lessens M1 
macrophage activation in mice. As DPP8 and DPP9 are abundantly present in 
atherosclerotic plaques, it has been suggested that the mouse could become a valid 
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model species for therapeutic targeting of DPPs in atherosclerosis (Waumans et al., 
2016). The use of a wide variety of cell lines and tissues can provide insights into the 
physiological and pathological roles of DPP8 and DPP9 in cell behaviour and survival. 
 
1.1.4.6.3 DPP8 and DPP9 in disease and inflammation 
There is increasing evidence in the literature that DPP8 and DPP9 may be associated 
with disease pathogenesis. In a gene expression profile study using human 
hepatocellular carcinoma (HCC) tissue, mRNA of DPP9 has shown differential 
expression and upregulation between non-tumour liver tissue adjacent to tumours and 
normal liver tissue (Kurokawa et al., 2003), suggesting a possible role in disease 
progression.  
Expression profiling of breast and ovarian carcinoma cell lines, along with 293T and 
HeLa cell lines, showed ubiquitous but differential expression of DPP8 and DPP9 mRNA 
and protein across these cell lines. There was, however, a lack of correlation between 
mRNA transcript and protein levels for both DPP8 and DPP9 which suggests that DPP8 
and DPP9 may be regulated post-transcriptionally in breast and ovarian cancer cell 
lines (Wilson and Abbott, 2012a). 
DPP8 mRNA expression is greater than other DPPs in breast and ovarian cancer cell 
lines (Wilson and Abbott, 2012a), DPP9 mRNA is abundant in chronic myelogenous 
leukemia (K-562) and immortalised cervical cancer (HeLa) cells (Olsen and Wagtmann, 
2002) and DPP8 and DPP9 mRNA can be detected in tumour infiltrating lymphocytes 
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with upregulation of DPP9 mRNA levels in human testicular tumours (Yu et al., 2009), 
thus suggesting that DPP8 and DPP9 may have roles in tumour pathogenesis. 
DPP activity inhibition partially attenuates dextran sulphate sodium (DSS) - induced 
colitis in mice, and DPP8 mRNA levels exhibit differential regulation during colitis 
development, which is suggestive of role of DPP8 in inflammatory bowel disease 
(Yazbeck et al., 2010). DPP8 mRNA and protein expression is significantly up-regulated 
in B-cell chronic lymphocytic leukemia (B-CLL) lymphocytes compared to normal tonsil 
B lymphocytes in B-CLL patients (Sulda et al., 2010). These findings suggest that DPP 
expression may have biological relevance in disease states. 
Meningiomas are inter-cranial tumours that are derived from the arachnoid cap cells 
and include a wide variety of subtypes. A study of the expression of all DPPs, including 
DPP8 and DPP9, has shown enzymatic activity of both was present in all benign 
meningiomas, with elevated levels in atypical meningiomas that are associated with 
higher cell proliferation (Stremenova et al., 2010).  An aggressive group of human 
paediatric malignancies, Ewing sarcoma family of tumours, are driven by an aberrant 
transcription factor that up-regulates specific target genes, such as NPY. ESFT cell 
death is stimulated by exogenous and endogenous NPY, however, this effect is 
prevented by cleavage of NPY by both membrane-bound DPP4 and intracellular DPP8 
and 9. Thus, DPPs act as survival factors for EFST and may become potential 
therapeutic targets for these tumours (Lu et al., 2011). 
A pathophysiologically significant role in asthma has been shown when DPP8 and DPP9 
enzymatic activity is regulated in a rat asthma model. The sites of expression of DPP8 
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and DPP9 were investigated in rat lungs, with and without an allergic-like inflammation 
status. Considering bronchi and lung parenchyma, DPP8 and DPP9 were primarily 
detected in the bronchial epithelium of the airways (Schade et al., 2008). DPP8 and 
DPP9, along with other DPPs, are elevated in human articular cartilage in osteoarthritis 
patients, which implicates these enzymes in the cascades leading to cartilage 
breakdown and/or collagenolysis that occurs in arthritis (Milner et al., 2008). 
Using a model of transient and unilateral cerebral ischemia in rats, another group 
studied the expression, localisation and activity patterns of DPP8 and DPP9 and several 
other proteases to gain insight into the action of cerebral inflammation and neuronal 
degeneration (Röhnert et al., 2012). It has been shown that mRNA expression of DPP9 
is diminished in the ischemic region of the brain at 6 hours and 3 days after induced 
ischemia whereas DPP8 levels remain the same at all time points. Also, DPP8 is present 
in activated microglia and macrophages at day 3 post-ischemia and in astroglial cells at 
day 7 post-ischemia, suggesting that DPP8 and DPP9 have potential roles in cerebral 
inflammation. 
As a role for DPP4 in atherosclerosis emerged (Matsubara et al., 2012), it was 
necessary to investigate the expression and role of DPP8 and DPP9. More recently, it 
has been shown that DPP8 and DPP9 are abundant in macrophage-rich regions of 
human atherosclerotic plaques (Matheeussen et al., 2013). That study showed that, 
while DPP4 is only present in endothelial cells of plaque, DPP8 and DPP9 are highly 
expressed in macrophages with a significant up-regulation of DPP9 protein expression 
in both pro-inflammatory M1 and anti-inflammatory M2 macrophages during 
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monocyte-to-macrophage differentiation. Since M1 macrophages play a role in 
atherogenesis, there may be future therapeutic prospects in the reduction of 
atherosclerosis and/or plaque rupture by inhibition of DPP9. Activation of 
macrophages in atherosclerotic plaques can cause indiscriminate tissue damage and 
attenuation of activiation by DPP8/9 inhibition would be a desirable outcome. 
A genome-wide association study which focused on human pulmonary fibrosis 
identified DPP9 as one of several novel susceptibility loci. Although the evidence for 
higher expression of DPP9 in lung tissue of pulmonary fibrosis cases compared to 
controls was slight, this group speculated that DPP9 may be involved in the integrity of 
lung epithelia via cell-to-cell adhesion (Fingerlin et al., 2013). This finding would need 
further investigation to show if DPP9 does have a role in the development of 
pulmonary fibrosis. 
The current understanding of the role of DPP8 and DPP9 in atherosclerosis has been 
reviewed (Waumans et al., 2015). Most recently, the role of DPPs in atherosclerosis 
was further studied focusing on macrophage activation in a mouse model and human 
M1 macrophages in vitro (Waumans et al., 2016). While, DPP8 and DPP9 expression 
was relatively low in mouse monocytes and macrophages, DPP8/9 inhibition was 
confirmed to attenuate macrophage activation and the viability of both mouse and 
human macrophages was unaffected by this inhibition.  
Overall, DPP8 and DPP9 are becoming increasingly implicated in disease pathogenesis. 
Increased understanding of the role they play may make them candidates future 
therapeutic targeting.  
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1.2 DPP4 family mouse phenotypes 
1.2.1 Mouse models 
As the mouse genome is amenable to genetic manipulation, there are great benefits to 
using mouse models. Many studies involve the use of gene knockout (GKO) mice as 
models for investigation of the biological properties of proteins in a physiological 
and/or pathophysiological context. In GKO mice, the protein of interest is absent from 
the resultant mouse. In the DPP4 gene family, GKO mice have been created for both 
DPP4 and FAP. The DPP4-GKO mouse was produced by a targeted inactivation in the 
DPP4 gene and resulted in healthy mice (Marguet et al., 2000). Similarly, the FAP-GKO 
mouse was constructed through exon deletion and also created fertile mice with no 
overt developmental defects or increased cancer susceptibility (Niedermeyer et al., 
2000). It has been speculated that, in the absence of these proteins, other proteins are 
up-regulated and have compensatory roles (Marguet et al., 2000, Niedermeyer et al., 
2000). To date, no DPP8-GKO mice have been reported. 
 
1.2.2 DPP9 gene knock-in (GKI) mouse 
 
Unlike in the case of GKO mice where the entire protein is absent from the mouse, in a 
GKI mouse the protein of interest is present but inactivated by a single amino acid 
change, thus it is still able to fulfill non-enzymatic functions, such as structural roles 
and protein-protein interactions. This study utilised a DPP9-GKI mouse which was 
found to display early neonatal lethality suggesting that enzyme activity of DPP9 has a 
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crucial role in neonate mouse survival. Those findings are published (Gall et al., 2013) 
and are the basis of Chapter 3 of this thesis. 
 
1.3 PhD project aims 
 
As outlined above, DPP9 has been implicated in the immune system, cell behaviour 
and survival, disease pathogenesis and inflammation, however clear physiological roles 
remain to be determined. There is a need to gain a greater understanding of the 
functional and biological properties of this ubiquitously-expressed protein. 
 
AIM 1: To demonstrate the importance of DPP9 enzymatic activity in vivo 
The creation of GKO mice lacking the other DPP4 family proteins, DPP4 and FAP, 
resulted in healthy mice with indications that the absence of these proteins have 
protective effects. The absence and/or inactivation of DPP9 enzymatic activity had not 
previously been reported when this thesis work began, so the importance of DPP9 
activity in mice was explored.  
 
AIM 2: To elucidate the biological roles of DPP9 in DPP9-GKI neonate and adult mice 
Concurrent to this thesis, in vitro studies using DPP9-GKI mouse embryonic fibroblasts 
(MEFs) and neonatal tissues isolated from wild-type (WT) or DPP9-GKI mice explored 
the role of DPP9 in neonate metabolism which later resulted in a publication from this 
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lab (Chen et al., 2016).  As there have been no reported DPP9-enzyme-activity-
deficient mice used in any in vivo studies, the potential causes of lethality in neonate 
mice and other possible physiological or pathological effects in adult heterozygous 
mice were investigated. The main areas of focus were potential defects in heart and 
autophagy in the neonate and the possible role of DPP9 enzymatic activity in adult 
heterozygous mouse skin as compared to WT. 
 
AIM 3: To explore the role of DPP9 in the regeneration of the mouse immune system 
DPP9 has been detected in immune cells and tissues in vitro and in vivo, however no 
study exists where the role of DPP9 in the regenerating immune system has been 
examined. This study used the creation of primary and secondary chimeras to 
investigate the role of DPP9 enzyme activity on the developing immune system of WT 
mice. These chimeras were produced using irradiated mice injected with WT and 
DPP9-GKI mouse fetal liver cells for primary chimeras in the first instance and then, 
subsequently, bone marrow cells from the primary chimeric mice. 
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2 General Materials and Methods 
 
 
2.1 Buffers, media, chemical reagents and antibodies 
 
2.1.1 General buffers 
 
1 x PBS 
Made from 10 x Dulbecco’s Phosphate-buffered saline (Cellgro).  
FACS wash 
10 ml FCS (5%), 800 µl of 0.5 M EDTA (2mM) and 200 µl of 10% NaN3 (0.01%) to a total 
volume of 200 ml with PBS. 
50 x TAE buffer 
242 g of Tris-base, 57.1 ml of acetic acid (glacial), 100 ml of 0.5 M EDTA (pH 8.0) was 
made up to 1 L with triple distilled H2O. A working solution of 1 x TAE was made by 
diluting 20 ml of 50 x TAE buffer in 980 ml of triple distilled H2O. 
0.5 M EDTA (pH 8.0) 
186.1 g of EDTA.2H2O was dissolved in 800 ml H2O under vigorous stirring. The pH was 
adjusted to 8.0 with NaOH and H2O was added to give a final volume of 1 L. 
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 1 M TrisXHCl (pH 7.6) 
121.14 g of Tris-base was dissolved in 1 L of H2O (buffer 1).  
157.64 g of Tris-HCl was dissolved in 1 L of H2O (buffer 2).  
Buffer 1 was added to buffer 2 until the pH reached 7.6. 
Red cell lysis (RBC) buffer 
8.26 g ammonium chloride (NH4Cl), 1 g potassium bicarbonate (KHCO3) and 0.037 g 
EDTA were dissolved in 1 L of dH2O. 
ACK/ RBC lysis solution 
5 ml FACS wash added to 95 ml RBC lysis buffer. 
 
Hydroxyproline assay reagents: 
Citrate-Acetate buffer 
34 g sodium acetate, 37.5 g sodium citrate and 5.5 g citric acid monohydrate were 
mixed with 385 ml isopropanol and dissolved in dH2O up to 1 L. 
Chloramine T  
7 g chloramine T was added to 100 ml of dH2O and stored in a dark bottle at 4
0C 
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Ehrlich’s reagent  
25 g p-dimethylaminobenzaldehyde and 37.5 ml 60% perchloric acid mixed well and 
stored in a dark bottle at 40C 
Chloramine T solution (Solution A) 
Mix 1 part chloramine T with 4 parts citrate-acetate buffer. Make up fresh for each 
experiment. 
Ehrlich’s solution (Solution B) 
Mix 3 parts Ehrlich’s reagent with 13 parts isopropanol and store at 40C 
10M sodium hydroxide 
400 g sodium hydroxide in 1 L of dH2O mixed in a plastic beaker on ice. 
3M hydrochloric acid 
25.5 ml 37% hydrochloric acid in 100 ml of dH2O 
 
Liver cell buffer 
5 ml Glutamax, 10 ml Penistrep and 50 ml FCS were added to 500ml of Dulbecco’s 
Modified Eagle’s Medium (DMEM) 
Cell freezing solution 
10 ml DMSO added to 90 ml FCS 
                                                                                Chapter 2: General materials and methods                                           
 
36 
 
2.1.2 Source of media and chemical reagents 
 
Table 2.1: List of media and chemical reagents 
Chemical Name Catalogue No. Supplier 
Agarose I 0710 AMRESCO 
Acetic Acid 100015N BDH Chemicals 
Ammonium Chloride A9434 Sigma Chemical Co 
Bovine Serum Albumin (BSA) A7906 Sigma Chemical Co 
Chloramine T hydrate C9887 Sigma Aldrich PL 
Citric Acid Monohydrate  C7129 Sigma Aldrich PL 
4',6-diamidino-2-phenylindole 
(DAPI) 
D8417 Sigma Aldrich PL 
p-dimethylaminobenzaldehyde  D2004 Sigma Aldrich PL 
Dimethyl Sulphoxide (DMSO) D2650 Sigma Chemical Co 
Dulbecco’s Modified Eagle’s 
Medium (DMEM) 
12430 Invitrogen Australia PL 
Dulbecco's Phosphate-Buffered 
Saline (10×DPBS) 
98-317-LB Cellgro 
Ethanol Absolute ET00162500 Scharlau 
Ethylene Diamine Tetraacetic Acid 
Disodium Salt (EDTA) 
E5134 Sigma Chemical Co 
Fetal Calf Serum (FCS) FBS500-S AusGeneX 
GelRed Nucleic Acid Stain 41003 Biotium 
GlutaMAX, 100× 35050 Invitrogen Australia PL 
Glycerol G7757 Sigma Chemical Co 
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HEPES 0511 AMRESCO 
Hydrogen Peroxide (H2O2) 28694.5B BDH Chemicals 
Instant Skim Milk Powder 3549 BonlacFoods 
Imidazole 10125 Sigma Chemical Co 
Isopropanol I-9516 Sigma Aldrich Pty Ltd 
Lipofectamine LTX and PLUS 15338-100 Invitrogen Australia PL 
Magnesium Chloride (MgCl2) M1028 Sigma Chemical Co 
Methanol M3641 BDH Chemicals 
Neutral Buffered Formalin, 10% HT5011 Sigma Chemical Co 
Penicillin-Streptomycin (P/S), 100× 15140 Invitrogen Australia PL 
Potassium Bicarbonate 237205 Sigma Chemical Co 
Proteinase K, recombinant, PCR 
Grade 
03115852001 Roche 
Sodium Acetate S2889 Sigma Chemical Co 
Sodium Azide (NaN3) E8751 Sigma Chemical Co 
Sodium Chloride (NaCl) 465 Ajax Chemicals 
Sodium citrate tribasic dihydrate C8532 Sigma Chemical Co 
Sodium Hydroxide (NaOH) 10252 BDH Chemicals 
Tris-Base 0497 AMRESCO 
Tris-EDTA buffer solution (100×) T9285 Sigma 
Tris-HCl 0234 AMRESCO 
Triton X-114 X-114 Sigma Chemical Co 
Trizol Reagent 15596 Invitrogen Australia PL 
Trypan Blue T8154 Sigma Chemical Co 
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TrypLE Express 12605 Invitrogen Australia PL 
Tween-20 P1379 Sigma Chemical Co 
 
 
2.1.3 Antibodies 
 
Table 2.2: List of antibodies 
 
Primary antibodies 
Antibody Supplier Catalogue No. Working Conc. 
β-Actin Sigma A2103 1:1000 
AF647 Ly6G BioLegend #127610 1:250 
Anti-LC3B GeneTex #GTX127375 1:100 
APC.Cy7 CD8a BD Biosciences #557654 1:250 
BUV395 CD19 BD Biosciences #563557 1:200 
BV421 CD3e BD Biosciences #562600 1:250 
DPP9 - Catalytic domain Abcam Inc Ab42080 1:2000 
APC TER-119 BD Biosciences #557909 1:250 
FITC CD11b BD Biosciences #557396 1:250 
GAPDH EnCor Biotechnology MCA-1D4 1:1000 
PE NK1.1 BD Biosciences #557391 1:250 
PerCP-Cy5.5 CD45.1 eBioscience #45-0453 1:250 
V500 CD45.2 BD Biosciences #562129 1:250 
 
                                                                                Chapter 2: General materials and methods                                           
 
39 
 
Secondary antibodies 
Antibody Supplier Catalogue No. Working Conc. 
Anti-Rabbit IgG-HRP DAKO PO448 1:100 
 
 
 
2.1.4 Source of specialty mouse supplies  
 
Table 2.3: List of specialty mouse treatment products 
Item Name Purpose Supplier 
Ampicillin Antibiotic Sandoz 
Isoflurane Anaesthetic I.S.O. 
Nair Hair removal Church & Dwight Co Inc 
Povidine-iodine Antiseptic lotion Betadine 
Temgesic Analgesic Reckitt Benckiser 
Tegaderm Wound dressing 3M Company 
 
 
2.2 General molecular biology methods 
Standard molecular biology techniques were used. Techniques specific to one 
experiment are detailed in the respective chapters. All water (H2O) used was 
commercially obtained sterile water (Baxter, NSW, Australia). 
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2.2.1 Genomic DNA extraction 
Mammalian genomic DNA (neonate mouse tail samples and mouse embryonic head 
samples) was extracted using the Wizard® Genomic DNA Purification Kit (Promega 
#A1120), according to the manufacturer’s instructions. 
Mouse tissues were resuspended using a tip in 600 L of pre-chilled EDTA/Nuclei Lysis 
Solution (120 μL of a 0.5 M EDTA solution to 500 μL of Nuclei Lysis Solution). 17.5 L of 
20 mg/mL Proteinase K was added to the sample and incubated overnight at 55°C with 
gentle shaking to make sure the tissues were completely digested. 3 L RNAse Solution 
was added to the nuclear lysate followed by inversion 2-5 times. The mixture was 
incubated at 37°C for 15-30 min and cooled to room temperature. 200 L of Protein 
Precipitation Solution was added to the cooled sample and vortexed vigorously for 20 s 
before the samples were chilled on ice for 5 min and centrifuged at 14,000 rpm for 4 
min, with the appearance of a tight pellet of precipitated protein. The supernatant was 
transferred to a new tube containing 600 L isopropanol and mixed gently by inversion 
until DNA threads formed a mass. The DNA was pelleted at 14,000 rpm for 1 min and 
washed with 600 L of 70% ethanol before spinning again at 14,000 rpm for 1 min. The 
ethanol was carefully aspirated and the DNA pellet dried by inversion of the tube on 
absorbent paper for 15 min. 50 L of DNA Rehydration Solution was added and the 
DNA dissolved at 65°C for 1 h or overnight at 4 °C. 
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2.2.2 Polymerase Chain Reaction (PCR) 
The PCR machine used was a DNA Engine (MJ Research, Bio-Rad Laboratories, 
Hercules, CA, USA). PCR reactions were set up in 0.2 mL thin walled PCR tubes. The 
reaction contained the designed forward and reverse primers (1 μL of 20 μM), 50 ng 
double-stranded template, dNTPs (1 μL of 10 mM; Roche), 1 unit (U) Advantage 2 
Polymerase Mix (Clontech #639201), 1 ×Advantage 2 SA PCR buffer (1.5 μL; Clontech 
#639147) and sterile water to a final volume of 15 μL. Cycling parameters comprised 
an initial 2 min hot start at 95°C to activate the DNA polymerase, followed by 39 cycles, 
each comprising of 95°C for 30 sec to denature DNA strands and 64°C for 30 sec to 
reanneal strands and 68°C for 30 sec to permit extension, and final extension at 68°C 
for 10 min. 
 
2.2.3 Agarose gel electrophoresis 
Horizontal gel electrophoresis was performed in HORIZON® 58 Gel tanks (Gibco BRL, 
Life Technologies, Gaithersburg, MD, USA) attached to an EPS 601 power pack 
(Amersham Pharmacia Biotech, Piscataway, NJ, USA). GelRed Nucleic Acid Gel Stain 
(1:10000) was added to agarose gels prior to pouring to enable visualisation under UV 
light. 6 × DNA Loading Dye (Fermentas) was added to DNA samples. Molecular weight 
markers used were GeneRulerTM 1 kb DNA ladder (Fermentas #SM0311) or 
GeneRulerTM Low Range DNA ladder (Fermentas #SM1191). Gels were run at 120 Volts 
for 30 min or as needed. Gels were photographed using a Polaroid® camera or an UVT-
400M transilluminator (International Biotechnologies, New Haven, CT, USA). 
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1% Agarose Gel 
1 g of agarose was dissolved in 100 mL of 1×TAE buffer, with heating. 
3% Agarose Gel 
3 g of agarose was dissolved in 100 mL of 1×TAE buffer, with heating. 
 
2.2.4 Protein Analysis 
 
2.2.4.1 Protein sample preparation 
Triton Lysis Buffer (pH 7.6) 
500 μL of 1 M Tris-HCl (50 mM), 20 μL of 0.5 M EDTA (1 mM), 10 μL of 1 M MgCl2 (1 
mM), 300 μL of 5 M NaCl (150 mM), 100 μL of Triton-114 (1%) and 1 mL of Glycerol 
(10%)was made up to 10 mL with Baxter H2O. The lysis buffer was stored at -20
0C as 
aliquots. 1X Roche complete protease inhibitor cocktail was added to the lysis buffer 
prior to use. 
2.2.4.2 Protein preparation for mouse tissues 
Frozen mouse tissues were weighed and homogenised in ice-cold lysis buffer, at the 
ratio of 1 mg tissue/ 10 µL lysis buffer, using a bead-based homogeniser (TissueLyser, 
Qiagen) for 2 min at 40C. The homogenates were sonicated on ice for 10 min, followed 
by spinning at 14000 rpm for 10 min at 40C to remove cell debris. The supernatants 
were collected and stored at -800C prior to analysis. 
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2.2.4.3 Protein quantitation 
Protein concentrations were determined using the Micro BCA™ Protein Assay Reagent 
Kit (Pierce Biotechnology). 70 µL of each standard or test sample was added into each 
well of a clear 96-well plate followed by 70 µL of working reagent. The plate was 
incubated at 370C for 30 min. The absorbance was measured at 570 nm on microplate 
reader (BMG Labtech) and the protein concentration estimated by comparing it to a 
standard curve generated with known BSA concentrations (1–40 µg/mL). 
 
2.2.4.4 SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
Protein samples were heated at 95C for 10 min in the presence of 1×NuPAGE LDS 
Sample Buffer (Invitrogen) and 1×NuPAGE Reducing Agent (Invitrogen) before being 
cooled on ice prior to loading. NuPAGE pre-cast gels (Invitrogen) were applied to 
resolve proteins for immunoblot analysis. An XCell SureLock Mini-cell electrophoresis 
unit (Invitrogen) was used for gel runs. 3-8% Tris-Actetate SDS-PAGE gels were run at 
150 V for approximately 60 min with 1×Tris-Acetate SDS Running Buffer, whereas 4-
12% Bis-Tris SDS-PAGE gels were run at 200 V for 45 min in 1×MOPS SDS Running 
Buffer. 500 µL of 1×NuPAGE Antioxidant (Invitrogen) was added to 200mL 1×SDS 
Running Buffer in the Upper (inner) Buffer Chamber. Relative molecular masses were 
estimated by comparison to PageRulerTM Prestained Protein Ladder (Thermo Scientific) 
and MagicMark XP Western Protein Standard (Invitrogen). 
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2.2.4.5 Immunoblotting  
Transfer of proteins from the gel to a polyvinylidene difluoride (PVDF) membrane was 
performed using an XCell SureLock Mini-cell with XCell II Blot module (Invitrogen). The 
gel was removed from the gel cartridge and then placed on a piece of Whatman 3 M 
paper. A piece of PVDF membrane was placed on top of the gel and a piece of 
Whatman 3 M paper was placed against the PVDF. This assembly was sandwiched 
between six sponges and the final assembly placed into the tank containing 1× 
Transfer Buffer (Invitrogen) such that the gel was facing the cathode and the PVDF was 
facing the anode. Transfer was carried out at 30 V for 2 h. The success of protein 
transfer was determined by the degree of transfer of the pre-stained protein standard 
markers. The PVDF was then removed from the assembly and blocked by incubations 
in Blotto for 1 h at RT, followed by primary antibody at 4C for overnight on rocker 
with gentle shaking. Following washing with Blotto for 10 min, PVDF membrane was 
incubated with a horseradish peroxidase (HRP) conjugated secondary antibodies for 
1.5 h at RT. Finally, the membrane was rinsed in PBST before incubating in 
Chemiluminescent HRP Substrate (ImmobilinTM, Millipore, Bedford, MA) for 5 min and 
detecting by ChemiDOC MP system (BIO-RAD). 
PBST 
100 μL Tween 20 was added to 1 L PBS. 
Blotto 
45 g instant skim milk powder and 200 μL Tween 20 was dissolved in 1 L PBS. 
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2.3 Mouse handling and maintenance 
All mice were maintained in the Centenary Institute of Cancer Medicine and Cell 
Biology animal facility under specific pathogen free conditions and exposed to a 12 h 
light-dark cycle. DPP9-GKI mice were bred on-site. C57BL/6J and PTPRCA mice were 
purchased from either Animal Resource Centre (Perth, WA, Australia) or Australian 
BioResources (Moss Vale, NSW, Australia). After arrival, the animals were housed four 
to six mice per cage with ad libitum access to rodent chow and water for a one week 
acclimation period before using them for experimental purposes. All the mice used for 
chimera experiments were at least 8 weeks old (adult age). All animal handling and 
experimental procedures were approved by Sydney Local Health District Animal 
Welfare Committee under ethics protocols Protocol No. 2013/ 017C – The biological 
roles of dipeptidyl peptidases (K75/5-2012/3/5754) and/or Protocol No. 2013/ 017D – 
The biological roles of dipeptidyl peptidases (K75/5-2012/3/5754). 
 
2.4 Statistics 
Where statistical analysis was used, the data were presented as mean ± standard 
deviation of the mean (SD) or mean ± standard error of the mean (SEM). Statistical 
analysis was performed using GraphPad Prism (GraphPad Software, La Jolla, CA, USA). 
Groups were compared by unpaired t-test or Mann-Whitney test. Specific details of 
statistical methods used for each analysis is contained in the Materials and Methods 
section of each data chapter. 
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Statement 
 
 
 
Section 3.2 in this chapter has been published: 
 
 
 
 
 
Gall MG, Chen Y, Vieira de Ribeiro AJ, Zhang H, Bailey CG, Spielman DS, Yu DMT, Gorrell 
MD (2013) Targeted Inactivation of Dipeptidyl Peptidase 9 Enzymatic Activity Causes 
Mouse Neonate Lethality. PLoS ONE 8(11): e78378. doi:10.1371/journal.pone.0078378 
 
 
 
 
 
Section 3.2 of this chapter is identical to the final submission, except for minor 
corrections. The written permission and statement of contribution by co-authors is 
attached in Appendix 2  
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3 DPP9 enzyme deficiency in the mouse 
 
3.1 General Introduction 
As discussed in Chapter 1, the use of mouse models is beneficial for providing in vivo 
data to assist in the understanding of normal and pathological biological conditions. 
Genetic manipulation of the mouse genome has enabled the creation of GKO and GKI 
mice which result in the deletion or inactivation, respectively, of one or more proteins 
of interest. GKO mice have been produced for both DPP4 (Marguet et al., 2000) and FAP 
(Niedermeyer et al., 2000) and are healthy and fertile. Thus, there was an expectation 
in our group that GKO mice for similar enzymes, such as DPP9, would be similarly 
healthy. 
In our lab, we created a DPP9-GKI mouse to study the loss of DPP9 enzymatic activity 
without altering other non-enzymatic interactions and characteristics of the DPP9 
protein. Surprisingly, the DPP9-GKI mouse displayed neonate lethality, which suggested 
a crucial role for this enzyme activity in early mouse survival. 
 
3.1.1 Aims 
The aims of the work in this chapter are: 
 to show that the DPP9-GKI mouse, bearing the DPP9-S729A mutation, displays a 
lethal phenotype and determine the developmental timing of death 
 to validate that DPP9-S729A and wild-type DPP9 have similar subcellular 
localisation and that the DPP9 protein is enzyme-inactive 
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 to investigate obvious histological and/or physiological differences between 
early neonate DPP9S729A/S729A homozygotes from their heterozygous and wild-
type littermates 
 
3.2 Targeted inactivation of dipeptidyl peptidase 9 enzymatic activity 
causes mouse neonate lethality 
 
(Section 3.2 of this chapter is published as presented with minor amendments. Section 
3.3 contains supplementary data not included in the published paper but undertaken 
as part of the neonate mouse studies to identify the lethal phenotype.) 
 
3.2.1 Introduction 
 
The DPP4 family of enzymes gained prominence with the success of oral DPP4 inhibitors 
as type 2 diabetes therapeutics (Deacon, 2011, Kirby et al., 2010). This enzyme family is 
unusual because its members, DPP4, FAP, DPP9 and DPP8, can hydrolyze the post-
proline bond two residues from the N-terminus of substrates. FAP, the closest relative 
of DPP4, is a potential target for cancer therapy (Yu et al., 2010, Brennen et al., 2012, 
Keane et al., 2012, Christiansen et al., 2013). DPP9 and its closest relative, DPP8, are 
primarily under study in cell biology, immunobiology and tumour biology (Zhang et al., 
2013). Medicinal chemistry has generated selective inhibitors of DPP4 and FAP but not 
of DPP9 and DPP8. However, some compounds inhibit DPP9 and DPP8 while not 
inhibiting DPP4 or FAP (Van Goethem et al., 2011, Wu et al., 2012). 
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DPP9 overexpression impairs cell adhesion (Yu et al., 2006b), is pro-apoptotic (Yu et al., 
2006b, Yao et al., 2011) and causes less Akt phosphorylation following EGF-stimulation 
(Yao et al., 2011). The role for DPP9-mediated proteolysis in antigen presentation 
involves DPP9 being rate-limiting for degradation of antigenic proline-containing 
peptides including the tumour-related antigen RU134-32  (Geiss-Friedlander et al., 2009). 
DPP9 is in B cells and both CD4+ and CD8+ lymphocytes and is upregulated by mitogen 
stimulation (Yu et al., 2009, Chowdhury et al., 2013). Inhibiting DPP9 and DPP8 
enzymatic activity dampens lymphocyte proliferation (Lankas et al., 2005, Reinhold et 
al., 2009) making DPP9 important in immunobiology. DPP9 and DPP8 enzymatic activity 
can protect Ewing sarcoma cells from neuropeptide Y (NPY)-driven death (Lu et al., 
2011). The potential importance of DPP9 in tumour biology has also been shown by 
inhibition of DPP9 and DPP8 enhancing parthenolide’s anti-leukemic activity in primary 
acute myeloid leukemia samples and lymphoma and leukemia cell lines (Spagnuolo et 
al., 2013). Moreover, an adjuvant effect triggered by inhibition of DPP9 and DPP8 
appears to be a mechanism by which the compound Val-boro-Pro mediates tumour 
regression (Walsh et al., 2013). DPP9 binds to the oncogene and GTPase H-Ras, but the 
functional consequences are unclear (Yao et al., 2011). Many cancers display 
upregulated DPP9 expression (Yu et al., 2009, Olsen and Wagtmann, 2002, Ajami et al., 
2004, Stremenova et al., 2010). 
 
While DPP4 and FAP are predominantly expressed on the cell surface, DPP9 and DPP8 
are intracellular enzymes that are ubiquitously expressed in tissues and most cell lines 
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(Yu et al., 2010, Yu et al., 2009). DPP9 and DPP8 are strongly expressed in lymphocytes 
and epithelial cells and in lymph node, thymus, spleen, liver, lung, intestine, pancreas, 
muscle and brain (Yu et al., 2009, Chowdhury et al., 2013, Schade et al., 2008, Harstad 
et al., 2013). Little is known of the natural substrates of DPP9 but it can cleave the DPP4 
substrates glucagon-like peptide (GLP)-1, GLP-2, peptide YY and NPY in vitro and may 
cleave NPY inside cells (Lu et al., 2011). Some very recently identified potential DPP9 
substrates, including adenylate kinase 2 and calreticulin, suggest a potential role in 
energy homeostasis (Wilson et al., 2013). These data suggest that the biological roles of 
DPP9 in vivo are probably diverse such that the major role of DPP9 may be elusive. 
 
Until now, no lethal gene knockout (GKO) mouse for a protein that possesses DPP 
activity has existed (Yu et al., 2010). The DPP4-GKO and FAP-GKO mice are 
phenotypically healthy (Yu et al., 2009, Niedermeyer et al., 2001, Marguet et al., 2000). 
DPP4-GKO mice have improved glucose tolerance after a glucose challenge and resist 
diet-induced obesity (Marguet et al., 2000, Conarello et al., 2003). Both DPP4- and FAP-
GKO mice have reduced fibrosis in liver injury (Wang et al., 2007). The knockout mice 
have been useful tools in evaluating the therapeutic potential of DPP4 and FAP enzyme 
inhibitors. However, care is necessary in evaluating such studies, as these animals have 
complete ablation of all protein function, rather than specific ablation of the enzymatic 
function alone (Yu et al., 2010, Keane et al., 2012). 
 
A report that certain DPP inhibitors that inhibit DPP9 and DPP8 activity are toxic in vivo 
(Lankas et al., 2005) is controversial (Kirby et al., 2010). Several subsequent studies 
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indicate that DPP9 and DPP8 (Wu et al., 2009) or DPP9, DPP4 and DPP8 (Wang et al., 
2012, Burkey et al., 2008) can be inhibited in adult rodents without harm. 
Structurally, DPP9 is predominantly a dimer (Tang et al., 2011) and has high sequence 
and topological homology with DPP4 (Ajami et al., 2004), as best seen by protein 
structure modeling (Park et al., 2008). Human recombinant DPP9 and natural bovine 
DPP9 protein have been characterized (Ajami et al., 2004, Park et al., 2008, Dubois et 
al., 2010). Interestingly, DPP9 protease activity may be influenced by several natural 
processes. It is redox-responsive; in oxidizing conditions the enzymatic activity is 
inhibited, likely due to reversible intra-molecular disulfide bonding between cysteine 
residues (Park et al., 2008). DPP9 is acetylated (Choudhary et al., 2009), which might 
influence activity. DPP9 has a novel SUMO1-specific interacting motif that, when 
engaged, allosterically upregulates DPP9 enzymatic activity (Pilla et al., 2012). Such 
changes in DPP9 enzymatic activity would be expected to influence downstream 
signaling pathways. 
 
DPP9 has an active-site catalytic triad that is conserved across the DPP4 protein family 
and can hydrolyse the post-proline bond two residues from the N-terminus of peptide 
substrates. The DPP4 family proteins are atypical serine proteases that have the 
catalytic triad in the reverse order to trypsin and are unusual in that the catalytic pocket 
is buried within the protein. In the 863 amino acid isoform (short form) of DPP9, the 
triad consists of Ser729, Asp807 and His839. We showed that mutation of the catalytic 
serine of DPP9 to alanine in amino acid position 729 of the short form of DPP9 (S729A) 
ablates enzymatic activity without affecting other characteristics of this protein (Yao et 
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al., 2011, Ajami et al., 2003). To examine the in vivo significance of DPP9 enzymatic 
activity, the first GKI mouse was generated containing the S729A point mutation. This 
biological strategy is expected to mimic the effect of a non-toxic selective DPP9 
inhibitor administered from the time of fertilisation. 
 
3.2.2 Materials and Methods 
 
3.2.2.1 Ethics statement 
The animal experiments were approved by the local Animal Ethics Committee of the 
University of Sydney (Ethics protocols K75/6-2012/3/5753 ‘Production of mice for 
studies on dipeptidyl peptidases’ and K75/5-2012/3/5754 ‘The biological roles of 
dipeptidyl peptidases’) and conducted in accordance with all applicable laws and 
guidelines. 
3.2.2.2 Generation of DPP9 enzyme-inactive mice 
Generation of DPP9 enzyme-inactive mice was performed by Ozgene (Bentley, Western 
Australia) using standard techniques. The DPP9 targeting construct was generated by 
cloning polymerase chain reaction (PCR) products of the 5’ and 3’ homology arms, as 
well as a short loxP arm containing the S729A mutation (Figure 3.1A), into the plasmid 
backbone, FLSniper (Ozgene), which contained the Phosphoglycerate Kinase (PGK) - 
Neo cassette flanked by Flippase Recognition Target (FRT) sites. The S729A mutation 
was generated by point mutagenesis of the sequence TCC TAC to GCA TAT, which 
introduced an NdeI restriction enzyme site for Southern blot screening. To allow for 
conditional deletion of DPP9 gene expression, the same exon containing the S729A 
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point mutation was flanked with loxP sites (exon 20 in the DPP9 short form), providing 
the option of exon deletion using Cre-recombinase and hence disruption of the entire 
protein molecule. In this study, this built-in strategy for exon excision was not utilised. 
The targeting construct was electroporated into C57BL/6 Bruce 4 embryonic stem (ES) 
cells and clones were selected for neomycin resistance. Southern blot analyses (Figure 
3.1B, Table 3.1) identified successfully targeted DPP9wt/flox ES cells. The clone chosen for 
generating the mutant mice, 1G6, was analysed by Southern blot and verified to be 
correctly targeted at each end of the construct (Figure 3.1B). Probing the blot with a 
neomycin probe confirmed a single integration event (data not shown).  
The DPP9wt/flox ES clone was microinjected into BALB/c blastocysts which were 
implanted into pseudo-pregnant foster mothers. Chimeric male mice from the resultant 
litters were mated with C57BL/6 wild-type females and offspring with coat-colour 
transmission were genotyped for germline transmission of the S729A mutation by 
Southern blot of tail DNA (Figure 3.1B). Genotyping confirmed germline transmission of 
the DPP9 serine-to-alanine point mutation locus. 
The neo cassette was FLPe-deleted in vivo using the FRT sites by mating heterozygous 
DPP9wt/flox mutant males with transgenic female wt/FLPe mice expressing the enzyme 
Flp recombinase. Southern blot genotyping of offspring confirmed deletion of the PGK-
neo selection cassette. Resultant positive offspring (DPP9wt/S729A) were mated with 
C57BL/6 mice for removal of the FLPe gene. 
Routinely, DPP9wt/S729A intercross progeny were genotyped by Southern Blot using the 5’ 
or 3’ probes (Figs. 3.1A and 3.1B, Table 3.1), or by PCR using primers (Figure 3.1C, Table 
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3.2) and Advantage2 Taq Polymerase (Clontech, Mountain View, CA). The PCR cycles 
used were 940C for 2 min, then 940C for 30 sec, 600C for 30 sec, 680C for 30 sec 
repeated 39 times followed by 680C for 10 min and 100C on hold. Sequencing of gel- 
isolated PCR product confirmed the correct amplification of the mutant allele region 
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and the presence of the S729A mutation in the 349 bp PCR fragment 
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Table 3.1: Southern blot strategy for screening of DPP9S729A mice.  
 
Southern blot analyses identified successfully targeted DPP9wt/flox embryonic stem cells using 
probes described in this table. *NdeI restriction site was inserted during introduction of 
DPP9S729A mutation. 
 
 
 
Probe enP probe 5’ probe 3’ probe 5’ probe 5’ probe 
Restriction enzyme BamHI BamHI Sca I Nhe I Nde I * 
DPP9wt allele (kb) 14.3 14.3 8.8 13.6 23.0 
DPP9flox allele (kb) 5.7 10.8 6.7 7.5 9.4 
DPP9S729A allele (kb) 3.7 10.8 6.7 7.5 9.4 
Figure 3.1: Generation of DPP9wt/S729A mice.  
(A) Representation of the DPP9 wild-type locus, targeting vector, targeted locus, and FRT 
recombined locus. 5’ probe, 3’ probe, enP probe, approximate PCR screening primer 
positions (open arrowheads) and restriction sites (Nh- NheI, S- ScaI, Nd- NdeI, B-BamHI) are 
indicated.  
(B) Southern blot screening confirming targeted recombination at each end of DPP9 locus: 
enP probe on BamHI digest (DPP9wt/wt, DPP9wt/flox and DPP9wt/S729A offspring from a wt/flox x 
FLPe mating), 3’ probe on ScaI digest and 5’ probe on BamHI (ES cell clone 1G6 used for 
microinjection). Expected sizes for wild-type and DPP9 targeted locus were detected (Table 
3.1).  
(C) PCR screen distinguishing wild-type, DPP9S729A/S729A homozygote and DPP9wt/S729A 
heterozygote ED17.5 littermate embryos (wt allele, 142 bp; DPP9S729A allele, 349bp). 
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Table 3.2: PCR primers for routine screening of DPP9S729A  mice/ embryos/ MEFs.  
 
DPP9wt/S729A intercross progeny and MEFs generated from these progeny were genotyped by 
PCR using primers and PCR cycle outlined above. 
 
 
 
3.2.2.3 Embryonic and early neonate studies 
Embryonic day (ED) 12.5 (ED12.5), ED13.5, ED15.5 and ED17.5 embryos were harvested 
from DPP9wt/S729A intercrosses. Umbilical cord or embryonic tail was proteinase K- 
treated for genotyping, while the rest of the embryo was formalin fixed overnight. 
For post-natal studies, both observational and experimental studies were undertaken to 
define the phenotype. In observational studies, hourly litter examinations from birth 
ensured retrieval of non-surviving pups for genotyping and formalin fixation. All pups 
were closely observed for physical activity, breathing difficulties and unusual 
behaviours or appearance. In litters used for experimental studies, all pups were 
euthanised within six hours of birth, tails retained for genotyping and head and body 
fixed in 10% neutral buffered formalin. 
 
Primer name mDPP9_E20.F mDPP9_i20.R 
Sequence (5’ - 3’) AAGTATGGCTTCATTGACTTGAGC GGTGGGCATCAGGCTGCAGGTGG 
Wild-type allele (bp) 142 
DPP9S729A allele (bp) 349 
Annealing temp. (ºC) 64 
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3.2.2.4 Histochemical studies 
To undertake histological observations, paraffin-embedded pups were sectioned at 5 
µm and H&E stained. To immunolocalise DPP9 protein, the anti-DPP9 antibody (Abcam; 
Cambridge, UK, #ab42078, 1:100) was used which bound to both the wild-type and 
S729A DPP9 proteins. Briefly, 5 µm sections were deparaffinised and rehydrated and 
then a pressure cooker and Universal Decloaker solution (Biocare Medical, Concord, CA) 
was used to retrieve antigen. Sections were then covered with Background Sniper 
(Biocare Medical) for 10 mins, rinsed in PBS and incubated at room temperature for 1 h 
with primary antibody with 1% BSA in PBS and Renaissance Background Reducing 
Diluent (Biocare Medical). After thorough washing in PBS, sections were incubated for 
30 mins with goat anti-rabbit conjugated to HRP (Dako, Glostrup, Denmark, #P0448, 
1:100), washed and then stained in 3,3-diaminobenzidine (DAB) with H2O2. Bright-field 
imaging was performed using a Leica DM6000B microscope. 
 
3.2.2.5 Immunofluorescence Imaging 
DPP9-WT-EGFP and enzyme-inactive mutant DPP9-S729AEGFP constructs [10] were 
transiently transfected into human hepatocarcinoma cell line (Huh7) cells using 
Lipofectamine® 2000 (Invitrogen, Carlsbad, CA, USA) at 0.4 mg/mL. Forty hours post-
transfection, cells were fixed with 4% paraformaldehyde as described previously (Yu et 
al., 2006b). Immunostaining used rabbit anti- DPP9 antibody (Abcam, #ab42080, 1:200), 
Alexa Fluor® 647 goat anti-rabbit IgG (Invitrogen, #A-21245, 1:200) and DAPI 
counterstain. Z-stack images were captured on a Leica TCS SP5 confocal microscope and 
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the stacks above and below the nucleus were removed. The remaining stacks were 
reconstructed into a z-projection with ImageJ software. 
 
3.2.2.6 SDS-PAGE urine analysis 
In litters used for detection of protein in urine, pups were euthanised within 6 hours of 
birth by decapitation, then urine collected and analysed by a method modified from 
Putaala et al (Putaala et al., 2001). Briefly, 3 µL of urine from each pup together with 1 
µL of SDS-sample buffer was run on a 4-12% Bis-Tris SDS-PAGE gel (Invitrogen) under 
non-reducing conditions. Gels were stained with Coomassie Blue. 
Supplementary to the data contained in this section, additional SDS-PAGE analysis of 
urine samples was carried out to identify low molecular weight proteins and is 
described in Section 3.3.2. 
 
3.2.2.7 Generation and immortalisation of mouse embryonic fibroblasts (MEFs) 
ED13.5 embryos from DPP9wt/S729A intercrosses were harvested under sterile conditions 
and MEFs prepared using standard protocols (Xu, 2005). Briefly, the uterus of each 
pregnant mouse was removed post mortem and each embryo separated from its 
placenta and surrounding membranes and placed in complete growth medium (DMEM 
with 10% FCS). The embryonic liver and head were removed and then the body was 
homogenised in TrypLE (Life Technologies, Mulgrave, Victoria, Australia) using a syringe 
and 23 G needle. The homogenate was incubated at 370C for 10 min before transfer to 
complete growth medium and culturing at 370C with 5% CO2 as passage zero. 
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Genotyping by PCR was performed on DNA isolated from embryonic head treated with 
proteinase K using the Wizard® Genomic DNA isolation kit (Promega, Madison, WI, 
USA). 
After the third passage, primary MEFs from wild-type and DPP9S729A/S729A littermates 
were infected with SV40 large T antigen-expressing lentivirus to generate immortal cell 
lines (Vince et al., 2007). Briefly, primary MEFs were transduced with the pFU-SV40-LT-
puro lentiviral vector encoding the SV40 large T antigen pseudotyped with the Moloney 
murine leukemia virus ecotropic envelope (pCAG4-Eco) and the structural component 
(pCMV δ R8.2). Cells (1x105) plated out 24 h earlier were transduced in 6-well culture 
plates containing 2 mL complete growth medium and 8 µg/mL Polybrene (Sigma-
Aldrich, Castle Hill, Australia), ‘spinoculated’ at 1,500 rpm for 1 h and then cultured for 
4 days at 370C. Puromycin selection (1 µg/mL) was added for 3 days to remove non-
transduced cells. Colonies of immortalised MEFs emerged after 10 days. 
 
3.2.2.8 Enzyme assays 
DPP8/9 enzyme assay using the DPP fluorogenic substrate H-Gly-Pro-AMC (Mimotopes, 
Clayton, Victoria, Australia) was adapted from described methods (Yu et al., 2009, 
Keane et al., 2011). Briefly, 3x104 MEF cells or 10 µg of liver sample lysate per well were 
added to black 96-well plates (Greiner Bio One, Frickenhausen, Germany) in triplicate in 
the presence or absence of a selective DPP4 inhibitor, sitagliptin (Merck, Rahway, NJ, 
USA), at 1 µM and TE buffer to a volume of 50 µL per well. 50 µL of substrate was added 
to a final reaction concentration of 1 mM in TE buffer (pH 7.6) with 5% methanol. The 
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fluorescence produced by substrate cleavage was monitored every 5 min over 1 h at 
370C in a Polarstar Omega microplate reader (BMG Labtech, Offenburg, Germany) with 
excitation at 355 nm and emission at 450 nm. 
 
3.2.2.9 Immunoblotting 
For immunoblot sample preparation, MEFs were harvested by trypsinisation and 
washed with ice-cold PBS before re-suspension in ice-cold lysis buffer (50 mM Tris-HCl, 
1 mM EDTA, 1 mM MgCl2, 150 mM NaCl, 1% Triton-114, 10% glycerol, 1 x Roche 
complete protease inhibitor cocktail (Roche Applied Science, Indianapolis, IN, USA; pH 
7.6) and stored at -200C. Frozen neonate mouse liver samples were homogenised in 
lysis buffer using a bead-based homogeniser (TissueLyser, Qiagen Venlo, Netherlands) 
at 40C. Protein concentration was determined using the Micro BCA Protein Assay Kit 
(Thermo Scientific, Waltham, Massachusetts, USA) following the manufacturer’s 
protocol. 
Whole cell lysates (50 µg protein per track) were resolved on 4–12% Bis-Tris SDS-PAGE 
(Invitrogen) followed by immunoblotting with anti-DPP9 antibody (1:2000) (Yao et al., 
2011) and anti-β-Actin (Sigma-Aldrich, #A2103, 1:5000). Relative band intensities were 
quantitatively analysed using ImageJ and normalised against control proteins as 
indicated. 
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3.2.2.10 Quantitative real-time PCR (qPCR) 
Total RNA was isolated using Trizol (Invitrogen) and cDNA synthesis was performed 
using SuperScript VILO cDNA Synthesis Kit (Invitrogen). qPCR was performed as 
described previously  (Chowdhury et al., 2013) using Taqman gene expression assays 
(Applied Biosystems, Foster City, CA, USA) for mouse DPP4 (Mm00494548_m1), DPP8 
(Mm00547049_m1), DPP9 (Mm00841122_m1) and FAP(Mm00484254_m1), with β-
Actin (Mm00607939) as a standard. 
 
3.2.3 Results 
 
3.2.3.1 DPP9S729A/S729A homozygotes die in the neonatal period 
Heterozygous DPP9wt/S729A mice on a C57BL/6 background were generated and supplied 
to our lab where sequencing of purified PCR products verified the presence of the 
S729A mutation in the DPP9 allele (Figure 3.1). However, intercrossing of DPP9wt/S729A 
mice and subsequent absence of any detectable DPP9S729A/S729A homozygote offspring at 
weaning was suggestive of lethality. 
To determine the time of death, litters were observed and genotyped at embryonic and 
early neonatal stages. Live homozygote embryos and pups were detected in ED 12.5, 
13.5, 15.5, 17.5 and early neonate (Day 1) litters. Analysis of embryo genotype numbers 
(n =41) confirmed that the DPP9 S729A allele was present in the expected Mendelian 
frequency (Section 3.3.1, Table 3.6). Thus, it appeared that enzyme-active DPP9 is not 
essential for development of the mouse embryo to term. 
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Directly after birth, normal cyanosis was present and all pups breathed normally and 
became pink (n=92). Littermates were of a similar size and weight with no significant 
gender or genotype difference found for Day 1 neonates (p>0.05) (Table 3.3). All 
appeared to feed normally with milk in the stomach shown by a milk spot and later by 
histological examination of whole neonate sections. At this early stage, pups showed no 
discernible behavioral differences, however, after several hours, some pups were found 
dead or showing weak respiratory movements and lethargy. There were no visual 
differences between genotypes in skin color or hydration. 
 
 
Table 3.3: Average neonate weights (in grams) for genotype and gender on Day 1 after 
birth.  
 
Observed weights are expressed as the mean ± standard deviation. 
 
 
 Genotype Gender 
 DPP9S729A/S729A DPP9wt/S729A DPP9wt/wt Total ♂ ♀ Total 
Neonate 
number 
21 53 18 92 40 52 92 
Observed 
average 
weight 
1.09 ± 0.13 1.12 ± 0.13 1.16 ± 0.11  
1.13 ± 
0.13 
1.09 ± 0.12  
Expected 
average 
weight 
1.12 1.12 1.12  1.12 1.12  
 χ2 = 0.002      p = 0.999 χ2 = 0.003      p = 0.959 
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Investigating the mortality of newborn pups revealed that, of the 27 found dead in the 
first 24 hours, all were either DPP9S729A/S729A or DPP9wt/S729A. This suggested a negative 
effect on survival to weaning for offspring carrying the S729A mutation. 
Subsequent genotyping of newborn DPP9wt/S729A intercross pups showed that the DPP9 
S729A allele occurred in the expected Mendelian ratios. From 33 litters from 
DPP9wt/S729A breeding pairs, 317 pups were produced with 68 DPP9S729A/S729A, 167  
DPP9wt/S729A and 82 DPP9wt/wt. Chi-square analysis confirmed no significant deviation 
from a 1:2:1 ratio (p>0.05). Similarly, a lack of significant gender bias shown in neonates 
precludes a gender effect by the DPP9 S729A allele on embryonic development (Table 
3.4). 
 
 
 
Table 3.4: Neonate mouse genotype and gender numbers and ratios compared to expected 
Mendelian ratios.  
 Genotype Gender 
 DPP9S729A/S729A DPP9wt/S729A DPP9wt/wt Total ♂ ♀ Total 
Observed 
number 
68 167 82 317 123 147 270 
Expected 
number 
79.25 158.5 79.25  135 135  
Expected 
ratio 
0.25 0.5 0.25  0.5 0.5  
Actual ratio 0.21 0.53 0.26  0.46 0.54  
 χ2 = 2.148      p = 0.342 χ2 = 2.133      p = 0.144 
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At weaning, from 110 tracked DPP9wt/S729A intercross litters resulting in 563 weaned 
pups, only DPP9wt/S729A and DPP9wt/wt pups were present with no DPP9S729A/S729A pups. 
Interestingly, Chi-square analysis showed a significant bias towards DPP9wt/wt pups (p 
=0.008), rather than an expected 2:1 genotype ratio (Table 3.5). This confirmed a 
heterozygous effect on survival to weaning. The group of surviving DPP9wt/S729A 
heterozygous pups also showed a slight variation from a 1:1 ratio of males to females 
(Table 3.5), however this result is consistent with previous studies on mouse sex ratios 
(Rugh, 1968, Hardy, 1997, Schlager and Roderick, 1968) and, thus, not attributable to 
the heterozygous effect. There was no gender bias amongst pups that did not survive to 
weaning. 
 
 
 
 
 
 
 
 
 
 
Table 3.5: Weaned mouse genotype and gender numbers and ratios compared to expected 
Mendelian ratios.  
 Genotype Gender 
 DPP9wt/S729A DPP9wt/wt Total ♂ ♀ Total 
Observed 
number 
346 217 563 307 256 563 
Expected 
number 
375.5 187.5  281.5 281.5  
Expected ratio 0.67 0.33  0.50 0.50  
Actual ratio 0.62 0.38  0.55 0.45  
 χ2 = 6.969      p = 0.008 χ2 = 4.620      p = 0.032 
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Therefore, while the DPP9S729A/S729A embryos and neonates were indistinguishable 
morphologically from their wild-type and heterozygote littermates, neonates died 
shortly after birth indicating that DPP9 enzymatic activity is required for neonatal 
survival. 
 
3.2.3.2 Early neonate DPP9S729A/S729A homozygotes show no histological, 
histochemical or urinary protein difference from their heterozygous and wild-
type littermates 
 
Light microscopic observations of H&E-stained whole neonate sections (Day 1) by a 
trained pathologist (Derek S Spielman) revealed no histological differences between 
DPP9S729A/S729A pups (n =4) and their DPP9wt/S7 29A (n= 2) and DPP9wt/wt (n= 4) littermates. 
Organs examined were gut, heart, lung, brain and skin (Figure 3.2A) along with kidney, 
liver, thymus (Figure 4.5), pancreas, muscle and cartilage (Figure 4.6).     
Immunohistochemistry using an antibody specific to DPP9 (Harstad et al., 2013) that 
has been used extensively by us (Yao et al., 2011, Yu et al., 2009, Chowdhury et al., 
2013) and others  (Harstad et al., 2013, Dubois et al., 2009), showed no DPP9 
localisation differences between DPP9wt/wt, DPP9wt/S729A or DPP9S729A/S729A on early whole 
neonate sections. Many neonate organs were strongly immuno-positive for DPP9 
protein, most notably kidney, skin, liver (Figure 3.2B), brain and thymus. Overall, the 
immunostaining was consistent with published data (Yu et al., 2009, Schade et al., 
2008). 
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Figure 3.2: Histology and immunohistochemistry of early neonate tissues are comparable 
between genotypes.  
 
(A) Light micrographs of H&E-stained DPP9S729A/S729A lung, heart, gut, brain and skin tissue 
compared to DPP9wt/wt show no differences in histological structure and (B) Anti-DPP9 
antibody staining showed no DPP9 localisation differences between DPP9wt/wt and 
DPP9S729A/S729A early neonate sections. Scale bar 50µm. 
 
 
Neonatal death of mice within 24 hours of birth can be due to nephrin deficiency and, 
hence, massive proteinuria (Putaala et al., 2001). SDS-PAGE analysis of urinary protein 
in early neonates (Section 3.3.2) showed no proteinuria and no urinary protein band 
differences between DPP9wt/wt, DPP9wt/S729A or DPP9S729A/S729A littermates, thus excluding 
renal damage as a cause of death. 
 
3.2.3.3 DPP9S729A/S729A mouse embryonic fibroblasts express intact DPP9 mRNA and 
enzyme-inactive DPP9 protein 
 
To verify the expression of DPP9 enzyme-inactive protein, immortalised MEFs and 
neonate livers of DPP9S729A/S729A and wild-type littermates were characterised for DPP 
mRNA and protein expression and activity. DPP9 protein and mRNA levels were 
measured by immunoblot and qPCR respectively. 
                                          Chapter 3: DPP9 enzyme deficiency in the mouse     
 
70 
 
qPCR results indicated that DPP9S729A/S729A MEFs and neonatal liver expressed similar 
levels of DPP9 mRNA, as well as FAP, DPP8 and DPP4 mRNA, to wild-type (Figs. 3.3A and 
3.3B). When immunoblotting with a DPP9 antibody, DPP9 bands run at different sizes in 
different cell lines   (Yao et al., 2011, Chowdhury et al., 2013). Immunoblotting of MEFs 
showed similar levels of intact DPP9 protein expression in DPP9S729A/S729A MEFs and wild-
type MEFs (110 and 130 kDa) (Figure 3.3C) and was confirmed by densitometry (Figure 
3.3D). These results demonstrated that the targeted point mutation did not influence 
the expression of DPP9 mRNA and protein. In addition, it indicates that there was no 
detectable compensatory upregulation of the other DPPs due to the lack of DPP9 
enzymatic activity. 
Enzyme activity derived from DPP9 and DPP8 can be measured in the presence of a 
DPP4 inhibitor and a substrate that is hydrolysed by all three proteases (Yu et al., 2009). 
Enzyme activity assays on whole MEFs showed that DPP9S729A/S729A MEFs had 
significantly less DPP enzymatic activity than wild-type MEFs (Figure 3.3E). Moreover, in 
neonatal liver lysates (Figure 3.3F), DPP9S729A/S729A neonatal liver contained significantly 
less DPP8/ 9-derived enzymatic activity than wild-type liver, which is consistent with a 
lack or large reduction of DPP9 enzymatic activity. Together with the immunoblot and 
qPCR data, this provides evidence that DPP9-S729A enzyme-inactive protein was 
expressed at similar levels to DPP9-WT enzyme-active protein in MEF cell lines and 
neonatal livers. 
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3.2.3.4 DPP9-S729A and wild-type DPP9 have the same subcellular localisation 
A point mutation in rat DPP4 (Erickson et al., 1992) causes mis-localisation and 
intracellular degradation of DPP4 rather than normal cell surface expression. To 
examine whether enzyme- inactive DPP9 protein and active DPP9 protein are similarly 
localised in vitro, DPP9- overexpressing Huh7 cells and endogenous DPP9 in MEFs were 
examined by immunofluorescence staining and confocal microscopy. DPP9-S729A-EGFP 
had an intracellular distribution similar to DPP9-WT-EGFP (Figure 3.4A). Similarly, 
endogenous DPP9 expression in DPP9S729A/S729A MEFs was indistinguishable from DPP9 
protein in wild-type MEFs (Figure 3.4B). 
 
Figure 3.3: DPP9 expression in DPP9wt/wt and DPP9S729A/S729A MEFs and neonatal liver is 
equivalent.  
By qPCR, (A) DPP9S729A/S729A MEFs (n=3) and (B) neonatal liver (n=8) showed similar mRNA 
expression levels of DPP4, DPP8, DPP9 and FAP compared to DPP9wt/wt.  
(C) Similar levels of intact DPP9 protein were detected by immunoblotting in DPP9S729A/S729A 
MEFs compared to DPP9wt/wt littermate MEFs.  
(D) Densitometry analysis of this immunoblot; the 110 kDa and 130 kDa bands were 
combined. DPP8/9 enzyme assays showed less enzymatic activity in (E) DPP9S729A/S729A MEFs 
compared to WT MEFs (n=3), **p < 0.001 and (F) DPP9S729A/S729A neonatal livers (n=4) 
compared to WT livers (n=6), *p < 0.05.  
The DPP enzyme activity contributed by DPP9 and DPP8 is the proportion of non-inhibited 
control activity which was calculated as the hydrolysis of H-Gly-Pro-AMC observed after 
inhibition of DPP4 by sitagliptin. dF is change in fluorescence. 
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Figure 3.4: Active DPP9-WT and enzyme-inactive DPP9-S729A show the same intracellular 
localisation.  
 
DPP9-EGFP visualisation in Huh7 cells transfected with (A) DPP9-WT-EGFP or (B) DPP9-S729A-
EGFP showed no localisation difference. Similar expression patterns of antibody-stained DPP9 
(red) were observed in (C) wild-type MEFs and (D) DPP9S729A/S729A MEFs. Confocal images were 
created only from Z-stacks that contained the nuclear region. Scale bar 15 μm. 
 
 
                                          Chapter 3: DPP9 enzyme deficiency in the mouse     
 
74 
 
3.2.4 Discussion 
 
In this study, we found that DPP9 enzymatic activity is essential for neonatal survival in 
the mouse. The mice express intact DPP9 protein but with the loss of enzymatic activity. 
This did not alter pre-natal development but resulted in neonatal deaths. Thus, the 
complete disruption of DPP9 expression was not necessary for early lethality, 
highlighting the biological importance of the enzyme activity of DPP9 at this stage of 
development. The lethality of lacking DPP9 activity indicates that DPP9 is unique such 
that no other enzyme can compensate for this enzyme at this developmental stage. The 
cause of death was not apparent. All neonates suckled and contained milk spots and 
males and females of each genotype were of similar body weight. No differences were 
seen by histological examination and no urinary proteinuria was observed. 
The close structural similarity of DPP9 to DPP8 makes the development of selective 
DPP9 inhibitors challenging (Van Goethem et al., 2011, Rummey and Metz, 2007) and 
has not been achieved. Thus, the DPP9 enzyme-inactive mouse is a useful and unique 
model for emulating the biological effects of selective DPP9 inhibition from the 
embryonic stage and avoids potential off-target effects that chemical compounds may 
produce in mice. Our genetic targeting approach is the only DPP9-specific model for 
understanding the biological significance of DPP9 enzymatic activity in vivo. The biology 
in this model is very different to previous studies that have treated adult animals with 
inhibitors of both DPP9 and DPP8 or of DPP9, DPP4 and DPP8 together (Wu et al., 2009, 
Wang et al., 2012, Burkey et al., 2008). 
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To verify the status of DPP9 protein in our mice, the MEF and neonatal liver data 
indicate that the S729A mutation produced a full-length DPP9 protein with no 
enzymatic activity. Comparable sizes and intracellular localisations of DPP9 intact 
protein and similar DPP mRNA levels were shown in DPP9 enzyme-inactive MEFs 
compared to MEFs and neonatal liver derived from wildtype littermates. In addition, 
related dipeptidyl peptidases were not upregulated in the DPP9 enzyme-inactive mouse 
to compensate for the absence of DPP9 activity. We similarly observed in our enzyme 
distribution studies on DPP4-GKO mice (Yu et al., 2009) and FAP-GKO MEFs (Hamson, 
Yu, Gorrell, unpublished data) that DPP4-related dipeptidyl peptidases are not 
upregulated in those mouse strains. 
Like DPP9, DPP8 has intracellular expression (Yu et al., 2006b, Abbott et al., 2000b) and 
DPP4, FAP and DPP8 all have DPP enzymatic activity (Kirby et al., 2010, Yu et al., 2009, 
Ajami et al., 2004, Abbott et al., 2000b, Heymann and Mentlein, 1978, Park et al., 1999, 
Wang et al., 2005, Abbott et al., 1999). Since DPP4-GKO and FAP-GKO mice are 
phenotypically healthy, DPP9 neonate lethality was unexpected. This lethality shows 
that DPP4, DPP8 and FAP are unable to fulfill an essential role of DPP9 in early mouse 
neonate life, thereby highlighting a unique role for DPP9 activity within the DPP4 gene 
family. 
Many factors can contribute to neonate deaths but the time of death can provide clues 
to the potential causes (Turgeon and Meloche, 2009). While there are numerous 
examples of neonatal lethality in genetically modified mice (Turgeon and Meloche, 
2009), very few die so quickly and without morphological differences from their 
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heterozygous or wild-type littermates. Having survived the stress of parturition, 
neonates fulfill new metabolic needs by their own homeostasis, failure of which can 
result in poorer survival. As the DPP9S729A/S729A pups survived parturition with no 
obvious gross anatomical and histological differences, it seems the resultant lethality in 
DPP9S729A/S729A mice is probably attributable to metabolic impairment (Chen et al., 
2016). The literature reports dysfunctions in homeostasis due to failures in autophagy 
(Kuma et al., 2004), kidney filtration (Putaala et al., 2001), transcriptional controls in cell 
nuclei (Calogero et al., 1999) and in vivo glucose homeostasis (Scheuner et al., 2001). 
The nature of the dysfunction caused by lacking DPP9 enzymatic activity at birth needs 
to be elucidated by further investigations. 
 
 
3.3 Supplementary data 
 
This section includes data not shown in Section 3.2 (published paper) but undertaken as 
part of the neonate mouse studies to identify the lethal phenotype and discussed in the 
Results (Section 3.2.3) and Discussion (Section 3.2.4). 
 
3.3.1 Embryo studies 
Initial investigations of the DPP9 mouse showed that no DPP9S729A/S729A mice were 
present at weaning. To more accurately observe times of death of DPP9S729A/S729A 
neonatal mice, litters were first observed and genotyped at embryonic stages. Live 
homozygote embryos were detected in ED (embryonic day) 12.5, 13.5, 15.5 and 17.5 
litters.  
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Analysis of embryo genotype numbers (n=41) harvested from pregnant females at 
various embryonic stages confirmed that the DPP9 S729A allele was present in the 
expected Mendelian frequency as indicated by the high p value (Table 3.6). This 
confirmed that enzyme-active DPP9 is not essential for development of the mouse 
embryo to parturition (Gall et al., 2013). 
 
 Genotype 
 DPP9S729A/S729A DPP9wt/S729A DPP9wt/wt Total 
Observed number 5 24 12 41 
Expected number 10.25 20.5 10.25  
Expected ratio 0.25 0.5 0.25  
Actual ratio 0.12 0.59 0.29  
 χ2 = 3.585      p = 0.167 
 
Table 3.6: Total embryo genotype numbers compared to expected Mendelian ratios. 
 
 
3.3.2 Neonate and weaned mouse gender analysis 
As discussed in Section 3.2.3.1, no gender bias was observed in total neonate numbers 
(Table 3.4) or total weaned mouse numbers (Table 3.5). While this finding suggests that 
a gender bias within genotype groups is unlikely, analysis was undertaken to confirm 
this. These analyses showed no difference in the expected 1:1 Mendelian ratio between 
male and female neonates for each genotype group (Table 3.7). Similarly, for the mice 
which survived to weaning (Table 3.8) , there was a slight bias towards male mice for 
the WT genotype consistent with with previous studies on mouse sex ratios (Rugh, 
1968, Hardy, 1997, Schlager and Roderick, 1968).  
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Genotype 
DPP9S729A/S729A DPP9wt/S729A DPP9wt/wt 
Gender 
♂ ♀ ♂ ♀ ♂ ♀ 
Observed number 
56 50 112 119 54 47 
Expected number 
53 53 115.5 115.5 50.5 50.5 
Expected ratio 
0.5 0.5 0.5 0.5 0.5 0.5 
Actual ratio 
0.53 0.47 0.48 0.52 0.53 0.47 
χ2 
0.339 0.212 0.485 
p value 
0.560 0.645 0.486 
 
Table 3.7: Neonate mouse gender numbers and ratios for each genotype compared to 
expected Mendelian ratios. 
Genotype DPP9wt/S729A DPP9wt/wt 
Gender ♂ ♀ ♂ ♀ 
Observed number 183 163 124 93 
Expected number 173 173 108.5 108.5 
Expected ratio 0.5 0.5 0.5 0.5 
Actual ratio 0.53 0.47 0.57 0.43 
χ2 1.156 4.429 
p value 0.282 0.035 
 
Table 3.8: Neonate mouse gender numbers and ratios for each genotype compared to 
expected Mendelian ratios. 
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3.3.3 Neonate urinalysis 
 
3.3.2.1 Introduction 
 
The kidney plays a critical role in regulation of fluid homeostasis and mice which 
completely lack genitourinary structures die soon after birth (Miyamoto et al., 1997). 
Most newborn mice with kidney anomalies die in the first 2 days of life, with the timing 
dependent on the defect severity (Turgeon and Meloche, 2009). The normal gross 
morphology and histology of the kidneys of DPP9S729A/S729A pups meant that any of the 
many known developmental renal defects are very unlikely to occur in this mouse 
strain. 
Defects in kidney function that impair production and concentration of urine, however, 
are more subtle and harder to detect. One such functional impairment causing early 
neonatal death in mice, while displaying no gross morphological kidney defect, is due to 
a deficiency in the production of nephrin. This malfunction results in the development 
of massive proteinuria and oedema (Putaala et al., 2001). Therefore, the DPP9S729A/S729A 
pups were examined for the possibility of high levels of urinary protein.  
3.3.2.2 Methods 
SDS-PAGE analysis on mouse neonate urine samples to identify high protein levels was 
carried out in duplicate as described in Section 3.2.2.6. Further SDS-PAGE analysis of 
urine samples was also carried out in duplicate using a tricine gel to identify the 
absence, presence or other difference in abundance of low molecular weight proteins 
between GKI and WT samples. In this instance, 4 µL of urine from each pup together 
with 5 µL sample buffer and 1 µL reducing buffer was heated at 850C for 2 min before 
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being run on a Novex™ 16% Tris-Glycine gel (Invitrogen) under reducing conditions. An 
XCell SureLock Mini-cell electrophoresis unit (Invitrogen) was used for gel runs at 175 V 
for 60 m in in 1× Tricine SDS Running Buffer. Gels were stained with SYPRO® Ruby 
Protein Gel Stain (Invitrogen). Relative molecular masses were estimated by comparison 
to an Ultra-low Range Molecular Weight Marker (Sigma). 
3.3.2.3 Results 
 
There were no urinary protein band differences seen between DPP9wt/wt, DPP9wt/S729A or 
DPP9S729A/S729A littermates after SDS-PAGE analysis, nor any evidence of proteinuria 
(Figure 3.5). No gender differences were observed. These findings, in conjunction with 
the normal histological and gross morphological appearance of the neonate kidneys 
confirmed that renal damage was very unlikely to have contributed to death in the 
DPP9S729A/S729A pups.  
However, the gel showed the possible absence of a low molecular weight band in 
DPP9S729A/S729A urine samples as compared to the WT and DPP9wt/S729A samples (Figure 
3.5B, red arrows and circles) at the 10 kDa level corresponding to an unknown urinary 
protein. As gel resolution is poor at this level, the samples were re-run using a tricine 
gel to gain higher protein band resolution. Close examination of the resultant gel 
(Figure 3.6) showed no absent protein bands around the 10 kDa region while comparing 
DPP9S729A/S729A and WT urine samples, nor any absent or extra bands across the range of 
sizes. 
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Figure 3.5: Comparative gels indicate the urinary proteins levels in early neonates with and 
without proteinuria and with comparable gel patterns between genotypes. 
SDS-PAGE gels on neonate urine samples showing (A) massive proteinuria from nephrin-deficient 
mice (from (Putaala et al., 2001)), and (B) the absence of proteinuria in DPP9S729A/S729A versus 
WT and DPP9wt/S729A littermate mice. Red arrows and circles indicate the possible absence of an 
unidentified low molecular weight protein in DPP9S729A/S729A urine samples. 
A B 
Figure 3. 6: Low molecular weight urinary proteins in early neonates are comparable between 
genotypes.  
Tricine gel using neonate urine samples showing comparable banding between DPP9S729A/S729A 
and WT littermates with no discernible absence of bands.  (C buffer only sample; L ladder) 
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4 Characterisation of neonate DPP9-GKI mice lacking DPP9 
enzymatic activity 
 
4.1 General introduction 
 
The lethality of the DPP9-GKI mouse was described in Chapter 3 and confirmed as 
occurring in the early neonatal period with the death of all DPP9S729A/S729A pups, along 
with a small but significant number of  DPP9wt/S729A pups (Gall et al., 2013).   At this 
critical stage, there is a disadvantage in carrying the S729A mutant allele. The post-
weaning life expectancy of heterozygous mice, however, did not differ from their wild-
type littermates, suggesting that adult mice are no longer reliant on DPP9 enzymatic 
activity for survival.  
 
With this in mind, further investigation was undertaken on early neonatal mice at Day 
1 post birth. As previously described, there are many potential causes for early 
neonatal lethality but most are associated with gross morphological or behavioural 
defects that are easily observed (Figure 4.1) (Turgeon and Meloche, 2009). In the case 
of the DPP9-GKI mice, there were no defects in gross morphology or behaviour, with 
all neonates having normal appearance and feeding, moving and breathing in a 
manner consistent with their littermates.  
 
Although initial histological investigations showed no obvious altered tissue histology 
or pathology, further organ samples were collected from neonate mice to validate 
previous results. The focus for general histological reassessment of organs was brain,  
    Chapter 4: Characterisation of neonate DPP-GKI mice lacking DPP9 enzymatic activity 
84 
 
 
 
Figure 4.1: Cause-to-effect relationships between defects and physiology causing neonatal 
death.  
 
Complex biological networks are revealed in the neonatal death of mutant mice. Cause-to-
effect relationships are shown in this diagram between organ defects and the affected 
physiological processes critical for neonatal survival. Modified from (Turgeon and Meloche, 
2009). 
 
 
kidney, liver, thymus, pancreas and gut, with a detailed focus on heart. 
Consideration was also given to the possibility of an autophagy defect in the early 
DPP9-GKI neonates as previous studies have found lethality occurring in mutant mice 
deficient for Atg5 with autophagy impairment (Kuma et al., 2004) . Autophagy, while 
low during embryogenesis, is upregulated in a variety of tissues immediately after birth 
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and maintained for up to 12 hours before returning to basal levels within several days 
(Kuma et al., 2004). 
 
4.1.1 Aims  
 
The aims of this chapter are: 
 to further investigate the possible causes of neonate lethality in DPP9-GKI 
mice by: 
o considering possible developmental and/or physiological causes of the 
lethality by analysing organ morphology, histology and function in 
newborn mice, with specific focus on the heart 
o assessing whether there is a defect in autophagy  
 
4.1.2 Presentation 
 
This chapter is presented in two parts.  
 Section 4.2 covers the investigation of organ morphology, histology and 
function and  
 Section 4.3 covers autophagy investigations.  
Each section contains its own introduction, materials and methods, results and 
discussion. 
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4.2 General neonate histology 
 
While original histological investigations were undertaken on whole body neonate 
sections and published (Gall et al., 2013), individual organs from Day 1 neonates were 
later used, in order to undertake a more detailed examination of neonate histology. 
Organs were isolated, sectioned and stained using methods described in Section 
3.2.2.4. 
 
 
4.2.1 Heart 
 
4.2.1.1 Introduction 
The heart is the first organ to form in the developing embryo and embryonic survival 
depends on the establishment of a normal circulatory function. Many cardiovascular 
defects are responsible for in utero embryonic lethality (Conway et al., 2003). In the 
post-natal heart, the initiation of breathing at birth and the increased burden 
associated with newborn activity causes dramatic changes to occur in the circulatory 
system. Many neonate-lethal mutant mice have heart morphology and functionality 
defects and the study of these mutants is useful for the understanding of congenital 
heart diseases in humans (Table 3.7) (Turgeon and Meloche, 2009).  
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Gene Gene product Time of Death Comments 
Heart outflow 
tract 
  Models of human CHD 
Foxc2 
Forkhead transcription 
factor 
10 min after birth Aortic arch anomalies 
Plxnd 1 Plexin 24 h Truncus arteriosus 
Sema3c Semaphorin Soon after birth Various penetrance 
Ductus 
arteriosus 
   
Hpgd 
Prostaglandin 
dehydrogenase 
12-24 h Model of human disease 
Ptger4 Prostaglandin receptor 12-48 h  
Ptgs1/2 Prostaglandin synthase 30 min-12 h Secondary lung anomalies 
 
 
Table 4.1: Typical neonatal lethal cardiac mutations in mice associated with respiratory 
failure 
Examples of cardiac defects that compromise mouse neonate survival due to defective 
circulatory and/or respiratory function. Modified from (Turgeon and Meloche, 2009). 
 
 
 
As stated in Section 3.2.3, the DPP9S729A/S729A mice showed no obvious histological or 
gross morphological difference in the heart compared to WT littermates, and neonate 
pups appeared to have normal respiratory function and no cyanosis. However, the 
timing of death after parturition was suggestive of a possible heart defect. Since the 
heart muscle appeared histologically normal (Figure 3.2A), it was decided to 
investigate the possibility of less readily observable morphological defects that may 
impair the survival ability of neonates.  Defects in internal heart structure, such as 
malformation of valve leaflets, heart septa or atrial and ventricular size are not 
possible to determine by single sections alone. Serial sections and whole heart 
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dissection are necessary to investigate heart structure. 
4.2.1.2 Methods 
 
For further gross morphological studies, neonate hearts were removed from newborn 
pups as described previously (Section 3.2.2.4). Hearts (n=2 WT and n=2 GKI) were 
serially sectioned at 5µm and checked microscopically at various planes of section to 
identify any septal, atrial, or ventricular defects. 
 
For detailed morphological studies, neonate heart/ lung blocks were: 
 removed and stored long-term in neutral buffered formalin until dissection or  
 removed and treated for 10 min in 60mM KCl solution to arrest the heart 
muscle at diastole and then stored in neutral buffered formalin until use. 
Hearts were dissected by Dr Christine Biben who has a high level of expertise and 
skill in mouse neonate heart structure and fine dissection (Biben et al., 2000, 
Sierro et al., 2007), with the assistance of Dr Frederic Sierro. 
 
4.2.1.3 Results 
4.2.1.3.1 Gross heart morphology 
 
Neonate whole heart sections of WT and DPP9S729A/S729A mice showed similar 
histology and gross morphology of major heart structures (Figure 4.2).  Slight 
variations in the transverse plane of section made comparison of valve leaflets 
between genotypes difficult. However, when valves were present in sections, no 
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differences in valve leaflet morphology could be confirmed and valves appeared to 
have comparable histology. 
 
In sections, the presence of an intra-ventricular septal hole or defect in the 
neonate hearts would be indicated by a discontinuity or unusual morphology in 
the intra-ventricular septum (Minette and Sahn, 2006). However, serial sections 
through the ventricular region of neonate hearts from the apex to the base showed no 
apparent discontinuities (Figure 4.3) in either WT or DPP9S729A/S729A hearts, thus 
suggesting no intra-ventricular septal defects.  
 
4.2.1.3.2 Detailed heart morphology 
 
Macroscopic assessment of WT and DPP9S729A/S729A neonate hearts by Dr Christine 
Biben found the major vessels to be grossly normal. Fine dissection of hearts, 
however, appeared to show a possible abnormality of the aortic valves in two of 
the three GKI hearts while four WT littermates were normal. Pulmonary valves 
appeared normal, however mitral and tricuspid valves have yet to be investigated.  
At the time of writing this thesis, further dissection of neonate hearts was ongoing. 
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4.2.1.4 Discussion 
 
This study investigated the possible presence of a heart defect as the cause of neonate 
lethality in the case of the DPP9S729A/S729A mice. Problems with heart structure and 
function may certainly cause or contribute to neonate lethality (Turgeon and Meloche, 
2009) and can often be detected by histological observation as a starting point. In the 
case of the DPP9S729A/S729A mice, the heart muscle histology (Section 3.2.3.2 and 
Figure 3.2) showed no apparent differences with a normal striated appearance of 
the muscle and nuclei present. 
 
The next step was to investigate aspects of fine morphology and internal heart 
structure. Cardiovascular abnormalities that bypass embryonic lethality are often 
associated with cyanosis from poor blood oxygenation and cause respiratory 
distress. Since no cyanosis or respiratory distress was observed in the 
DPP9S729A/S729A neonates, further study focused on more subtle heart abnormalities 
such as septal discontinuities or defects (Biben et al., 2000, Sierro et al., 2007). 
Serial sections of neonate hearts showed no discontinuity between the left and 
right ventricles and no evidence of an intra-ventricular septal defect. Attempting 
to identify atrial septal defects via serial sections was beyond the scope of this 
current study. 
 
A collaborative study with Dr Christine Biben, to identify defects in hearts valves, 
atrial and ventricular chamber size and outflow tract and aortic arch vessels, is 
ongoing. Major vessels and pulmonary valves appeared to be normal which is 
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consistent with no observed cyanosis or obvious respiratory distress in newborn 
mice. While the observed possible aortic valve defects could contribute to neonate 
lethality, it is unlikely to be the sole cause as the current literature suggests an 
incomplete penetrance of such defects and a delayed onset of problems (Garg et 
al., 2005, Hinton et al., 2008, Laforest et al., 2011). Future results from our 
collaborator may clarify this point. 
 
 
4.2.2 Kidney, liver, thymus, pancreas, muscle and cartilage 
 
4.2.2.1 General introduction 
 
The kidney, liver, thymus, pancreas, muscle and cartilage of the neonatal mouse are 
the focus of this section as many organs can be implicated in mouse neonate lethality 
(Turgeon and Meloche, 2009) and observation of the histology of tissue can provide 
evidence of organ malformation. 
 
4.2.2.1.1 Kidney 
 
The kidney in the neonate mouse plays a crucial role in the regulation of fluid 
homeostasis and normal development and function is important for survival. 
Anomalies in kidney development or complete lack of kidneys is due to the inactivation 
of many genes and results in neonate lethality in mice (Turgeon and Meloche, 2009). 
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As an example, the transcription factor Brn1 is necessary for normal development of 
Henle’s loop and the distal convoluted tubule (Nakai et al., 2003). Another example is 
that mutation of the  α3 integrin gene results in abnormal nephrogenesis with marked 
abnormalities in renal structure (Kreidberg et al., 1996).  Aside from morphological 
defects, deficiencies in kidney function can cause death in mice and this has been 
investigated and discussed in Chapter 3 of this thesis. In newborn mice, the kidney 
stroma is loosely arranged and capillaries have narrow linings with thick endothelium. 
The tubules and glomeruli are less proximally placed than in adult mice and glomeruli 
are smaller as dilation of the capillaries associated with normal kidney function has yet 
to occur (Clark, 1957). 
 
4.2.2.1.2 Liver 
 
In neonatal mice, the characteristic liver architecture takes two to three weeks after 
birth to establish. The first week is represented histologically by developing hepatocyte 
chords interspersed with clumps of hematopoietic cells of mixed cell lineages 
(Crawford et al., 2010, Liu et al., 2014). Functionally, the newborn mouse liver has to 
cope with a rapidly changing environment in order to provide glucose necessary for 
energy needs which was previously provided by a maternal source. The glucose is 
produced via the gluconeogenic pathway and involves many enzymes which are 
essential for the proper functioning and differentiation of hepatocytes. Mutations that 
interfere with normal liver development can result in neonatal death (Turgeon and 
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Meloche, 2009). CCAAT/enhancer-binding protein α – deficient mice die soon after 
birth from hypoglycemia due to an inability to store hepatic glycogen (Wang et al., 
1995). Neonate lethality due to hypoglycemia also occurs in high mobility group 1-
deficient mice when abundant glycogen accumulation in the liver results in a glucose 
metabolism defect which is critically damaging at the time of birth (Calogero et al., 
1999). Defective gluconeogenesis resulting in hypoglycemia causes death in mice with 
a mutation at the eukaryotic translation initiation factor 2 phosphorylation site 
(Scheuner et al., 2001) and liver dysfunction along with hypoglycemia also causes 
death when fumarylacetoacetate hydrolase is depleted (Grompe et al., 2011). 
 
4.2.2.1.3 Thymus 
 
The thymus, which is present in most vertebrates, is a primary lymphoid organ of the 
immune system. It is the major organ involved in T-cell production and, in the mouse, 
increases its size and upregulates its function during the neonatal period (Shanley et 
al., 2009). Neonatal mice require the population of the peripheral immune system with 
T-cells at birth and there is an increased migration of cells out of the thymus during the 
early neonatal stage (Hess et al., 1967). Hence, the thymus is important for effective 
immune function during the neonatal period. 
 
4.2.2.1.4 Pancreas 
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The mouse pancreas is composed of the endocrine and exocrine components which 
develop in a biphasic manner. The endocrine Islet cells are present at birth and achieve 
adult form in the first two weeks of neonate life, with the proliferation and growth of 
the exocrine tissue increasing later (Dore et al., 1981, Kaufman et al., 2010). Mutations 
in neonate pancreas structure and/or function affect energy balance and glucose 
homeostasis and pose a serious threat to survival. Some examples include the gene Arx 
involved in endocrine pancreas development and the protein PTF1-p48 which is 
essential for exocrine pancreatic formation and endocrine pancreatic spatial 
organisation. Arx-deficient mice die two days after birth after developing 
hypoglycemia, dehydration and lethargy (Collombat et al., 2003) and the null PTF1-p48 
mutation leads to a complete absence of exocrine pancreatic tissue resulting in 
abnormal spatial assembly of the endocrine pancreas (Krapp et al., 1998). 
 
4.2.2.1.5 Muscle 
 
Normal muscular activity, while important for general mobility, is of critical importance 
directly after birth for the initiation of respiration. An inability to breathe can result 
from defects in muscle development, muscle function or in the development of a 
functional neuromuscular junction. Many lethal phenotypes exist which are associated 
with respiratory failure (Turgeon and Meloche, 2009) and with death occurring very 
rapidly after birth. Also important for neonate survival is the ability to suckle normally. 
Morphological abnormalities in skeletal muscle lacking junctophilin type 1 (JP-1) result 
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in muscle with less contractile force. Mice deficient in JP-1 have impaired contractile 
activity of the jaw muscles and an inability to suckle effectively (Ito et al., 2001).  
 
4.2.2.1.6 Cartilage 
 
The mouse skeleton consists of both cartilage and bone which is spread throughout 
the body and abnormal development can result in many neonatal lethal phenotypes 
(Turgeon and Meloche, 2009). Hyaline cartilage, which is the precursor to bone, is 
recognized by its homogenous and highly hydrated matrix interspersed with spaces 
enclosing chondrocytes. As well as imparting structural resilience, cartilage tissue also 
allows the diffusion of small metabolites through its avascular matrix (Karsenty and 
Wagner, 2002).  
Bone develops by endochondral ossification of cartilage and, because of its structural 
and developmental importance as a bone precursor, defects in cartilage can have 
catastrophic impacts on neonate survival. Rib cage cartilage plays a role in protection 
of body organs but, most importantly, enables proper respiration. Rib cage dysmorphia 
is associated with respiratory failure and neonatal death in connective tissue growth 
factor (CTFG)-deficient mice due to impaired matrix remodeling during chondrogenesis 
(Ivkovic et al., 2003). The proteoglycan perlecan has an important role in matrix 
structure and cartilage development and disruption of the gene encoding perlecan 
results in both embryonic and neonatal lethality in mice with varying degrees of 
abnormality (Arikawa-Hirasawa et al., 1999).  
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4.2.2.2 Methods 
Individual organs were removed from genotyped newborn pups, combined into groups 
of 3 to 5 organs per genotype and processed as described previously (Section 3.2.2.4) 
into organ-specific paraffin blocks for sectioning.  
 
4.2.2.3 Results 
 
Consistent with results from Chapter 3, no obvious morphological defects were 
observed in the DPP9S729A/S729A kidney and both WT and DPP9S729A/S729A kidney 
(Figure 4.4A and D) histology showed small compact glomeruli and loosely 
arranged stroma as expected in the cortical region. 
Both WT and DPP9S729A/S729A liver (Figure 4.4B and E) display normal neonate liver 
histology, with large numbers of hematopoietic cells present and evidence of 
developing hepatocyte chords. No abnormalities were observed. 
The cortex of the thymus (Figure 4.4C and F) shows large numbers of intensely staining 
nuclei of developing T-cells, with the dense accumulation of cells giving a highly 
basophilic appearance in H & E stained sections. This was consistent with published 
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Figure 4.4: Histology of early neonate tissues is comparable between genotypes.  
 
Neonate kidney cortex (A and D), liver (B and E) and thymus (C and F) DPP9 wt/wt tissue 
compared to DPP9S729A/S729A tissue show no differences in histological structure. 
Haematoxylin and eosin stained. Scale bar 50 µm.   
A
B
C
D
E
F
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Figure 4.5: Histology of early neonate tissue is comparable between genotypes.  
 
Neonate pancreas (A and D), thigh muscle (B and E) and rib cartilage (C and F) DPP9wt/wt 
tissue compared to DPP9S729A/S729A tissue show no differences in histological structure. 
Haematoxylin and eosin stained. Scale bar 50 µm.  
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data (Theiler, 1989) and no differences can be seen between WT or DPP9S729A/S729A 
thymus. 
Both endocrine and exocrine pancreatic components are visible in WT and 
DPP9S729A/S729A pancreas (Figure 4.5A and D) with the presence of accumulations of 
endocrine cells making up the islets of Langerhans and intervening exocrine acinar 
cells. No differences or abnormalities could be detected in either tissue type.  
Skeletal muscle cells in longitudinal section (Figure 4.5B and E) show multiple 
nuclei within fibres and capillaries and connective tissue of the endomysium 
between fibres. Both WT and DPP9S729A/S729A muscle fibres show normal histology.  
Cartilage (Figure 4.5C and F) of both WT and DPP9S729A/S729A mice display a normal 
homogeneous amorphous matrix with basophilic staining and chondrocytes are clearly 
visible in lacunae. The matrix is avascular and associated connective tissue appears 
normal. There are no observed differences between genotypes in cartilage. 
 
 
4.2.2.4 Discussion 
 
This study investigated the possibility of histological defects or differences between 
WT and DPP9S729A/S729A mouse tissues. The presence of defects can be an indicator 
of organ dysfunction which could contribute to early neonate death. The organs 
chosen for presentation in this section of the thesis covered those not previously 
discussed in detail (in Chapter 3 or Chapter 4 Section 4.2.1) which are considered 
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important for neonate survival in the first 12-24 hours after birth (Turgeon and 
Meloche, 2009). The  timing of death is consistent with this group’s DPP9 enzyme 
inactive mice which died within 12 hours of birth (Chapter 3 of this thesis) (Gall et 
al., 2013). 
 
In comparing the WT and DPP9S729A/S729A neonate mouse organs of kidney, liver, 
thymus, pancreas, skeletal muscle and cartilage, no differences could be found. 
The appearance of all tissue types examined was consistent with published works. 
This confirmed previous findings (Chapter 3 of this thesis) and suggested that the 
cause of neonate death in the DPP9 enzyme activity-deficient mice may be due to 
other factors rather than abnormal organ structure or histology. 
 
 
 
4.3 Autophagy 
 
4.3.1 Introduction 
 
Autophagy in mammals is a critical process whereby cytoplasmic elements are broken 
down to remove damaged proteins and organelles and re-use essential molecules, 
such as amino acids (Figure 4.6). The mechanism required to achieve this is by the 
internalisation of these components into autophagosomes which then fuse with 
lysosomes to enable proteolytic digestion of the contents. It is important for both cell 
homeostasis and the growth and development of organisms (Levine and Kroemer, 
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2008). The impairment or activation of autophagy can result in disease state 
pathogenesis, including inflammatory disorders and neurodegenerative disease such 
as Crohn’s disease and Parkinson’s disease respectively (Mizushima and Komatsu, 
2011). 
Autophagy post-partum is involved in the immediate supply of energy, tissue 
remodelling and metabolic changes. Directly after birth, neonates face a period of 
starvation during the transition from maternal nutrient supply until their metabolic 
requirements can be met through milk nutrients. Since the mechanisms of glucose 
production via gluconeogenesis are not yet entirely established in the neonate, a 
transient period of hypoglycemia exists (Kotoulas et al., 2006). Studies in young and 
adult mice have shown starvation induces autophagy in most organs but this process is 
regulated differently in different organs (Mizushima et al., 2004, Levine and Klionsky, 
2004). The role of autophagy in neonatal tissues, however, is not solely to overcome 
starvation and, thus, displays different tissue patterns and effects than in older animals 
(Schiaffino et al., 2008). 
The level of autophagy is low during embryogenesis but, after birth, induction is 
immediate in many tissues and reaches its maximum threshold in three to six hours. 
This upregulation of autophagy is maintained for up to 12 hours and is critical for early 
neonate survival. As such, mutations that interfere with normal autophagic processes 
result in neonate lethal phenotypes (Turgeon and Meloche, 2009).  
Autophagy-related (ATG) genes, originally identified in yeasts, are conserved in higher 
eukaryotes and required for autophagosome formation. A study using transgenic mice, 
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in which autophagosomes were labelled with  GFP-microtubule-associated protein 
light chain 3 (GFP-LC3), has shown that autophagy is extensively induced in neonate 
mice directly after birth, especially in heart muscle, diaphragm, alveolar cells and skin 
(Kuma et al., 2004). Mice deficient in Atg5, a protein necessary for autophagosome 
formation, die within one day of birth. This is believed to be due to the essential role of 
autophagy for supply of energy during the early starvation period. This result, 
however, was confounded by the fact that the Atg5 deficient neonates also display a 
suckling defect (Kuma et al., 2004).  
Mice deficient in another ATG family protein, Atg7, also display a neonate lethal 
phenotype. In Atg7-deficient neonates, plasma amino acid concentrations are lower 
than in WT neonates,  which causes lower nutrient supply (Komatsu et al., 2005). More 
recently, the RagA-D family GTPases, which enable the mTORC1 pathway to sense 
amino acids, have been shown to have a key role in nutrient homeostasis and 
autophagy induction in neonates by signaling glucose and amino acid concentrations 
to mTORC1 (Efeyan et al., 2013). Mice with constitutive RagA activity prevent mTORC1 
inhibition which leads to defective autophagy. 
 
In this study, immunohistochemical and protein analysis of autophagy in mouse 
neonate tissues was undertaken as represented by autophagosome formation 
detection. MAP1LC3 (microtubule-associated protein 1 light chain 3) (LC3), a 
mammalian ortholog of yeast Atg8, is a protein known to contribute to major steps of 
autophagy and autophagosome formation. Although LC3 functions primarily in the 
cytoplasm, it is also abundant in the nucleus where it is thought to be the primary 
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source of membrane-bound LC3 (Huang and Liu, 2015). GFP-tagged LC3 has also been 
shown to bind to the smooth endoplasmic reticulum independently of autophagy, 
creating an artefact for consideration in LC3 analysis  (Korkhov, 2009). In this study, an 
antibody against the B isoform of LC3, which detects membrane-bound LC3-II in the 
 
 
 
Figure 4.6: Mammalian autophagy is a cellular defence against two forms of nutrient stress, birth 
and starvation. 
Diagrammatic representation of autophagy function in mammals showing the process of 
nutrient depletion and protein degradation for recycling of amino acids for protein synthesis 
and energy production. Modified from (Levine, 2005). 
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autophagic vacuole fraction, was used to identify the LC3 protein localisation. The aim 
of this study was to determine if autophagy dysfunction occurs and, thus, could 
contribute to the lethal phenotype of the DPP9-GKI mouse. 
4.3.2 Methods 
4.3.2.1 Immunohistochemical studies 
Neonate mouse organs were isolated and sectioned using methods described in 
Section 3.2.2.4. To immunolocalise LC3B protein as a marker for autophagy, the 
polyclonal anti-LC3B antibody (GeneTex; Irvine, CA, #GTX127375, 1:100) was used 
which bound to the autophagosome membrane proteins. Briefly, 5 µm sections were 
deparaffinised and rehydrated and then a pressure cooker and Universal Decloaker 
solution (Biocare Medical, Concord, CA) was used to retrieve antigen. Endogenous 
peroxidase activity was quenched with 3% H2O2 in PBS for 10 mins followed by 
thorough rinsing in water. Sections were then covered with Background Sniper 
(Biocare Medical) for 10 mins, rinsed in PBS and incubated at room temperature for 1 
h in primary antibody with 1% BSA in PBS and Renaissance Background Reducing 
Diluent (Biocare Medical). Control sections were treated with rabbit Ig or water in 
place of primary antbody. After thorough washing in PBS, sections were incubated for 
30 mins with goat anti-rabbit conjugated to HRP (Dako, Glostrup, Denmark, #P0448, 
1:100), washed and then stained in 3,3-diaminobenzidine (DAB) with H2O2. Sections 
were counterstained in Harris haematoxylin (Sigma-Aldrich, St Louis, MO), rinsed in 
running water and blued in freshly made Scott’s tap water substitute for 2 mins before 
dehydration through successive increasing percent alcohols to histolene and mounting 
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with Eukitt (Sigma-Aldrich). Bright-field imaging was performed using a Leica DM6000B 
microscope. 
 
In all tissues, intensity readings (r) of LC3B staining levels were calculated from 25 
measurements taken from 5 different tissue sections containing 5 regions of interest of 
fixed area in ImageJ software (Schindelin et al., 2012). The tissue sections were 
sourced from 5 WT and 5 DPP9-GKI mice. The WT mouse sections were from two sets 
of two littermates and one single mouse and the DPP9-GKI tissue sections were from 3 
littermate mice from one litter and two from another. Regions of interest (ROI) within 
each section were from corresponding areas of tissue. ROIs containing high levels of 
white background space were avoided. For lung, ImageJ thresholding tools were used 
to avoid staining contributed by red blood cells in alveolar spaces and thereby obtain 
true measurement of lung tissue staining. In all tissues, measurements were converted 
to reciprocal intensity (255 – r) to focus on areas of low intensity which indicate darker 
staining (Nguyen et al., 2013). All images used in IHC quantification were analysed 
after subtraction of background staining and removal of the colour contribution from 
hematoxylin by colour deconvolution in ImageJ. Data were analysed by unpaired t-test 
using GraphPad Prism (GraphPad, San Diego, USA) and significance was assigned to p 
values less than 0.05. 
4.3.2.2 Immunoblotting studies 
Neonate mice were euthanised by decapitation within six hours of birth and brains 
were harvested in 2 mL screwcap tubes (Astral Scientific, NSW, Australia) for snap 
freezing in liquid nitrogen and storage at -70˚C. Samples were prepared as detailed in 
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Section 2.2.4.2 of Materials and Methods. Briefly, for immunoblot sample preparation, 
frozen neonate mouse brain samples were homogenised in lysis buffer using a bead-
based homogeniser (TissueLyser, Qiagen Venlo, Netherlands) at 40C. Protein 
concentration was determined using the Micro BCA Protein Assay Kit (Thermo 
Scientific, Waltham, Massachusetts, USA) following the manufacturer’s protocol. 
Brain lysates from DPP9S729A/S729A (n=5) and WT (n=5) littermate mice sourced from 
three litters were used for immunoblotting. Lysates (30 µg protein per lane) were 
resolved on 4–12% Bis-Tris SDS-PAGE (Invitrogen) followed by immunoblotting with 
anti-LC3B antibody (GeneTex; #GTX127375, 1:4000), anti-DPP9 (OriGene, #TA503937, 
1:6000) and anti-β-Actin (Sigma-Aldrich, #A2103, 1:6000). Relative band intensities 
were quantitatively analysed using ImageJ and normalised against control proteins as 
indicated. 
4.3.3 Results 
4.3.3.1 Immunohistochemical studies 
Immunohistochemistry, where an antibody specific to LC3B was used as an autophagy 
marker (Lee et al., 2014, Hung et al., 2015), showed strong immune-positivity on both 
WT and DPP9S729A/S729A samples. Autophagy is upregulated in most tissues directly after 
birth in the early neonatal period (Kuma et al., 2004). 
In heart muscle (Figure 4.7 A and B), LC3B immunoreactivity was observed in the 
cardiomyocytes with staining of the muscle fibres and intense staining of nuclei in both 
the WT and DPP9S729A/S729A samples. Staining was significantly stronger, however, in the 
DPP9S729A/S729A heart muscle nuclei. In lung, staining was most prominent in the 
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Figure 4.7: LC3B immunohistochemistry in mouse early neonate heart muscle and lung 
Paraffin sections of tissues were stained with anti-LC3B antibody and DAB chromogen and 
counterstained with hematoxylin. In heart muscle (A and B), LC3B was detected in cardiomyocytes 
with strong nuclear staining (arrows). In lung (C and D), LC3B was detected in alveolar cells (arrows) 
of the lung parenchyma. Upper right insets show staining for secondary antibody only controls 
(A and C) and isotype controls (B and D). Scale bar 50µm. The reciprocal intensity of positive 
immunoreactivity was calculated in random tissue section areas from DPP9wt/wt (n=5) and 
DPP9S729A/S729A (n=5) neonate mice (E). Horizontal bars (red) are means and error bars depict SD. 
Significance was assigned where p < 0.05 (*), p < 0.01 (**), p < 0.001 (***). Abbreviations: a.u., 
arbitrary units. 
 
alveolar sacs with alveolar cell nuclei showing strong staining (Figure 4.7 C and D). As 
with the heart muscle, the DPP9S729A/S729A sample showed significantly more staining 
than the WT suggesting and upregulation of autophagy in these GKI tissues. 
Gut (Figures 4.8 A and B) showed greater staining intensity in the epithelial layer than 
in the lamina propria for both samples. In the gut epithelium, nuclei of enterocytes and 
goblet cells stained strongly, with the most intense staining seen in the regions of 
proliferating cells at the bottom of intestinal crypts. LC3B immunoreactivity was 
significantly higher and staining more intense in nucleus than cytoplasm in the 
DPP9S729A/S729A samples than in the WT samples. Liver (Figures 4.8 C and D) showed 
diffuse low level staining throughout with stronger staining of nuclei in some 
hepatocytes. While the down-regulation of staining in the DPP9S729A/S729A samples 
compared to the WT was slight but significant, the pattern of staining appeared 
different. In the WT samples, nuclear LC3B immunoreactivity encompassed the entire 
nucleus in positive hepatocytes, whereas the GKI samples showed perinuclear staining 
of many hepatocyte nuclei. 
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The area of the brain shown (Figure 4.9 A and B) and used for quantification was the 
thalamic region of the diencephalon as classified by Lee et al. in mouse neonate brain 
(Lee et al., 2005).  This region was the only area consistently present in all mouse 
sections and so was used for analysis. Staining was strongest in the nuclei of neurons 
but also present less intensely in the nuclei of glial cells. There was a significant down-
regulation of LC3B immunoreactivity in the DPP9S729A/S729A samples compared to the 
WT samples. In the spinal cord (Figure 4.9 C and D), however, no significant difference 
was observed between samples. Staining was observed in the perinuclear region of the 
glial cell nuclei and also in the dendritic branches of neurons for both tissue samples.  
 
 
Figure 4.8: LC3B immunohistochemistry in mouse early neonate gut and liver 
Paraffin sections of tissues were stained with anti-LC3B antibody and DAB chromogen and 
counterstained with hematoxylin. In gut (A and B), LC3B was detected in epithelium with 
strong staining of the nuclei of enterocytes and goblet cells (arrows). In liver (C and D), LC3B 
was diffuse with strong staining of the nuclei of some hepatocytes (arrows). Upper right 
insets show staining for secondary antibody only controls (A and C) and isotype controls 
(B and D). Scale bar 50µm. The reciprocal intensity of positive immunoreactivity was 
calculated in random tissue section areas from DPP9wt/wt (n=5) and DPP9S729A/S729A (n=5) 
neonate mice (E). Horizontal bars (red) are means and error bars depict SD. Significance was 
assigned where p < 0.05 (*), p < 0.01 (**), p < 0.001 (***). Abbreviations: a.u., arbitrary units. 
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Neonate kidney (Figure 4.10 A and B) of both the DPP9S729A/S729A and WT mice showed 
diffuse staining in the distal tubules with more intense staining in the connecting 
tubules and glomeruli and no significant difference in overall staining intensity 
observed. The adrenal gland (Figure 4.10 C and D) had diffuse staining throughout with 
the presence of many dark granules in the DPP9S729A/S729A samples and very few visible 
in the WT. As the adrenal gland is the organ where catecholamine production is 
undertaken, these are probably storage granules of secretory cells.  
Very low levels of LC3B immunoreactivity were observed in all samples in skeletal 
muscle (Figure 4.11 A and B) and skin (Figure 4.11 C and D) although some staining of 
the hair follicle was apparent. Both pancreas (Figure 4.12 A and B) and thymus (Figure 
4.12 C and D) showed strong overall staining in both the WT and DPP9S729A/S729A 
samples. The pancreas showed stronger staining of acinar cell nuclei than cytoplasm. 
The islet cell cytoplasm stained less intensely than the acinar cell cytoplasm, however, 
their nuclei were as immunoreactive as the acinar cell nuclei. The thymus showed 
strong staining in both neonate genotypes, which was apparent in the reticulocytes 
and lymphocytes. 
With respect to the quantification of staining intensity in tissue samples, heart muscle, 
lung, brain, gut and liver showed significant differences in LC3B staining between WT 
and DPP9S729A/S729A samples. Staining of LC3B in heart muscle, lung and gut was more 
intense in DPP9S729A/S729A samples compared to WT (Figures 4.7 E and 4.8 E) suggesting 
increased levels of autophagy in those organs in DPP9S729A/S729A neonates, whereas 
liver and brain showed less staining in the DPP9S729A/S729A samples (Figures 4.8 E and   
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Figure 4.9: LC3B immunohistochemistry in mouse early neonate brain and spinal cord 
Paraffin sections of tissues were stained with anti-LC3B antibody and DAB chromogen and 
counterstained with hematoxylin. In brain (A and B), LC3B was strongly detected in the nuclei 
of neurons (arrows). In spinal cord (C and D), LC3B was present in the dendritic branches of 
neurons and glial cells (arrows). Upper right insets show staining for secondary antibody 
only controls (A and C) and isotype controls (B and D). Scale bar 50µm. The reciprocal 
intensity of positive immunoreactivity was calculated in random tissue section areas from 
DPP9wt/wt (n=5) and DPP9S729A/S729A (n=5) neonate mice (E). Horizontal bars (red) are means 
and error bars depict SD. Significance was assigned where p < 0.05 (*), p < 0.01 (**), p < 0.001 
(***). Abbreviations: a.u., arbitrary units; ns, no significance. 
 
Figure 4.10: LC3B immunohistochemistry in mouse early neonate kidney and adrenal gland 
Paraffin sections of tissues were stained with anti-LC3B antibody and DAB chromogen and 
counterstained with hematoxylin. In kidney (A and B), LC3B was detected at low levels in the 
distal tubules (red arrows) and more intensely in the connecting tubules and glomeruli (blue 
arrows). In adrenal gland (C and D), LC3B was present in secretory cell nuclei (black arrows) 
and structures that are probably storage granules (green arrows). Upper right insets show 
staining for secondary antibody only controls (A and C) and isotype controls (B and D). 
Scale bar 50µm. The reciprocal intensity of positive immunoreactivity was calculated in 
random tissue section areas from DPP9wt/wt (n=5) and DPP9S729A/S729A (n=5) neonate mice (E). 
Horizontal bars (red) are means and error bars depict SD. Abbreviations: a.u., arbitrary units; 
ns, no significance. 
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Figure 4.11: LC3B immunohistochemistry in mouse early neonate skeletal muscle and skin 
Paraffin sections of tissues were stained with anti-LC3B antibody and DAB chromogen and 
counterstained with hematoxylin. In skeletal muscle (A and B), LC3B was detected at low 
levels with some stronger staining in muscle cell nuclei visible (arrows). In skin (C and D), LC3B 
was most intense in the hair follicles (arrows). Upper right insets show staining for 
secondary antibody only controls (A and C) and isotype controls (B and D). Scale bar 
50µm. The reciprocal intensity of positive immunoreactivity was calculated in random tissue 
section areas from DPP9wt/wt (n=5) and DPP9S729A/S729A (n=5) neonate mice (E). Horizontal bars 
(red) are means and error bars depict SD. Abbreviations: a.u., arbitrary units; ns, no 
significance. 
 
Figure 4.12: LC3B immunohistochemistry in mouse early neonate pancreas and thymus 
Paraffin sections of tissues were stained with anti-LC3B antibody and DAB chromogen and 
counterstained with hematoxylin. In pancreas (A and B), LC3B was detected with strong 
staining in acinar cells (red arrows) and less intensity in islet cells (blue arrows). In thymus (C 
and D), LC3B was most intense in lymphocytes (black arrows) and reticulocytes (green 
arrows). Upper right insets show staining for secondary antibody only controls (A and C) 
and isotype controls (B and D). Scale bar 50µm. The reciprocal intensity of positive 
immunoreactivity was calculated in random tissue section areas from DPP9wt/wt (n=5) and 
DPP9S729A/S729A (n=5) neonate mice (E). Horizontal bars (red) are means and error bars depict 
SD. Abbreviations: a.u., arbitrary units; ns, no significance. 
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4.9 E) suggesting decreased levels of autophagy. All other tissue types, namely spinal 
cord (Figure 4.9 E), kidney and adrenal gland (Figure 4.10 E), skeletal muscle and skin 
(Figure 4.11 E) and pancreas and thymus (Figure 4.12 E) showed no significant 
difference between the levels of staining of WT and DPP9S729A/S729A tissue sections. 
Quantification results are summarised in Table 4.2. 
Tissue type 
LC3B staining levels in 
DPP9S729A/S729A tissue 
compared to WT 
p value 
< 0.05 
Heart muscle   
Lung  
Gut   
Liver  
Brain  
Spinal cord  ns 
Kidney   ns
Adrenal  ns
Skeletal muscle  ns
Skin  ns
Pancreas  ns
Thymus  ns
 
 
 
 
 
 
Table 4.2:  Summary list of staining reciprocal intensity difference with LC3B autophagy marker in 
DPP9S729A/S729A neonate tissues compared to WT.  
Symbols represent: 
Up-regulation of autophagy in DPP9S729A/S729A tissue compared to WT     () 
Down-regulation of autophagy in DPP9S729A/S729A tissue compared to WT    ()  
No change of autophagy in DPP9S729A/S729A tissue compared to WT    ()  
Abbreviation:  ns,  not significant 
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4.3.3.2 Immunoblotting studies 
 
To verify the presence of autophagy as indicated by LC3B protein expression, neonate 
brain lysates of WT and DPP9S729A/S729A littermates were characterised for protein 
expression by immunoblot. Using the LC3B antibody with neonatal brain showed less  
Figure 4.13: LC3B protein expression in neonate brain tissue lysates 
Brain tissue lysates of littermate neonate mice (GKI n=5, WT n=5) were analysed by 
immunoblot (A) and densitometry analyses of LC3B normalised against β-Actin (B). 
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LC3B protein in the DPP9S729A/S729A brain lysate than the WT (Figure 4.13A). However, 
densitometry (Figure 4.13B) showed that this difference was not significant. 
 
4.3.4 Discussion 
The purpose of this study was to assess whether a defect in autophagy may contribute 
directly or indirectly to death of DPP9-GKI mice. An anti-LC3B antibody, which binds to 
the autophagosome membrane proteins, was used as a marker for autophagy. High 
levels of autophagy are expected in most neonate tissues directly after birth as the 
post-partum period is a time of extensive energy consumption and metabolic change. 
The strong immunoreactivity of LC3B detected in all neonate tissues studied supported 
this for both WT and DPP9S729A/S729A samples.  
Ideally, LC3B immunohistochemical staining should clearly define autophagic vacuoles 
as a marker for autophagy. However, it has been suggested in a published work that 
there are low levels of this protein in paraffin-embedded tissue when using routine 
preparation techniques which may impair unambiguous detection (Martinet et al., 
2013). Also problematic is the use of DAB as the chromogen for visualisation of LC3B 
immunoreactivity, as its macromolecular structure causes light scattering and the 
production of non-stoichiometric signals which can introduce errors in quantification 
of intensity readings (Haub and Meckel, 2015). 
To overcome these problems, the observation and quantification in this chapter was 
done as a comparative assessment of autophagy with WT levels assumed as normal for 
early neonate tissue types.  Although LC3 function in autophagy happens in the 
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cytoplasm, it is known to be abundantly distributed in the nucleus where it is the main 
source of membrane-conjugated LC3 on autophagosomes (Huang and Liu, 2015). In 
many tissue types investigated in this chapter, where strong staining was observed, 
the staining localisation occurred in the nuclear or perinuclear regions of cells in both 
WT and DPP9S729A/S729A samples which is consistent with published work.  
Whereas significant differences in overall staining intensity were seen in heart muscle, 
lung, gut, liver and brain, in most cases the localisation patterns were identical. One 
exception was the liver, where positive perinuclear staining was seen in the 
DPP9S729A/S729A samples but throughout the entire nucleus in the positive WT nuclei. 
This may suggest a different interplay between the nuclear and cytoplasmic autophagy 
processes in the GKI neonate liver.  
Also displaying staining pattern variations was the adrenal gland, where dark secretory 
granules could be seen prominently in the DPP9S729A/S729A samples but were far less 
evident in the WT tissue. The increased number of these granules in the 
DPP9S729A/S729A samples compared to the WT samples suggests that there might be 
abnormal retention of catecholamines in adrenal cells, which may have an impact on 
critical metabolic processes in these neonates. To elucidate whether this issue exists in 
the neonates would require specific focus on neonate adrenal histology and function. 
While this was beyond the scope of the current study, it would be interesting to 
investigate in the future as a potential contributor to neonate lethality in the 
DPP9S729A/S729A and DPP9wt/S729A mice. 
    Chapter 4: Characterisation of neonate DPP-GKI mice lacking DPP9 enzymatic activity 
124 
 
As well as nuclear staining, notable cytoplasmic staining was observed in alveolar cells 
of the lung, gut epithelial cells, dendritic branches of neurons in spinal cord, myosin 
fibrils of skeletal muscle, hair follicle cells in skin, acinar cells of the pancreas and 
lymphocytes in the thymus. This finding is consistent with increased autophagic 
activity in tissues undergoing development and metabolic change. 
In the early neonate, autophagy is at high levels in brain tissue and normal brain 
function is imperative for survival. As reduced autophagy was indicated in 
DPP9S729A/S729A brain tissue in this study, LC3B protein levels were measured by 
immunoblotting to confirm the down-regulation. The results indicated a trend towards 
less autophagy occurring in DPP9S729A/S729A brain but analysis showed no significant 
difference between samples. This may be due to variable localisation of LC3B protein 
to the various cell types or regions of the brain, and immunoblotting of whole brain 
lysates is necessarily an average of the whole. Microscopic observation of 
immunoreactivity to LC3B in various brain tissue samples suggested that different 
regions displayed different levels of staining intensity, however, the small number of 
brain samples and varied orientation of tissues in blocks meant that there were 
insufficient replicates of most brain areas to verify such ideas in the current study. 
Of interest is the quantitative analysis which showed an up-regulation of autophagy in 
heart muscle, lung and gut in DPP9S729A/S729A tissue and a down-regulation in 
DPP9S729A/S729A liver and brain compared to WT. Either an overall up-regulation or an 
overall down-regulation of autophagy in affected tissue types may be expected to 
result in neonate lethality but these findings are more indicative of a systemic 
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dysregulation, which suggests that autophagy may only be a contributing factor or a 
flow-on effect of the event(s) that result in the death of all DPP9S729A/S729A and some 
heterozygous neonates. Alternatively, the mechanisms of DPP9-driven altered 
autophagy intensity might be direct in some organs but indirect in others.  
Consideration of technical aspects of immunostaining such as sample preparation, 
antibody specifity and sensitivity of staining are important. While the quantification of 
immunostaining presented in the literature needs to be interpreted with caution due 
to the shortcomings of immuneperoxidase-based staining methods, the data do 
provide a useful starting point for future investigations. Further quantitative analysis of 
additional mouse sections using this and other staining methods would provide greater 
knowledge of the role of autophagy in the DPP9-enzyme deficient mouse. 
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5 Comparative analysis of adult DPP9wt/S729A and WT 
mouse skin 
 
5.1 Introduction 
 
In both neonatal and adult mice, any major defect and damage to the skin is life 
threatening. Tissue regeneration and restoration of structural integrity relies on 
redundant reservoirs of stem cells in both the epidermis and dermis (Kimlin and 
Virador, 2013). For murine skin, these stem cells are found in the hair follicle bulge and 
dermal papilla and the dermis, the same regions where DPP9 is present. Many studies 
have shown defects in wound healing and skin integrity resulting from protease 
impairments or deficiencies (Basu et al., 2001, Drew et al., 2001, Bradshaw et al., 2003, 
Leitch et al., 2008). 
The role of other DPPs has been reported in wound healing and skin repair. DPP4-
positive T cells are involved in regulating granulation tissue formation (Kohl et al., 
1991). DPP4-like activity mediates anti-fibrotic effects in fibroblasts and may regulate 
fibroblast functions (Thielitz et al., 2008). Inhibition of DPP4 in keratinocytes of skin 
can enhance healing (Schürmann et al., 2012, Sinagra et al., 2015). Also, FAP has long 
be reported as being expressed in the granulation tissue of healing wounds and FAP 
expression is strongly induced during scar formation (Garin-Chesa et al., 1990).  
Recent work in vitro has shown that inhibition of DPP9 results in less cell mobility and 
adhesion compared to control cells (Zhang et al., 2015a), indicating DPP9 enzymatic 
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function may have a role in skin repair. No enzyme activity assay exists that detects 
DPP9 alone (Yu et al., 2009) which makes accurate assessment of activity levels in 
DPP9-GKI heterozygous mouse skin difficult. Thus, the level of specific DPP9 enzymatic 
activity in skin has not been examined. Others have previously evaluated DPP9 enzyme 
activity using whole MEFs in the absence or presence of a DPP8/9 inhibitor (Yu et al., 
2009, Yao et al., 2011, Chen, 2013) which showed activity present at similar low levels 
in both WT and heterozygous MEFs. However, the role of DPP9 in wound healing in 
vivo has not been investigated.  
The early focus of the work in this thesis was placed on identifying the developmental 
stage and cause of DPP9-GKI mouse lethality. It has been shown that death occurs in 
the neonatal stage, however, the cause of lethality remains elusive. Working with 
neonate pups is technically challenging and time intensive and the early timing of 
death limits the scope of experimentation. Neonatal mice possess a very small total 
skin area and their collagen levels are less than 10% of adult mice (Mao et al., 2002). 
Therefore, in-depth analysis of neonatal skin for tensile strength and collagen content 
was beyond the scope of this work.  
Because of this, and the increased logistical and technical ease of working with larger 
mice, further investigation was undertaken on adult DPP9-GKI heterozygous mice. 
While heterozygous mice appear normal and healthy, it has been shown previously 
that carrying the DPP9 S729A mutant allele affects survival to weaning in neonate mice 
(Gall et al., 2013).  Since most heterozygous neonates survive to weaning, this suggests 
that variability in the levels of DPP9 enzymatic activity expression at the neonatal stage 
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may influence the post-weaning structure or function of organs without causing 
lethality or serious impairments. Once weaned, the long term survival of adult DPP9 
heterozygous mice does not differ from their wild-type littermates. Nevertheless, 
there is a possibility that the neonatal differences of DPP9 enzyme activity in these 
mice result in adult biological functions which are altered, impaired or even enhanced.  
In chapter 3 of this thesis, the presence of positive DPP9 immunoreactivity in skin of 
WT, DPP9-GKI heterozygous and DPP9S729A/S729A neonates was shown. This was 
expected as the anti-DPP9 antibody binds with DPP9 protein and, thus, detects both 
enzyme-active and enzyme-inactive DPP9. Positive immunostaining was seen in the 
cytoplasm of epidermal basal keratinocytes and dermal lymphoid cells. There was also 
strong staining of hair follicles. While displaying similar localisation, the levels in adult 
skin are much lower than in embryonic and neonatal skin. This localisation of staining 
was consistent with other published works where DPP9 in skin has been assessed by in 
situ hybridisation and immunohistochemistry (Yu et al., 2009, Harstad et al., 2013, 
Pantano et al., 2013). 
In this chapter, the novel characterisation of adult DPP9-GKI heterozygous and WT 
mouse skin was undertaken to investigate a potential role of DPP9 in cutaneous 
wound healing and skin structure, integrity and strength. As well as wound repair, 
other changes in skin could relate to its tensile strength and collagen content. With 
consideration of this along with the known role of other DPPs in skin function and the 
lack of information available in relation to skin functions of DPP9, various aspects of 
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skin structure and function were investigated for DPP9-GKI heterozygous and WT adult 
mouse skin.  
5.1.1 Aims 
The aims of the work in this chapter are: 
 to determine whether carrying the S729A mutant allele in DPP9 heterozygous 
adult mice affects wound healing by causing a delay in wound closure 
 to measure tensile strength of wounded and healthy steady-state mouse skin in 
DPP9wt/S729A mice compared to WT littermates and WT C57BL/6J mice 
 to investigate collagen levels in skin of DPP9wt/S729A mice and wild-type 
littermates 
5.2 Methods 
5.2.1 Cutaneous model of wound healing 
DPP9wt/S729A mice, DPP9wt/wt mice and C57BL/6J mice aged 8 weeks were used in this 
study. Mice were anaesthetised using isoflurane (flow rate of 0.4X0.8 L/min) (I.S.O., 
Figure 5.1: Schematic representation of mouse wound location 
 
In this experiment a full thickness wound (red oval) was created 
on the dorsal midline of the mouse using an 8 mm biopsy punch. 
During skin harvesting for analysis, a size-matched section of non-
wounded steady-state skin adjacent to the wound area (green 
rectangle) was collected for comparison purposes. 
                          Chapter 5: Comparative analysis of adult DPP9wt/S729A and WT mouse skin 
131 
 
VCA) and the surface of the dorsum was shaved, washed with warm water and then 
excess hair removed using Nair sensitive hair removal cream (Nair®, Church & Dwight 
Co Inc., Ewing, NJ, USA). Prior to wounding, the skin was cleaned with Povidone-iodine 
(Betadine, Stamford, CT, USA). An 8 mm biopsy punch (Kays Medical, Liverpool, UK) 
was used to make an incision wound on the dorsal midline of the mice. Post-wounding, 
mice were given a subcutaneous injection of ampicillin [50 mg/kg] (Austrapen) and 
temgesic [0.03 mg/kg] (Reckitt Benckiser) and recovered on a heating pad. The wound 
was covered for 12 h with Tegaderm (Tegaderm™, 3M Company, Maplewood, MN, 
USA). After removal of the Tegaderm, a second subcutaneous dose of 
ampicillin/temgesic was given to the mice.  
Daily measurements of wound closure rates were undertaken for 5 or 10 days by 
photographing wounds then analysing the wound image using ImageJ software. Data 
were analysed by unpaired t-test using GraphPad Prism and significance was assigned 
to P values less than 0.05. 
 
5.2.2 Tissue harvest and staining 
 
Wound and non-wound steady-state tissue for histological analysis was harvested 5 
days post-wounding, flattened onto biopsy pads in histosettes, incubated overnight in 
10% formalin and then processed routinely through to paraffin blocks. To undertake 
histological observations, paraffin-embedded skin samples were sectioned at 5 µm 
and hematoxylin and eosin (H and E) stained. For localisation and assessment of 
collagen, sections were stained with Sirius Red. H and E and Sirius red staining were 
                          Chapter 5: Comparative analysis of adult DPP9wt/S729A and WT mouse skin 
132 
 
performed by the Histopathology Department, Discipline of Pathology, Blackburn 
Building, University of Sydney. 
 
Microscopic analysis of sections was performed using a Leica DM6000 B microscope 
and ImageJ software was used to quantify levels of collagen as represented by positive 
Sirius red staining (Hadi et al., 2011). Data were analysed by unpaired Mann-Whitney t 
test using GraphPad Prism and significance was assigned to P values less than 0.05. 
 
5.2.3 Hydroxyproline assay 
 
Wound and non-wound steady-state tissue was harvested at Day 5 post-wounding, 
weighed (ranging between 100-250 mg) and then placed in a 2 ml screw cap tube. 150 
µl of concentrated HCl (Sigma) was added to each tube and samples were hydrolysed 
on a heat block at 110˚C for 3 h. After samples had liquefied they were vortexed then 
quickly spun in a centrifuge (30 sec). Standards were prepared by diluting 1 mg/ml 
hydroxyproline (Sigma #MAK008) in TDW to make a standard curve ranging from 0-20 
µg/ml. After samples had cooled they were transferred to wells of a 96-well clear, flat-
bottomed plate in triplicate along with standards samples. The plate was placed in a 
dry oven at 60˚C until samples had completely dried. 100 µl of solution A (chloramine 
T/citrate-acetate buffer) was added to each well and left for 5 min at RT. 100 µl of 
solution B (Erhlich’s solution) was then added and the plate was incubated at 60˚C for 
90 min. Absorbance was read at 560 nm using a BMG plate reader (BMG Labtech, 
Germany). Using the BMG plate reader software (Omega Mars, BMG Labtech, 
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Germany), the values for each well were corrected for background and triplicates were 
averaged. 
5.2.4 Biomechanical analysis of tissue 
 
Skin tensile strength was measured using an Instron 5567 tensiometer (Instron 
Corporation, Buckinghamshire, UK) after training by Mr Trevor Shearing at the School 
of Aerospace, Mechanical and Mechatronic Engineering, University of Sydney. Dorsal 
skin samples from the wound area and adjacent non-wound steady-state skin were 
harvested 14 days post-wounding. At this stage, wounds from all the groups (n = 3-8) 
had closed completely. Skin samples were trimmed to approximately 3 cm x 1 cm and 
attached to paddle pop sticks using super glue to clamp them firmly (Figure 5.2). The 
glue was applied with care to avoid contamination of the 1 cm x 1 cm analysis area.  
Figure 5.2: Preparation of samples for tensile strength measurements. 
A strip of wounded or steady-state skin was cut to approximately 3 cm x 1 cm and the two 
ends were glued between two paddle pop sticks using super glue. The sticks were used to 
attach samples to the upper and lower clamps of the Instron tensiometer. Samples were then 
stretched until breaking point to measure tensile strength. 
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Samples were flattened onto cardboard, wrapped in tissue then foil, snap frozen in 
liquid nitrogen and stored at -80˚C until they were ready for analysis. Upon thawing, 
samples were prevented from drying out by dampening them with PBS. Advice for the 
preparation and tensile strength measurement of skin samples was given by Dr Philip 
Boughton (Biomedical Engineering, School of Aerospace, Mechanical and Mechatronic 
Engineering, University of Sydney).  
Tensile force was applied using a 100 N load cell and motor drive speed was 
controlled by Instron Merlin software (version 5.52). The output force was 4 g and 
the sample cycle was 0.2 sec. The paddle pop sticks were placed between two clamps 
and stretched at 5 mm/min until breaking. Data were analysed for toe region, linear 
region and maximum load (Figure 5.4) using GraphPad Prism and significance using t 
test was assigned to p values less than 0.05. 
 
5.3 Results 
 
5.3.1 Wound closure and healing 
In the first 24 hours post-wounding, wound sizes increase in all mice due to skin 
flexibility and stretchiness. Hence, all analysis was determined from Day 1 onwards 
with subsequent measurements being normalised against Day 1 percentage wound 
areas.  Since no percent-wound-area difference was seen between DPP9wt/wt mice, 
which are raised on a C57BL/6J background, and C57BL/6J mice (data not shown), the 
means of all WT mice (DPP9WT + C57BL/6J) from both sources were combined for 
wound closure analysis and graphing. Macroscopic analysis of wounds from daily 
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measurements revealed no significant delay in wound closure in DPP9wt/S729A mice 
compared to either DPP9wt/wt mice or C57BL/6J (Figure5.3).  All wounds had completely 
closed by Day 10-11 in all groups. 
 
5.3.2 Skin tensile strength 
To give an indication of skin strength and elasticity after the closure of wounds, tensile 
strength was investigated on wounded and adjacent steady-state tissue harvested 14 
days post-wounding. Because the mechanical behaviour of skin is not the same in 
every direction (Funk, 2007, Annaidh et al., 2010, Yang et al., 2015), several different 
methods of analysis were employed to overcome the variability in data. The physical 
behaviour of skin, when subjected to stretching, differs from properties observed with 
non-biological materials. Figure 5.4 represents a simplified diagram of the behaviour of 
the collagen fibres in skin when subjected to a load. In the toe region of stress-strain 
graphs the collagen fibres are pulled into alignment reflecting skin stretchiness, while 
the linear region reflects the stiffness, density and cross-linking of the fibres after 
alignment (Mao et al., 2002). Once the stretch of the skin is beyond the physiological 
range, collagen fibrillar failure results in rupture of the skin at maximum load.  
Raw tensiometer data was used to create stress-strain curves (data not shown) which 
were used to extrapolate the toe region length, linear region slope and maximum load 
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Figure 5.3: Wound closure rate of WT and DPP9wt/S729A adult mouse skin 
No difference was seen in wound closure rates between WT and DPP9wt/S729A adult 
mouse skin. Wound area change during healing is represented as a percentage of the 
initial wound size at Day 1. Wounds were measured daily using ImageJ software to 
determine area by analysis of wound images. n = 8 (DPP9het) and 11 (DPP9WT + 
C57BL/6 WT). The error bars depict standard deviation. 
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point. Most stress-strain curves generated for the skin samples measured displayed 
the expected format of initial stretch, extension and finally skin breakage (Figure 5.4). 
However, from sample to sample, the points where extension and breakage occurred 
was reasonably variable. In a small number of samples the curve was skewed away 
from the expected format which is most likely due to the mechanical nature of skin 
and microscopic differences between skin samples.  
Figure 5.4: Diagrammatic representation of the stress-strain curve for skin 
When a load is applied to a skin sample the crimped collagen fibres first straighten and align, 
then stretch and eventually fracture. The toe region is an indicator of skin stretchiness. The 
linear region indicates the ability of the collagen fibres to slide past each other. The skin 
ruptures when the collagen fibres fracture. Modified from (Funk, 2007) 
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The toe region of the curve gives an indication of the normal range of skin deformation 
and, hence, the elasticity of skin when first subjected to a load. Not surprisingly, there 
was a significant difference in the toe region of the stress-strain curves for both 
DPP9wt/S729A and WT mouse skin when comparing wounded skin with normal steady-
state skin (Figure 5.5). At Day 14 post-wounding, re-epithelialisation is complete but 
the resultant scar has reduced tensile strength (Schafer and Werner, 2008). Therefore, 
the stretchiness of wounded skin will be reduced. However, when considering the 
difference in elasticity of skin from heterozygous and WT mice, there was no statistical 
difference in toe length between them for either wounded or adjacent steady-state 
skin (Figure 5.6).  
The linear region of the stress-strain curve sits within the physiological range where 
skin has not yet undergone any microscopic failure and this region gives an indication 
of the ability of the collagen fibres to move past each other once straightened. This is a 
measure of skin stiffness (Mao et al., 2002). In order to avoid the toe region and any 
potential microscopic failure, the slope was measured using the central half of the 
linear region. Wounded skin (Figure 5.7) showed no statistical difference in the slope 
of the linear region for DPP9 heterozygous skin as compared to WT. Similarly, no 
statistical difference was seen in the slope of the linear region between heterozygous 
and WT skin for steady-state skin (Figure 5.8).  
The final consideration of skin properties between samples is ultimate tensile strength 
which is the point at which macroscopic failure and rupture of the skin occurs. This 
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Figure 5.5: Estimated length of the toe region of the stress-strain curve for 
DPP9wt/S729A and WT mice from steady-state and wounded skin  
The toe region of the stress-strain curve of Day 14 mouse skin showed 
significant differences between the wounded and adjacent steady-state skin 
for both DPP9wt/S729A and WT mice. The analysis of the toe region was 
determined with GraphPad Prism software. n = 7-8 (DPP9het) and 10-11 
(DPP9WT + C57BL/6 WT). Error bars denote SD and significance was assigned 
where p < 0.05 (*), p < 0.01 (**), p < 0.001 (***). 
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Figure 5.6: Estimated length of the toe region of the stress-strain curve for 
wounded and steady-state skin from DPP9wt/S729A and WT mice 
The toe region of the stress-strain curve of Day 14 mouse skin showed no 
significant differences between DPP9wt/S729A and WT mice for either the 
wounded or the adjacent steady-state skin. The analysis of the toe region was 
determined with GraphPad Prism software. n = 7-8 (DPP9het) and 10-11 
(DPP9WT + C57BL/6 WT). Horizontal bars (red) are means and error bars depict 
SD. 
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Figure 5.7: Analysis of the slope of the linear region of the stress-strain curve for 
wounded mouse skin 
The slope of the linear region of the stress-strain curve from Day 14 wounded mouse 
skin from DPP9wt/S729A and WT mice showed no significant difference between 
genotypes. Stress-strain curves were measured using an Instron tensiometer and the 
analysis of the linear region was determined with GraphPad Prism software. n = 7 
(DPP9het) and 10 (DPP9WT + C57BL/6 WT). Horizontal bars (red) are means and error 
bars depict SD. 
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Figure 5.8: Analysis of the slope of the linear region of the stress-strain curve for 
steady-state skin adjacent to the wound area in mouse skin 
The slope of the linear region of the stress-strain curve from Day 14 steady-state 
mouse skin from DPP9wt/S729A and WT mice showed no significant difference between 
genotypes. Stress-strain curves were measured using an Instron tensiometer and the 
analysis of the linear region was determined with GraphPad Prism software. n = 8 
(DPP9het) and 11 (DPP9WT + C57BL/6 WT). Horizontal bars (red) are means and 
error bars depict SD. 
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Figure 5.9: Maximum stress of the stress-strain curve for steady-state and 
wounded mouse skin 
The maximum stress measurements of Day 14 mouse skin showed no significant 
differences between DPP9wt/S729A and WT mice for either the wounded or the 
adjacent steady-state skin. The analysis maximum was determined with GraphPad 
Prism software. n = 7-8 (DPP9het) and 10-11 (DPP9WT + C57BL/6 WT). Horizontal 
bars (red) are means and error bars depict SD. 
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failure force was measured as the point of maximum stress which corresponds directly 
with the maximum load applied for skin breakage. No statistical difference was found 
for the ultimate tensile strength of DPP9wt/S729A and WT mouse skin in the wounded 
skin and adjacent steady-state skin (Figure 5.9). The maximum stress needed to cause 
skin breakage was, however, fifty fold greater in steady-state skin compared to 
wounded skin which is consistent with the presence of scar tissue and reduced tensile 
strength as mentioned previously. 
 
5.3.3 Skin collagen levels 
Collagen levels were estimated by two methods: Sirius red staining and skin 
hydroxyproline content. The Sirius red staining and hydroxyproline assays were 
performed on wound tissue and adjacent steady-state tissue harvested 5 days post 
wounding.  
 
5.3.3.1 Sirius Red staining 
Skin tissue from wounded or the adjacent steady-state skin in DPP9wt/S729A and WT 
mice was harvested at Day 5 post-wounding and sections were stained with Sirius Red. 
In these sections, the presence of cross-linked collagen was indicated by positive red 
staining. All measurements for wounded tissue were taken in the areas of granulation 
tissue formation at the edges of the wound. All measurements for steady-state tissue 
were taken from random areas along the skin section length. In steady-state skin  
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Figure 5.10: Collagen levels indicated by positive Sirius Red staining of steady-state 
and wounded mouse skin 
Skin tissue from wounded and adjacent steady-state skin in DPP9wt/S729A and WT mice 
was harvested at Day 5 post-wounding and sections were stained with Sirius Red. 
Positive staining corresponded to the presence of cross-linked collagen. No significant 
differences between DPP9wt/S729A and WT mice for either the wounded or the adjacent 
steady-state skin were detected. Each value represents the average of 5 separate ROIs in 
5 separate areas analysed from the same slide. The percentage positive staining was 
determined with GraphPad Prism software. n = 8 (DPP9het) and 6 (DPP9WT). Horizontal 
bars (red) are means and error bars depict standard error of the mean. 
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 (Figure 5.10), positive staining was lower in DPP9wt/S729A mouse skin compared to 
DPP9WT skin but this difference was not statistically significant. In wounded skin 
(Figure 5.10), no differences in collagen levels between DPP9wt/S729A and WT mice were 
detected. This finding is consistent with the wound healing data (Figure 5.3) where 
wound closure rates were not significantly different between genotypes at Day 5 post-
wounding. Across all data, however, collagen levels were at least two times higher 
overall in steady-state skin compared to wounded skin. This result is expected as the 
early stage of wound healing has depleted levels of collagen where only small amounts 
of newly synthesised collagen exist (Sabol et al., 2012).  
5.3.3.2 Hydroxyproline assays 
Since hydroxyproline is a major component of cross-linked collagen, total collagen can 
be estimated from skin samples by acid hydrolisation of proteins and measurement of 
hydroxyproline content by colorimetric assay. As with Sirius Red staining, 
hydroxyproline levels were also measured in Day 5 post-wounding skin tissue. 
In line with the collagen levels measured in Sirius Red-stained skin wound tissue, the 
hydroxyproline content measured by assay in wound samples (Figure 5.11) showed no 
significant difference between DPP9wt/S729A mouse skin compared to DPP9WT skin. 
Interestingly, the adjacent steady-state tissue shows significantly reduced levels of 
hydroxyproline (p = 0.0082) in the DPP9wt/S729A mouse skin compared to DPP9WT skin. 
This is consistent with the trend towards reduced positive staining in steady-state 
Sirius Red-stained skin (Figure 5.10), although no statistical significance was shown 
there. 
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Figure 5.11: Collagen indicated by hydroxyproline levels in steady-state and wounded 
mouse skin 
Skin tissue from wounded and adjacent steady-state skin in DPP9wt/S729A and WT mice 
was harvested at Day 5 post-wounding and tissue was assayed for hydroxyproline. No 
significant difference between DPP9wt/S729A and WT mice for wounded skin was 
detected. Steady-state skin showed a significantly lower level of hydroxyproline in 
DPP9wt/S729A mice compared to WT mice (P=0.0082). n = 7-8 (DPP9het) and 6 
(DPP9WT). Column heights are means and error bars depict SD. Data were analysed by 
unpaired Mann-Whitney t test using GraphPad Prism and significance was assigned 
where p < 0.05 (*), p < 0.01 (**), p < 0.001 (***). 
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5.4 Discussion 
In this chapter, the aim was to characterise adult DPP9-GKI mouse skin and determine 
differences, if any, between DPP9-GKI heterozygous skin and that of their WT 
littermates and WT C57BL/6J mice. This was undertaken by sampling mouse skin 
subjected to a full thickness wound or adjacent skin in a non-wounded steady state. 
Other members of the DPP4 protein family are known to be involved in wound healing, 
fibroblast regulation and skin function, but no in vivo studies have been undertaken in 
relation to DPP9. Also, no published works have addressed the structural integrity of 
adult mouse skin partially deficient in DPP9. 
In this study, macroscopic monitoring of wound closure rates were investigated 
comparatively in WT and DPP9-GKI heterozygous mice. It has been shown that the skin 
of loose-skinned animals, such as mice, can move and retract over subcutaneous fascia 
enabling relatively rapid bridging of the wounded edges by granulation tissue and new 
epithelium. (Davidson, 2001). All wounds in the mice in this study had closed by 11 
days after wounding and no difference was seen between C57BL/6J WT, DPP9wt/wt and 
DPP9wt/S729A adult mouse skin in relation to the rate of wound closure. Since the ability 
of skin to heal after wounding is essential to survival, there are almost certainly 
redundant pathways that ensure healing occurs when regular processes are slow or 
non-functional. With this in mind, it may be surmised that, if DPP9 plays a part in the 
healing process, its role is non-essential. 
Consideration of steady-state skin provides a benchmark with which to compare the 
effect of wounding on skin structure and function. Most importantly, however, it 
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provides a comparison between DPP9-GKI heterozygous and WT skin which directly 
relates to the possible role of DPP9 in skin of the adult DPP9-GKI mouse. 
Biomechanical analyses were used to assess the overall tensile strength, with stress-
strain curves providing data on skin elasticity, skin stiffness and ultimate tensile 
strength before rupture. For skin elasticity, as shown by the toe region of stress-strain 
curves, no statistical difference was seen between WT and DPP9-GKI heterozygous 
steady-state skin, although there was a trend towards increased elasticity in the DPP9 
heterozygous skin over the WT skin suggesting a possible variation from the normal 
range of skin deformation. 
When a load is applied, collagen fibres in the skin straighten and slide past each other 
within the physiological range of normal steady-state skin extension and stiffness. This 
is displayed by the linear region of the stress-strain curve. While most steady-state skin 
samples measured on the tensiometer displayed a smooth linear region, the levels of 
variability amongst samples was fairly high. Because the mechanical nature of skin is 
multi-directional, some samples showed abnormal curves in the linear region which 
most likely corresponded to microscopic fracture of collagen fibres preceding 
macroscopic skin rupture. Despite this variability, analysis of the slope measurements 
resulted in fairly close grouping of data points, with few outliers, in steady-state 
heterozygous and WT skin and no statistically significant difference was observed 
between these groups for linear region slope. 
The point of macroscopic failure of skin is generally considered to be its ultimate 
tensile strength. While no significant difference was seen between WT and DPP9-GKI 
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heterozygous samples in the steady-state skin, there was a trend towards earlier 
breakage in DPP9-GKI heterozygous skin compared to WT. However, the data for the 
steady-state skin encompassed a large range of maximum stress readings and this 
variability conferred some uncertainty about the strength of heterozygous compared 
to WT skin. 
Both collagen and elastin fibres are components of skin. Elastin makes tissues elastic 
and allows recoil after deformation and a mixture of collagen and elastin prevents skin 
from overstretching (Starcher et al., 2005). Collagen, however, is the most common 
fibrous protein in the extra-cellular matrix of skin and has an important role in the 
structural integrity of skin and in wound healing. It was, therefore, the focus of this 
study.  
To better compare whether changed collagen accumulation existed between healing 
and/or steady-state DPP9 heterozygous skin and WT skin, collagen content was 
assessed in Day 5 post-wounding skin by two methods. Firstly, Sirius Red staining of 
skin sections was undertaken to assess in situ collagen and, secondly, hydroxyproline 
assay of digested skin samples was used to estimate total collagen.  
With Sirius Red staining analysis, the steady-state tissue was of interest since the 
collagen levels were less in the DPP9-GKI heterozygous skin compared to WT skin. 
While this result was not statistically significant, it was consistent with the trends 
observed previously for tensiometer data of steady-state skin and possibly suggested 
reduced collagen present in heterozygous adult mouse skin. Tissue collagen level of 
steady-state skin at Day 5 post-wounding was also assessed using a hydroxyproline 
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assay as a measurement of cross-linked collagen.  Interestingly, for this analysis, there 
was a statistically significant decrease in hydroxyproline levels in the DPP9-GKI 
heterozygous skin compared to WT skin. As DPP9 is able to hydrolyse the post-proline 
bond of a hydroxylated proline (Zhang et al., 2015b), it is very likely that this 
hydroxyproline measurement was an accurate reflection of total collagen. 
This result supports the trends shown in the tensile strength and Sirius Red staining 
data towards reduced collagen levels in steady state heterozygous skin. This is a novel 
finding for the DPP9-GKI heterozygous mouse and raises the question as to whether 
this low level of collagen in skin is confined to that organ. It would be interesting to 
measure collagen in other organs throughout the DPP9-GKI heterozygous mouse in 
future studies to assess whether any of these also display reduced collagen levels. 
Two weeks post-wounding, when the healing was complete, the wounded skin was 
analysed biomechanically in the same manner as steady-state skin for skin elasticity, 
skin stiffness and ultimate tensile strength. Assessment of skin elasticity also showed 
no statistical difference between WT and DPP9-GKI heterozygous wounded skin, but a 
similar trend towards increased elasticity in the DPP9-GKI heterozygous skin was seen.  
When comparing steady-state and wounded skin, however, significantly shorter toe 
regions were seen between wounded and steady-state skin reflecting the decreased 
integrity of wounded skin. This is not surprising as it has been previously reported that 
skin never regains its full tensile strength after wounding (Broughton et al., 2006) or at 
least has reduced tensile strength in the scar region (Schafer and Werner, 2008). 
However, unlike other organs such as liver where scarring is detrimental to normal 
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function (Chowdhury et al., 2013), scarring in skin is well tolerated, possibly due to the 
looseness of mouse skin. 
Analysis of the linear region in stress-strain curves of wounded skin showed no 
significant difference between WT and DPP9-GKI heterozygous skin suggesting that, 
like the steady-state skin, these samples displayed a similar level of stiffness and skin 
extension ability. While the ultimate tensile strength of wounded skin did not vary 
between heterozygous and WT groups, the maximum stress needed to cause wounded 
skin to break was only around 2% of that needed than for steady-state skin. This 
finding is consistent with the reduced strength of scar tissue mentioned previously. 
Analysis of collagen content in wounded skin, as with steady-state skin, was 
undertaken by Sirius Red staining and hydroxyproline assays. For Sirius Red staining of 
the skin wound regions, measurements and analysis was confined to the granulation 
region. In this region, remodelling of the extra-cellular matrix enables the body to 
replace damaged tissue. The secretion of collagen by fibroblasts after wounding acts as 
a framework for the migration of cells involved in replenishing the extra-cellular matrix 
and is an essential process in wound healing (Broughton et al., 2006). In wound tissue, 
there was no significant reduction in cross-linked collagen levels, as represented by 
Sirius red staining, between WT and DPP9-GKI heterozygous skin which is consistent 
with the wound closure rate data at Day 5. The percentage of positive staining of 
collagen was around 25% of total tissue area and reflects the lessened levels of 
collagen in early stages of wound repair. 
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Wounded skin also showed no significant difference in hydroxyproline content 
between WT and DPP9-GKI heterozygous skin. The amounts of hydroxyproline 
observed in wounded skin were only slightly reduced compared to those seen in 
steady-state skin which is contrary to the expected reduced level of collagen present in 
early wound healing. However, the harvest of wound tissue for assay included some 
surrounding healthy tissue, as well as wound tissue, and this may have increased the 
overall hydroxyproline levels. Careful excision of wound tissue to avoid surrounding 
steady-state tissue may overcome this and provide more accurate levels of 
hydroxyproline content.  
In summary, detailed analyses of wounded skin showed no significant differences in 
skin strength or collagen content between DPP9-GKI heterozygous and wild-type 
controls. For wounded skin, clear conclusions cannot be made about skin tensile 
strength or collagen content differences between DPP9-GKI heterozygous skin and WT 
skin because of the confounding factor of scar formation and some inclusion of steady-
state skin in harvest tissue. Future experiments should focus on examining greater 
numbers of wounds which will increase the statistical power of data and help to 
overcome the high variability between samples. 
The overall analyses of adult mouse skin showed that skin in the steady state contains 
less collagen in DPP9-GKI heterozygous mice than in their WT littermates and WT 
C57BL/6J mice. When DPP9 is genetically altered, this may cause a reduction in early 
collagen deposition in developing skin, which results in reduced tensile strength and 
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collagen levels. This effect is likely via its enzymatic activity, as DPP9 intact protein is 
still present in heterozygous mouse skin, although some may be inactive.  
Future studies could include investigation of collagen levels in DPP9-GKI embryos 
and/or neonates in skin and other organs. Also, if a specific DPP9 inhibitor becomes 
available, it may be possible to assess collagen levels in WT C57BL/6J mouse skin, with 
and without inhibitor administration to ascertain if the DPP9-GKI results can be 
emulated. Nevertheless, the suggestion of reduced collagen levels in DPP9-GKI 
heterozygous skin compared to WT skin in the steady-state condition is intriguing and 
the possibility that carrying the DPP9 S729A mutant allele affects the collagen content 
and integrity of DPP9-GKI heterozygous skin is worthy of further investigation 
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6 The role of DPP9 enzymatic activity in immune 
regeneration and function 
 
6.1 Introduction 
 
DPP9 has been shown to have roles in both innate and adaptive immunity. DPP9 has 
extensive in vivo expression in immunological tissues (Yu et al., 2009) and leukocyte 
populations (Abbott et al., 2000b, Lankas et al., 2005, Maes et al., 2007, Bank et al., 
2011, Chowdhury et al., 2013). DPP9 mRNA and protein is up-regulated in vitro in 
some cell lines upon B and T cell activation (Heimburg et al., 2008, Chowdhury et al., 
2013). DPP9 has been shown to be involved in antigen presentation (Geiss-Friedlander 
et al., 2009) and activation and proliferation of immune cells may be affected by DPP9 
enzymatic activity (Lankas et al., 2005, Reinhold et al., 2009, Waumans et al., 2015, 
Waumans et al., 2016) suggesting a role for DPP9 in the regulation of immune 
function. 
The role of other dipeptidyl peptidases in recovery from irradiation and subsequent 
hematopoiesis have been studied and shown to have potential for therapeutic utility. 
Using irradiated DPP4-deficient mice or mice treated with an oral DPP4 inhibitor, 
hematopoiesis and engraftment can be enhanced while maintaining normal 
hematopoietic stem cell (HSC) function (Broxmeyer et al., 2012). The dipeptidyl 
peptidase inhibitor Val-boro-Pro, which inhibits DPP4, DPP8, DPP9 and FAP (Okondo et 
al., 2016), resulted in increased hematopoietic progenitor cell growth in vivo and up-
regulation of erythrocyte and neutrophil regeneration in mouse models of acute 
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anemia (Jones et al., 2003). DPP4 has also been shown to be expressed on immune 
cells of both the myeloid and lymphoid lineages including activated NK cells, activated 
B cells, T cells and myeloid cells and the current knowledge of its interactions has been 
recently reviewed (Klemann et al., 2016).  
Of possible clinical significance, FAP-positive mesenchymal stromal cells have been 
shown to be resistant to lethal levels of irradiation. While host HSCs are destroyed, the 
stromal cells survive, leaving them to support hematopoietic reconstitution along with 
donor HSCs (Sugrue et al., 2013). Despite these findings, there have been no studies 
examining the role of DPP9 in the regenerating immune system and/or whether the 
absence of DPP9 enzymatic activity can affect short term and long term repopulation 
of immune cells of the lymphoid or myeloid lineages. 
This study aims to expand the current knowledge of DPP9 in immune regeneration by 
the creation of mouse chimeras using donor fetal liver cells or adult bone marrow cells 
injected into irradiated myelo-ablated recipient mice. As the DPP9S729A/S729A mice are 
neonate lethal but embryonically stable, it was necessary to use fetal liver tissue for 
the primary chimera creation to bypass this lethality.  
In the mouse, HSCs migrate into the fetal liver between ED 11 and 12 where their 
numbers expand massively and the fetal liver becomes the main hematopoietic organ 
until birth (Ema and Nakauchi, 2000, Mikkola and Orkin, 2006). Although 
hematopoiesis in the liver is sustained throughout the first week after parturition, it is 
no longer a prime hematopoietic site, instead becoming the functional hub of 
metabolism. Between ED 13.5 and 14.5, the fetal liver contains a large number of 
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hematopoietic foci with erythropoiesis constituting a major part of their activity 
(Takeuchi and Miyajima, 2004) but myelopoiesis and lymphopoiesis are also occurring 
(Traver et al., 2001).  
While it is technically challenging using fetal liver cells for transplantation, there is an 
advantage in that the regenerative capacity of fetal liver is much more effective than 
bone marrow for long term repopulation as the fetal liver HSCs are actively cycling 
(Harrison et al., 1997, Mikkola and Orkin, 2006). Additional to the increased 
effectiveness of fetal liver cells, the long-term reconstituting HSCs are up to seven fold 
more frequent in fetal liver than in adult bone marrow (Morrison et al., 1995). This can 
be important for the creation of a primary chimera as it reduces the chances of failure 
of hematopoietic cell reconstitution. 
After transplant, the identification of the progeny of the transplanted HSCs is 
important to ascertain the effectiveness of the original graft and the properties of the 
regenerating immune system. The most common method used to achieve this is by the 
CD45 allelic model where the genetic differences between donor and recipient mouse 
strains of the pan-leukocyte antigen CD45 can be traced using specific markers and 
flow cytometry analysis (Spangrude, 2001, Gudmundsson et al., 2012, Wognum and 
Szilvassy, 2015). The DPP9 mouse strain has been raised on a C57BL/6 background 
which has the CD 45.2 allelic variant, therefore donor cells were transplanted into a 
congenic mouse strain expressing the CD 45.1 allele (Shen et al., 1985), thus enabling 
identification of donor and recipient cells for this experiment.   
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The establishment of a long-term detectable graft is dependent on the self-renewal 
activity of the original HSCs. Mouse HSCs have been shown to include at least three 
multipotent populations consisting of long-term (LT)-HSC, short-term (ST)-HSC and 
multipotent progenitor (MPP) cells. However, the MPP cell population has lost the self-
renewal capacity of HSC and, therefore, engraftment can only be achieved with HSCs 
(Morrison and Weissman, 1994, Seita and Weissman, 2010). The mechanisms that 
determine whether self-renewal is stable or transient are under continuing 
investigation and refinement (Benveniste et al., 2010). While LT-HSCs are capable of 
Figure 6.1: Diagram of the fate of hematopoietic stem cells in immune regeneration 
 
Hematopoietic stem cells derived from fetal liver or adult bone marrow differentiate through 
lymphoid and myeloid cell lineages into a variety of cell types. Modified from (Tai et al., 2012) 
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self-renewal for life, ST-HSCs can self-renew for six to eight weeks and are known to 
give rise to the MPP population consisting of the common lymphoid (Kondo et al., 
1997) and myeloid (Akashi et al., 2000) progenitors which subsequently result in the 
production of all cell types existing in the regenerated bone marrow and peripheral 
blood of the recipient mice (Figure 6.1) (Shizuru et al., 2005, Tai et al., 2012).  
Donor-derived cells are detected in very low numbers at approximately two weeks 
after transplantation when chimerism is being established and are easily detectable by 
the 4 week time-point (Spangrude, 2001). The neutrophils and macrophages are the 
first cell types to recover after combined myelo-ablative irradiation and fetal liver or 
adult bone marrow cell transplant. They appear in the first few days after transplant 
followed closely by B cells. Platelets and red blood cell lineages then occur in the 
peripheral circulation at one to two weeks (Duran-Struuck and Dysko, 2009). As T cells 
are resistant to irradiation, surviving residual host T cells can be found within three 
weeks of transplant, while donor T cells do not usually appear in high numbers until 4 
to 5 weeks after irradiation (Spangrude, 2001). Interestingly, at 4 to 6 weeks post-
transplant, HSCs undergo a reprogramming ‘switch’ of many characteristics which 
results in a change in the gene expression pattern of the cells from fetal to adult genes 
(Bowie et al., 2007). The HSCs show less self-renewal and become more quiescent and 
this is similar to the situation that exists for endogenous HSCs in non-chimeric mice 
between birth and six weeks of age (Figure 6.2). 
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Transplants carried out using adult bone marrow are not as effective as fetal liver for 
long-term cell repopulation since BM cells need to first overcome their quiescent 
status. Once they have entered the cell cycle, however, BM cells undergo the same cell 
cycle transit time as fetal liver cells (Bowie et al., 2007). In a comparable manner to 
fetal liver cell transplant, donor-derived cells from bone marrow transplant, such as 
monocytes and neutrophils, can be found in recipient mice in the first week and by the 
third week after transplant the peripheral reconstitution of all cell lineages may be 
Figure 6.2: Diagram of programming of hematopoietic stem cells in immune 
regeneration 
Hematopoietic stem cells, after the time-point at 4 to 6 weeks post irradiation, show a 
coordinated reprogramming of multiple key properties which mimic the endogenous HSC 
changes in non-chimeric mice at a similar time-point. These include a reduction in cell 
cycling, a lower self-renewal potential, a decrease in myeloid cell output and a transition 
from a fetal to adult gene expression profile.  Modified from (Bowie et al., 2007) 
Pre-switch HSCs Post-switch HSCs
Cycling
High self-renewal
High myeloid cell
output
Fetal gene expression
pattern
Quiescent
Lower self-renewal
Reduced myeloid
cell output
Adult gene expression
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complete (Duran-Struuck and Dysko, 2009). However, as with fetal liver cell transplant, 
the functionality of the regenerated immune system at this early stage is not yet 
assured.  
As previously stated, it was necessary for the primary chimera to use fetal liver cells for 
transplant to overcome the neonate lethality of DPP9-GKI mice. The secondary 
chimera could then be created using adult bone marrow from primary chimeric mice. 
Fetal liver or adult bone marrow cells carrying the DPP9 mutant allele that have been 
transplanted into wild-type mice would enable detection of the intrinsic effect of DPP9 
deficiency on lymphoid and myeloid differentiation in a cell autonomous manner. 
Short term (30 to 60 days) and long-term (4 months) engraftment analysis would be 
expected to reveal whether DPP9 deficiency leads to defects in HSCs and/or 
hematopoietic progenitor cells.  
A successful short- term primary engraftment can provide confirmation that the 
progenitor cell pool is intact and that all myeloid and lymphoid cell types are present 
and, in the long term, whether the reconstituted HSCs are functional (Auletta et al., 
2004, Duran-Struuck and Dysko, 2009, Gudmundsson et al., 2012). However, even 
successful long-term engraftment in a primary transplant recipient may still have 
defects in self-renewal capability or the capacity for proliferation. It was therefore 
necessary to serially transplant the HSCs to overcome those issues. Hence, for this 
study, a secondary chimera was undertaken. Tertiary or even further serial transplants 
are often undertaken in chimera studies, however, any transplants after the secondary 
one undertaken were beyond the scope of the current work.  
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6.1.1 Aims 
The aims of the work in this chapter are to explore the role of DPP9 in the 
regeneration and function of the mouse immune system by: 
 creating chimeric mice via inoculation of irradiated PTPRCA mice with either 
fetal liver cells or adult bone marrow cells of DPP9S729A/S729A and DPP9wt/wt 
genotype origin 
 assessing the immune regeneration of irradiated chimeric mice by weight 
monitoring data and body scoring as an indicator of ongoing health and 
recovery 
 assessing donor engraftment and the degree of chimerism of resultant chimeric 
mice by flow cytometry of peripheral blood samples at two time-points 
 comparing cell types and percentages of regenerated immune cells in both 
primary and secondary chimeric mice to detect possible dysregulation of 
immune function in DPP9S729A/S729A–origin chimeras. 
 
6.2 Methods 
Immune regeneration was studied using irradiated recipient mice inoculated to 
produce either primary or secondary chimeras. DPP9S729A/S729A pups die in the early 
neonatal period and cannot be used for the harvest of bone marrow cells. Therefore, 
primary chimeras were produced by inoculating irradiated mice with donor fetal liver 
cells retrieved from embryonic mouse livers at embryonic day (ED) 13.5 – ED 14.5. 
Secondary chimeras were produced by using regenerated donor bone marrow cells 
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from adult primary chimeric mice as the inoculum for a new batch of recipient mice. 
After the completion of the flow analysis of peripheral blood, the remaining mice were 
subjected to an immune challenge. The experimental plan is detailed in Figure 6.3. 
 
6.2.1 Primary chimera methods 
 
6.2.1.1 Timed mates for embryo production 
Embryos required for fetal liver cells were obtained from pregnant females where 
pregnancy resulted from timed mating of DPP9wt/S729A intercrosses. Two days prior to 
mating, soiled male bedding was placed in female cages to stimulate ovulation 
(Whitten, 1956). For mating, single females were placed in the male home cage for a 
period of 12 h then checked for the presence of a vaginal plug as an indicator of 
mating prior to removal from the male cage. For the purposes of estimation of 
developing embryos, the time at which the female was separated from the male was 
assumed to be embryonic day (ED 0.5). Females were weighed at ED 0.5 to establish a 
baseline weight, then weighed daily from ED 4.5 until ED 13. Although most female 
mice increased their weight over this period, pregnancy was indicated if females 
displayed a noticeable increase in weight gain between ED 7.5 to ED 13.5 (Figure 6.4) 
(Mader et al., 2009).   
This method was found to be very accurate at estimating pregnancy and often gave an 
indication of the number of embryos being carried. 
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Figure 6.4: Graphical representation of body weight changes in female mice after 12 h 
timed exposure to males 
 
Baseline body weight of female mice was measured immediately after separation from 
male mice in a 12 h timed mate and daily thereafter. An increase in body weight, as 
compared to the baseline weight, between day 7 and day 13 after timed mating was used 
to indicate pregnancy of female mice. This graph is a representation of the pattern of 
observed differences in weight gain (as a percentage of baseline weight) between 
pregnant and non-pregnant female mice. 
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6.2.1.2 Fetal liver cell harvest and storage 
Only DPP9S729A/S729A or DPP9wt/wt fetal liver cells were used as donor cells for inoculation 
of irradiated mice, therefore it was necessary to isolate the liver cells and store them 
by freezing until genotyping results confirmed which samples were suitable for use in 
inoculation. 
 
6.2.1.2.1 Isolation of fetal liver cells 
Pregnant female DPP9wt/S729A were sacrificed at ED 13.5-14.5, uterine horns removed 
and individual embryos isolated under sterile conditions into 6-well plates containing 
liver cell (LC) buffer. The embryonic liver was carefully excised and placed on ice in a 
1.5 ml Eppendorf tube containing LC buffer until processing. A small piece of 
embryonic tissue was retained separately for genotyping. Each liver was mashed 
through a 70 µm sieve using a rubber stopper and rinsed into a 50 ml Falcon tube 
containing 5-10 ml LC buffer. A 20 µl aliquot of cell suspension was retained for cell 
count and viability checks. 
 
6.2.1.2.2 Freezing of fetal liver cells 
The cell suspension was centrifuged at 2000 rpm for 5 min, supernatant removed and 
the pellet resuspended by gentle pipetting in 500 µl of RT freezing solution. A 100 µl 
aliquot of this suspension was transferred to a cryotube for flow cytometry analysis 
and the remaining cell suspension to a separate cryotube for injection of irradiated 
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mice. Both tubes were placed in an isopentane-cooled container at -80o C overnight 
and then transferred into liquid nitrogen for deep storage until needed. 
 
6.2.1.2.3 Thawing of fetal liver cells 
Frozen aliquots of fetal liver cells were thawed for flow cytometry analysis or injection 
into irradiated mice. Each cryotube was swirled in lukewarm water to defrost the 
frozen pellet and the cell suspension transferred to a 15 ml Falcon tube containing 10 
ml RT LC buffer. The cell suspension was centrifuged at 2000 rpm RT for 7 min, 
supernatant removed and the pellet resuspended in 10 ml RT LC buffer. After standing 
at RT for 30 min to release the maximum amount of DMSO, the cell suspension was 
centrifuged at 4oC at 2000 rpm for 7 min.  
For injection, the pellet was resuspended in 400 µl of Hank’s balance salt solution 
(HBSS) and placed on ice. Cell suspensions were used to tail-vein inject two mice per 
sample at 200 µl per injection volume. 
For flow cytometry analysis, the pellet was resuspended in 1 ml ACK/ RBC lysis 
solution, transferred to an Eppendorf tube, vortexed briefly and left on ice for 5 min. 
The cell suspension was then processed as described in Section 6.2.1.2.4 below. 
 
6.2.1.3 Irradiation of recipient mice 
In order to later identify the origin of immune cells and the degree of donor 
engraftment in peripheral blood cells, PTPRCA mice were used as recipient mice for 
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immune regeneration studies. This C57BL/6 congenic strain is used widely in transplant 
studies because it carries the differential Ptprca pan leukocyte marker commonly 
known as CD45.1 or Ly5.1 (Shen et al., 1985), while DPP9-GKI mice have been bred on 
a C57BL/6 background and express the  CD45.2 allele. Male mice were used as they are 
known to show enhanced recovery of platelets in response to irradiation (Billings et al., 
2014) and their generally larger body weight also improves their ability to recover. 
Male mice can also be used as universal recipients in relation to possible immune 
responses due to the donor Y-chromosome and will accept either female or male 
donor grafts (Wang and Bunting, 2008). Before irradiation, all mice were weighed to 
provide a baseline weight. 
Eighteen 10 week old male PTPRCA mice received a myeloablative radiation using a 
Gammacell® 40 Exactor Low Dose-Rate Research Irradiator (MDS Nordion Inc.,Ontario, 
Canada).  Two doses with a 600 rad exposure (at a dose rate of 110 rad per minute) 
were administered 4 h apart. After each dose, mice were returned to their home cage 
and provided water containing the antibiotic Amphoprim (Virbac, New Zealand) at a 
dose of 1ml per 50 ml water bottle. Antibiotic water was provided for 14 days post-
irradiation and changed weekly. 
 
6.2.1.4 Inoculation of recipient mice 
After irradiation, mice were rested for 24 h before inoculation with fetal liver cells 
which were prepared as detailed in Section 6.2.1.2. The minimum number of cells 
required for fetal liver cell transplantation is 2 x 105 (Gudmundsson et al., 2012) and 
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each fetal liver yields 6 -8 x 106 cells. For this experiment, cells from each fetal liver 
were used to inoculate two mice only with a non-competitive strategy (Figure 6.5), 
ensuring cell numbers greatly in excess of those needed. Nine mice were injected with 
DPP9S729A/S729A-origin fetal liver cells which included four sets of replicate recipient 
mice (one donor liver per set) and one single recipient mouse. Similarly, nine mice 
were injected with DPP9wt/wt-origin cells. 
 
 
 
 
 
Figure 6.5: An example of a non-competitive strategy for transplanting fetal liver cells 
from a DPP9wt/wt (+/+) and a DPP9S729A/S729A (-/-) CD45.2 donor 
Fetal liver cells can be transplanted into a lethally irradiated PTPRCA (CD45.1) recipient 
and analysed for donor reconstitution 1-4 months post-transplantation. A CD45.1 
x CD45.2 staining usually shows some CD45.1-positive cells (5-10%) due to 
residual HSC and progenitor cells contributing to hematopoiesis. Modified from 
(Gudmundsson et al., 2012). 
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After warming for several minutes under a heat lamp, mice were placed in a mouse 
restrainer and injected with a 200 µl volume of fetal liver cells in HBSS via the tail vein 
using a 25-gauge needle. All tail vein injections were carried out by Dr Adam Cook who 
has extensive experience in mouse handling and tail vein injection. Mice were 
observed for signs of distress or adverse reaction to injection for 10 min before being 
returned to their home cage. 
 
6.2.1.5 Monitoring of irradiated mice 
All mice were checked 2 – 3 h after inoculation for adverse effects. Mice were then 
weighed and monitored daily for 14 days post-irradiation. A body scoring system was 
used recording details for each mouse of posture, activity and gait, breathing, 
hydration, the presence of abnormal excreta, body condition and body weight as 
compared to the baseline weight. A weight loss of greater than 15 % compared to 
original weight was considered as necessary for euthanasia of the mouse.  
After 2 weeks, antibiotic water was replaced with normal water. Mouse monitoring 
and weighing was reduced to twice weekly using the same scoring system as 
previously and continued until 6 weeks post-irradiation. At this point, it was 
undertaken weekly up until 16 weeks and termination of the experiment. 
 
6.2.1.6 Flow cytometry of fetal liver cells 
Flow cytometry analysis of aliquots of fetal liver cells was carried out to investigate 
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whether there was any difference between DPP9S729A/S729A and DPP9wt/wt fetal liver cells 
to be used for inoculation of irradiated mice to produce chimeras. Cell aliquots were 
thawed as described in Section 6.2.2.3 above. After initial RBC lysis, the cell suspension 
was centrifuged at 4oC at 2000 rpm for 5 min, the supernatant aspirated off and the 
pellet resuspended in ACK/ RBC lysis solution as previously. Centrifugation and 
washing of the cell suspension was repeated twice as above and the cell pellet was 
resuspended in 200 µl of FACS wash each time. During the wash/spin steps, the stain 
cocktail was prepared as described in Section 6.2.2.5. After the final washing step, 100 
µl of stain cocktail was added to each tube, the pellet resuspended by gentle pipetting 
and the tubes placed on ice in a covered container for 1 hr. Staining was followed by 
two repeats of centrifugation and resuspension of cells in 200 µl of FACS wash, then 
the cell suspensions were placed on ice until flow cytometry was carried out. Just prior 
to analysis, cells were filtered and DAPI was added [100 ng/ml]. Flow cytometry data 
were acquired using a BD LSRFortessa cytometer (BD Pharmingen) and subsequently 
analysed with FlowJo software (Treestar Inc., Ashland, OR, USA). 
 
6.2.1.6.1 Preparation of stain cocktail 
For the staining of fetal liver cells for flow analysis, the required fluorophore-
conjugated antibodies were added to an appropriate volume of FACS wash in a non-
transparent Eppendorf tube according to the number of samples and the chosen 
dilution, as detailed in Table 6.1. The stain cocktail was then centrifuged at maximum 
speed in a benchtop centrifuge at 4oC for 30 min to remove aggregates of non-specific 
fluorophores that can contaminate the stain. 
     Chapter 6: The role of DPP9 enzymatic activity in immune regeneration and function 
173 
 
Table 6.1: Antibodies used in the fetal liver stain and their target cells. 
 
Antibody 
 
Synonym/clone 
 
Target cell 
 
Dilution 
used 
 
Source: catalog 
# 
FITC CD11b M1/70 Myeloid cells 1:250 
 
BD Biosciences 
#557396 
 
APC TER-119 TER-119 Erythroid cells 1:250 
 
BD Biosciences 
#557909 
 
 
 
6.2.1.6.2 Gating strategy for flow analysis 
Beginning at ED 10.5 and through until the end of gestation, the mouse fetal liver acts 
as the main hematopoietic organ (Chagraoui et al., 2003). The production of 
hematopoietic stem cells (HSC) peaks between ED 13 and 15 (Morrison et al., 1995). 
During this phase, the fetal liver predominantly reflects active erythropoiesis and 
myeloid and lymphoid progenitors increase at a later stage (Mikkola and Orkin, 2006). 
The antibody TER-119 is reactive with mouse hematopoietic cells with a high specificity 
for erythroid cells at all developmental stages and, between ED 13.5 – 14.5, the 
majority of HSC are TER-119 positive (Kina et al., 2000, Kim et al., 2006).  CD11b is a 
non-erythroid lineage marker and positive HSC usually only occur in small numbers in 
mid-gestation in the mouse (Babovic and Eaves, 2014). 
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To compare whether the proportion of HSC present differed between DPP9S729A/S729A 
and DPP9wt/wt fetal liver cells to be used for inoculation, cells were stained with a 
simple stain panel using the markers TER-119 along with CD11b to define erythroid 
and myeloid cells respectively. Cells were gated to exclude RBC remaining after lysis 
and then gated to remove the contribution of cell doublets and dead cells. After this, 
the live cells were gated to identify the percentage of TER-119 positive and CD11b 
positive cells (Figure 6.6). 
Figure 6.6: FACS plot showing a representative final gate for fetal liver cell percentage 
comparisons of data from DPP9S729A/S729A and DPP9wt/wt aliquots. 
Panel shows the proportions of TER-119 and CD11b reactive cells after gating which 
excluded non-lysed RBC and isolated single cells and live cells. TER-119 positive cells 
indicate cells of the erythroid lineage while CD11b positive cells indicate cells of the 
myeloid lineage. This FACS plot is showing data from a WT aliquot. 
 
TER-119+CD11b-
CD11b+TER-119-
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6.2.2 Secondary chimera methods 
Prior to the harvest of bone marrow cells, all primary chimeric mice were genotype 
checked using a sample of peripheral blood. This confirmed that all chimeric mice 
displayed a peripheral blood genotype consistent with that of the fetal liver cells used 
in their original inoculation. Two healthy DPP9S729A/S729A –origin chimeric mice were 
then selected who had shared a cage but whose chimeric state was produced with 
different original fetal liver cell batches. Similarly, two DPP9wt/wt –origin chimeric mice 
were chosen. These four mice were used to provide bone marrow for the secondary 
chimera, along with two control PTPRCA mice used for competitor cells. 
 
6.2.2.1 Isolation of bone marrow cells 
Four PTPRCA primary chimeric male mice (8 weeks post-irradiation) and two PTPRCA 
non-chimeric male mice were used to harvest bone marrow cells for donor and 
competitor cells, respectively. Mice were sacrificed, pinned out belly up and swabbed 
with ethanol. After dissecting off the skin, the hind legs were removed and the femur, 
tibia and fibula separated and the muscle removed. The bones were then placed in a 5 
ml yellow-cap tube containing 3-4 ml of clean 2% FCS in PBS on ice. 
The tube contents were emptied into mortar and each bone was depressed with a 
pestle to crack and release bone marrow until the bones had no visible bone marrow 
and the buffer solution was pink. The supernatant was pipetted off and filtered 
through a 70 µm filter on top of 50 ml Falcon tube and several rinses carried out of the 
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mortar and filter to maximise the bone marrow cell yield. Tubes were centrifuged at 
300 x g for 5 min at 4oC and the supernatant carefully removed. The pellet was re-
suspended in 10-20 ml buffer then refiltered through a 40 µm filter into a clean 50 ml 
Falcon tube with rinsing as before. Tubes were centrifuged at 300 x g for 5 min at 4oC 
and the pellet re-suspended in 10 ml FCS buffer.  
10 µl of cell suspension was removed from each tube, treated with 2% acetic acid in 
PBS to lyse RBC and Trypan Blue to identify dead cells. Leukocytes were then counted 
in triplicate using a haemocytometer. For bone marrow transplant, 10 x 106 cells per 
recipient mouse are needed and the yield of bone marrow cells from mouse hind leg 
bones is approximately 125-150 x 106 cells per mouse. Once the count was 
determined, the volume of cell suspension needed to provide enough cells for each 
inoculation was calculated and master mixes made up in 15 ml Falcon tubes. Tubes 
were centrifuged at 300 x g for 5 min at 4oC and the each pellet was re-suspended in 
HBSS in a 1.5 ml Eppendorf tube at a volume of 200 µl per mouse for tail vein injection. 
Tubes were stored on ice until needed. 
 
6.2.2.2 Irradiation of recipient mice 
Mice were weighed to provide a baseline weight for monitoring before irradiation. 
Nineteen 10 week old male mice received a myeloablative radiation using a 
Gammacell® 40 Exactor Low Dose-Rate Research Irradiator (MDS Nordion Inc.,Ontario, 
Canada).  One dose with a 750 rad exposure (at a dose rate of 110 rad per minute) was 
administered. Mice were then returned to their home cage and provided water 
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containing the antibiotic Amphoprim (Virbac, New Zealand) at a dose of 1ml per 50 ml 
water bottle. Antibiotic water was provided for 14 days post-irradiation and changed 
weekly. 
 
6.2.2.3 Inoculation of recipient mice 
For the secondary chimera studies, a competitive strategy of bone marrow cell 
transplant was used with primary chimera bone marrow cells (carrying the CD45.2 
allele) as the donor cells and non-chimeric bone marrow cells from PTPRCA mice 
(carrying the CD45.1 allele) used as the competitor cells (Figure 6.7). 
The ratio of donor to competitor cells was 2:3 respectively for this study, with cell 
numbers of 6.7 x 106 donor cells combined with 10 x 106 competitor cells per 
inoculation. For bone marrow cells, a minimum of 10 x 106 cells are suggested for 
transplant and, therefore, an excess of cells was injected into each mouse increasing 
the chance of successful reconstitution of the immune system of recipient mice.  
     Chapter 6: The role of DPP9 enzymatic activity in immune regeneration and function 
178 
 
 
Four master mix tubes of donor plus competitor cells were used to inoculate the 
irradiated mice. Two tubes contained DPP9S729A/S729A –origin primary chimera BM cells 
sourced from two different mice and two contained DPP9wt/wt-origin BM cells, also 
sourced from two different mice (as per Section 6.2.2.1). Each tube was used to inject 
five mice. Individual mice were injected with a 200 µl volume of bone marrow cells in 
HBSS as detailed in Section 6.2.1.3 by Dr Adam Cook and checked for adverse reactions 
as previously. Mice were monitored as described in Section 6.2.1.5. 
 
6.2.3 Flow cytometry of peripheral blood from primary and secondary chimeras 
At 6 weeks and 16 weeks post-irradiation, flow cytometry analysis of peripheral blood 
of both primary and secondary chimeric mice was carried out to assess the level of 
reconstitution of the immune system of irradiated mice and to obtain information on 
the development of the different hematopoietic lineages. 
Figure 6.7: An example of a competitive strategy for transplanting adult bone marrow  
cells from DPP9wt/wt (+/+) and DPP9S729A/S729A (-/-) (CD45.2) donors with PTPRCA (CD45.1) 
competitors 
Bone marrow cells can be transplanted into a lethally irradiated PTPRCA (CD45.1) 
recipient and analysed for donor reconstitution 1-4 months post-transplantation. 
Different combinations of donor and competitor cells can be mixed to test the function 
of CD45.2 HSC and progenitor cells. Modified from (Gudmundsson et al., 2012). 
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After warming for several minutes under a heat lamp, each mouse was placed in a 
mouse restrainer. 5-6 drops of blood was taken via the tail vein into an Eppendorf 
containing 50 µl 0.1M EDTA and the tubes were placed on ice. 1.2 ml ACK/RBC lysis 
solution was added and each tube vortexed vigorously for 5 s and left for 5 min for 
lysis to occur. After centrifuging at 1500 rpm at 40 C for 5 min, the pellet was re-
suspended in 1 ml ACK/RBC lysis solution for 5 min for further lysis as before. 
Centrifugation was repeated and the pellet re-suspended in 200 µl FACS wash.  
Further washing and staining of cells was carried out as described in Section 6.2.1.6 
and using a stain cocktail prepared according to Section 6.2.1.6.1. with fluorophore-
conjugated antibodies in Table 6.3. 
 
6.2.3.1 Immune stain for flow cytometry of peripheral blood  
For flow analysis of immune cells, a number of antibodies were used to broadly 
identify and compare different immune cell populations represented in a reconstituted 
immune system after irradiation (Table 6.2). 
 
6.2.3.2 Gating strategies for peripheral blood flow analysis 
For all flow cytometry analysis of peripheral blood from DPP9S729A/S729A –origin and 
DPP9wt/wt-origin chimeric mice for both the primary and secondary chimera 
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Table 6.2: Antibodies used in the primary and secondary chimera peripheral blood 
cell stain and their target cells. 
 
 
Antibody 
Synonym/ 
clone 
Target cell 
Dilution 
used 
Source: 
catalog # 
BUV395 
CD19 
1D3 B cells 1:200 
BD 
Biosciences 
#563557 
BV421 CD3e 145-2C11 T cells, NK cells 1:250 
BD 
Biosciences 
#562600 
V500 
CD45.2 
104 Leukocytes 1:250 
BD 
Biosciences 
#562129 
FITC CD11b M1/70 Myeloid cells 1:250 
BD 
Biosciences 
#557396 
PerCP-Cy5.5 
CD45.1 
A20 Leukocytes 1:250 
eBioscience 
#45-0453 
PE NK1.1 PK136 NK cells 1:250 
BD 
Biosciences 
#557391 
AF647 Ly6G 1A8 
Myeloid cells, 
peripheral 
neutrophils 
1:250 
Biolegend 
#127610 
APC.Cy7 
CD8a 
53-6.7 T cells 1:250 
BD 
Biosciences 
#557654 
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experiment, the gating strategy to identify different cell types was the same. All 
samples were initially gated to exclude residual RBC remaining after RBC lysis was 
undertaken (Figure 6.8 A). Doublet cells, which result from cells adhering to each other 
or two cells passing through the laser in very close proximity, were excluded to leave 
single cells (Figure 6.8 B). The addition of DAPI to each sample before flow analysis was 
undertaken to exclude dead cells (Figure 6.8 C). The staining regime used here for 
peripheral blood flow analysis relied on the inclusion of the fluorophore BUV395 which 
bleeds into the DAPI channel. Therefore, a gating comparison between BUV395 and 
DAPI was used to identify live cells. While the contribution of autofluorescence in 
blood leukocytes is low, gating in empty channels, where there is no contribution from 
fluorophores in the stain cocktail, was used to exclude autofluoresence signals (Figure 
6.8 D). Once preliminary gating steps A to D were completed, further analysis was 
undertaken to identify different cell populations.  
Leukocyte cell populations were identified by gating for CD45 with donor cells carrying 
the CD45.2 allele and recipient cells the CD45.1 allele (Figure 6.8 E). Using only the 
donor leukocytes, myeloid cells were identified by their CD11b expression and T cells 
were included in the analysis by gating for CD3e+ cells (Figure 6.9 A). Next, B cells 
which have a lymphoid lineage and are CD19+ were gated along with neutrophils which 
have a myeloid lineage and high levels of Ly6G expression (Figure 6.9 B). Finally, 
natural killer (NK) cells were identified by first gating for CD3e and CD19 subsets and 
choosing the double negative population as NK cells are both CD3e and CD19 negative 
(Figure 6.10). 
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Figure 6.9: FACS plots showing the gating strategy for immune cell identification of T 
cells and B cells along with neutrophils and other myeloid cells .  
Following on from Figure 6.8, panel E, CD45.2 positive donor cells were identified for 
further gating of immune cells. The markers CD3e and CD11b were used to identify the 
general myeloid cell population and T cells. The markers Ly6G and CD19 were used to 
identify B cells and neutrophils. These are representative plots from DPP9wt/wt-origin 
chimeric mouse peripheral blood harvested 6 weeks post irradiation. 
 
 
Figure 6.8: FACS plots showing the gating strategy for donor and recipient cell 
identification.  
Panel A shows exclusion of residual red blood cells remaining after RBC lysis; panels B 
show the isolation of single cells. Live/dead cell gating is shown in panel C through 
DAPI staining and panels D shows gating to exclude non-specific staining due to 
autofluorescence. In panel E, CD45.2 positive donor cells are identified for further 
gating of immune cells. These are representative plots from DPP9wt/wt-origin chimeric 
mouse peripheral blood harvested 6 weeks post irradiation. 
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6.2.3.3 Data analysis 
Flow cytometry data were analysed with FlowJo software and preliminary analysis 
carried out in Excel. Data were then graphed and analysed by unpaired t-test using 
GraphPad Prism and significance was assigned to P values less than 0.05. 
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Figure 6.10: FACS plots showing the gating strategy for immune cell identification 
of NK  cells .  
Following on from Figure 6.8, panel E, CD45.2 positive donor cells were identified for 
further gating of immune cells. The markers CD3e and CD19 were used gate for the 
CD3e-CD19- subset of cells which includes NK cells. The markers CD8a and NK1.1 
were used to isolate the NK cell population. These are representative plots from 
DPP9wt/wt-origin chimeric mouse peripheral blood harvested 6 weeks post irradiation. 
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6.2.4 Immune challenge flu study 
In order to understand whether the reconstituted immune system has any functional 
alteration, mice from both primary and secondary chimera experiments were 
subjected to an immune challenge by infection with influenza. All influenza 
experiments were undertaken in collaboration with the Immune Imaging Lab of 
Centenary Institute by Dr Sioh-Yang Tan and Dr Lois Cavanagh with the assistance of 
Ms Lisa Shaw.  
The first influenza experiment was carried out on primary chimera mice (14 male mice 
at 40 weeks of age) and the second on the secondary chimera mice (19 male mice at 
35 weeks of age). Both experiments followed a similar experimental plan (Figure 6.11). 
Mice were anaesthetised by intraperitoneal injection of ketamine/xylazine (80/10 
mg/kg) and inoculated intra-nasally with a sub-lethal dose of A/Puerto Rico/8/1934 
(H1N1) [PR8] influenza virus. The doses were 50 pfu and 25 pfu in 30µl of sterile saline 
for the first and second experiment respectively. The virus suspension was placed 
drop-wise onto the nares using a sterile pipette tip.  
Mice were then replaced in their home cages and kept warm by placing the cage on a 
heating pad. All mice were observed to ensure normal breathing patterns until they 
recovered from anaesthesia and resumed normal behavioural patterns. Infected mice 
were then weighed daily for 21 days commencing from day 2 after infection. 
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fetal liver or BM
chimeric mice
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Daily weight monitoring (day 2 to 21)
Intranasal infection
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DPP9-GKI WT
Figure 6.11: Experimental plan for the immune challenge of primary and 
secondary chimera mice   
Two immune challenge experiments were undertaken with mice from the 
primary and secondary chimera experiments. Primary chimeric mice were 
infected with 50 pfu of [PR8] influenza virus and secondary mice with 25 pfu of 
[PR8] influenza virus. Daily weight data was collected to monitor the effect of flu 
infection on DPP9S729A/S729A –origin and DPP9wt/wt-origin chimeras. 
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6.3 Results 
 
6.3.1 Fetal liver cell flow analysis 
As the survival of irradiated mice with ablated immune systems is usually dependent 
on the reconstitution of immune cells, it is an important consideration whether the 
initial cell inoculum is viable and contains the hematopoietic stem cells necessary for 
immune regeneration. The fetal liver cells harvested from DPP9S729A/S729A and DPP9wt/wt 
embryos at ED 13.5 – 14.5 were stained using markers for erythroid and myeloid 
lineage HSCs. At this developmental stage the majority of HSCs are of the erythroid 
lineage as indicated by TER-119 reactivity (Kina et al., 2000, Kim et al., 2006) and only a 
very small proportion show the CD11b positivity  of non-erythroid lineage cells 
(Babovic and Eaves, 2014). The predominance of TER-119 positive cells was confirmed 
in the flow analysis of DPP9 fetal liver cells and no statistical difference was noted 
between DPP9S729A/S729A and DPP9wt/wt cells for either cell lineage (Figure 6.12), thus 
suggesting that the inoculum used for creation of the primary chimeras was potentially 
equally viable for both DPP9S729A/S729A and DPP9wt/wt test groups. 
6.3.2 Primary chimera results 
As stated previously, the creation of chimeras enables detection of dysregulation of 
hematopoietic and/or immune function in irradiated mice by consideration of weight 
monitoring and body scoring. It also shows the short-term and long-term engraftment 
success of immune regeneration by the use of peripheral blood flow cytometry 
analysis.  
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Figure 6.12: Percentage of TER119+ and CD 11b+ fetal liver cells prepared for 
inoculation of irradiated mice 
DPP9S729A/S729A and DPP9wt/wt fetal liver cells were used to inoculate irradiated 
mice via tail vein injection in order to reconstitute the immune system after 
ablation. Flow cytometry analysis of the markers TER-119 and CD 11b were used 
to indicate fetal liver cells of the erythroid lineage and the myeloid lineage 
respectively. No statistically significant difference was observed between the 
percentages of DPP9-GKI and WT cells in the inoculum aliquots for either cell 
lineage. 
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6.3.2.1 Weight change data 
Mice were monitored as described in Section 6.2.1.5 daily for 2 weeks post-irradiation 
and then twice weekly for the remaining weeks for signs of failure of immune 
regeneration. This was achieved by body scoring and weight monitoring. An initial 
weight loss is a normal consequence of total body irradiation (Duran-Struuck and 
Dysko, 2009), however losses of 20% or greater are usually an indicator of graft failure. 
Both the group inoculated with DPP9S729A/S729A fetal liver cells and the group inoculated 
with and DPP9wt/wt FL cells followed a similar pattern of weight loss and gain (Figure 
6.13) and no significant difference was observed for either mean weight of each group 
(Figure 6.13A) or mean percentage weight change per group (Figure 6.13B) throughout 
the experimental period. This indicated that the fetal liver cell grafts were successful at 
establishing immune reconstitution and no apparent functional difference existed 
between the HSCs from either fetal liver DPP9 genotype. 
 
6.3.2.2 Immune regeneration of primary chimeric mice 
The use of congenic PTPCA mice as irradiated recipients for the graft of fetal liver cells 
enabled later identification of the proportion of donor cells which survived 
engraftment using flow cytometry of peripheral blood samples. For this experiment, a 
lethal myeloablative dose of irradiation was received by the recipient mice which 
results in the presence of very small numbers of residual recipient immune cells after 
immune regeneration. 
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6.3.2.2.1 Donor cell survival and degree of chimerism in primary chimeric mice 
The proportion of residual recipient (CD 45.1+) cells present at 6 weeks post-irradiation 
for this experiment was less than 7% of total peripheral blood leukocytes (Figure 6.14), 
which is consistent with previous studies by others for successful HSC grafts. This result 
suggests that the donor cells survived the engraftment procedure and that the 
inoculum had a sufficient donor graft to ensure hematopoietic cell reconstitution.  
At 16 weeks post-irradiation, the residual recipient cells had dropped to ~2% showing a 
strong long term engraftment by the donor (CD 45.2+) cells and confirming their initial  
viability. This result was the same for both DPP9S729A/S729A and DPP9wt/wt donor cells 
with no statistical difference seen between the two groups at either time-point. Thus, 
fetal liver cells carrying the DPP9-GKI mutant allele were not impaired in their ability to 
engraft. 
Figure 6.13: Weight monitoring post-irradiation of primary chimeric mice 
Irradiated mice inoculated with DPP9S729A/S729A and DPP9wt/wt fetal liver cells were 
monitored for weight loss as a gross indicator of dysfunctional or failed immune 
regeneration. Both GKI and WT cell-origin groups displayed an initial weight loss for 
several days before gradual weight increase back to the original start weight at around 
4 – 5 weeks post-irradiation. Graphs are represented as (A) the mean actual weights 
per mouse group and (B) the mean percentage weight change per group where 0 (red 
dotted line) represents the start weight just prior to irradiation. Each mean value 
consists of weights measurements of 7 mice for both groups. 
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Figure 6.14: Proportion of donor and residual recipient cells of primary chimeric 
mice 
Irradiated mice inoculated with DPP9S729A/S729A and DPP9wt/wt fetal liver cells were 
assessed for the percentage of donor cell-origin and residual recipient cell-origin 
leukocytes at six and 16 weeks after irradiation of the recipient mice. Both GKI and 
WT cell-origin groups displayed a small percentage of residual recipient cells at six 
weeks post-irradiation which decreased at 16 weeks post-irradiation. Graphs are 
represented as mean percentages where n = 9 at the 6 week time-point and n = 7 
at the 16 week time-point.  
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6.3.2.2.2 Identification of myeloid and lymphoid cell types in primary chimeric mice 
To determine the development and repopulation of the different hematopoietic 
lineages, peripheral blood was taken at two different time-points of 6 weeks and 16 
weeks as representative analysis of short term and long term immune regeneration 
respectively. Comparison of the major cell types of innate immunity including 
neutrophils and other myeloid cells of the myeloid lineage and B cells, T cells and NK 
cells of the lymphoid lineage, provide insight into the effectiveness of the chimera and 
identify any dysregulation of specific cell types and lineages. For this analysis, the 
assumption was made that the WT-origin chimeras have a normal reconstitution after 
irradiation and, thus, these data can be used as a benchmark to detect any differences 
in the GKI-origin chimeras. Comparisons can also be made with normal peripheral 
blood leukocyte data for C57BL/6 mice (Chen and Harrison, 2002). In this way, the 
impact of the absence of DPP9 enzymatic activity on the immune system can be 
gauged.  
Cells of the myeloid lineage include basophils, eosinophils, monocytes, macrophages   
and neutrophils. At 6 weeks post-transplant, the total myeloid cells present are 
elevated (Figure 6.15) consistent with an initial inflammatory response to irradiation 
(van der Meeren et al., 2001, Duran-Struuck and Dysko, 2009). Neutrophils normally 
represent the largest percentage of myeloid cells, making up at least 50 – 60 %. This is 
also the case for the primary chimera where the proportion of total myeloid cells 
which are neutrophils is in this range for both the 6 week and 16 week time-point 
(Figure 6.15). There was no significant difference observed between the GKI and WT  
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Figure 6.15: Percentage of myeloid cell types in peripheral blood of primary chimeric 
mice 
Mice from the primary chimera were assessed by flow cytometry of peripheral blood for 
the percentage of total myeloid and neutrophil leukocytes at six and 16 weeks after 
irradiation. There was no difference observed between GKI-origin groups compared to 
WT-origin groups. There were significant differences between the 6 and 16 week time-
points (green asterisks) for cell types from this lineage with a decrease in myeloid and 
neutrophils cells at the 16 week time-point. Graphs are represented as mean percentages 
where n = 9 at the 6 week time-point and n = 7 at the 16 week time-point. Error bars 
denote SD and significance was assigned where p < 0.05 (*), p < 0.01 (**), p < 0.001 (***). 
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cell-origin groups in the peripheral blood analysis for either time-point for both total 
myeloid cells or neutrophils suggesting that carrying the mutant DPP9 allele does not 
affect hematopoietic regeneration in the primary chimeric mice. 
There is, however, a highly significant decrease in myeloid cells for both genotype-
origin groups between the six week and the 16 week time-points (Figure 6.15, green 
asterisks). As this decrease is similarly represented in the groups of both genotype-
origin cells, it is consistent with this being a normal change which occurs from short-
term to long-term regeneration after irradiation and donor engraftment. This finding is 
supported by studies undertaken by others where myeloid cells, especially neutrophils 
and macrophages, are found to dominate early after engraftment (Spangrude, 2001, 
Bowie et al., 2007). Also, after 5 to 6 weeks post-irradiation, a change in HSC 
programming results in a reduced myeloid cell output (Figure 6.2)(Bowie et al., 2007). 
By 16 weeks, myeloid cell levels are comparable to those found in normal mouse 
peripheral blood (Chen and Harrison, 2002). 
Lymphoid lineage cells are represented in this analysis by B, T and NK cells. After 
engraftment, these cells arise via a common lymphoid progenitor that can only give 
rise to B, T and NK cells while lacking myeloid differentiation capability (Kondo et al., 
1997). NK cells, which contribute to the early detection of virus-infected and cancer 
cells, are important for defense against pathogens and regain normal cell numbers and 
function within a month of transplantation (Awwad, 1990, Auletta et al., 2004, Sungur 
and Murphy, 2014). In the primary chimera, no significant difference was observed 
between the different genotype-origin groups or between different regeneration time-
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points (Figure 6.16), suggesting that, once re-established in the peripheral blood, NK 
cell numbers remain stable. 
B cells exist as two main populations of B lymphocytes known as B-1 and B-2 B cells 
and are part of the innate and adaptive immune systems respectively (Montecino-
Rodriguez and Dorshkind, 2012). These two populations display different functional 
roles and show variable levels of activity and regenerative capacity depending on the 
mouse developmental stage from which the cells are sourced (Ghosn et al., 2016). For 
the purpose of this study, total B cell populations were observed without individual 
identification of B cell subpopulations or subsets. As B cell reappearance after 
irradiation is an early event occurring in the first few days after engraftment, the 
percentage of B cells amongst the total lymphoid donor cells was expected to have 
reached a stable level by 6 weeks post irradiation. This was the case for peripheral 
blood of the primary chimeric mice, although there was a small but statistically 
significant reduction observed in the B cells present in the GKI-origin groups compared 
to WT-origin groups at the six week time-point (Figure 6.16). This may represent a 
small delay in the re-establishment of B cells in the GKI-origin chimeric mice or, as the 
deficit was only small, perhaps arise as a result of the range of variation in B cell 
numbers between mice in the flow cytometry analysis. By 16 weeks post-irradiation, 
however, the B cell numbers for both genotype-origin groups of mice are matched, 
with the GKI-origin B cell numbers recovering to the WT level (Figure 6.15) and 
consistent with normal peripheral blood B cell percentages (Chen and Harrison, 2002). 
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T cells, which augment the adaptive immune response, do not recover after irradiation 
and transplant by replication of the usual cellular developmental pathways. T cell 
subset ratios are skewed in the early period after engraftment (Auletta and Lazarus, 
2005). Residual T cells of host origin, which are the most resistant to irradiation, may 
be apparent within the first three weeks but donor-derived T cells take 4 to 5 weeks 
after transplant to appear (Spangrude, 2001). Since the primary chimeric mice received 
a lethal level of myelo-ablative radiation, residual host T cells would be expected to be 
at minimum levels and, hence, contribute very little to total T cell numbers. This is 
supported by the low percentages of donor T cells at the 6 week time-point (Figure 
6.16). While no significant differences are seen between WT-origin and GKI-origin 
groups, there is a significant increase in T cell numbers between the 6 week and 16 
week time-points consistent with the recovery of T cell numbers after initial depletion. 
As T cells comprise roughly 20% of blood leukocytes in normal peripheral blood (Chen 
and Harrison, 2002), it appears that full reconstitution of the T cell complement has 
not yet been attained at this time-point. 
Considering the overall peripheral blood leukocytes of both myeloid and lymphoid 
lineages (Figure 6.17), the trend in the primary chimeric mice from the 6 week to the 
16 week time-points seems to be from a lower to a higher lymphoid-biased output. 
This is consistent with a move from unlimited self-renewal ability of HSCs towards 
limited self-renewal ability as the regenerated immune system moves from short term 
to long term reconstitution (Kent et al., 2009). Also of note in Figure 6.17, the total 
percentage of donor blood leukocytes for all cell types sits at approximately 93%. The 
appearance of a shortfall below 100% is most likely due to the method of analysing the  
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Figure 6.16: Percentage of lymphoid cell types in peripheral blood of primary chimeric mice 
Mice from the primary chimera were assessed by flow cytometry of peripheral blood for the 
percentage of lymphoid lineage leukocytes at six and 16 weeks after irradiation. There was a 
significant decrease of B cells (red asterisk) at six weeks post-irradiation in GKI-origin groups 
compared to WT-origin groups. However, no difference was observed for any other cell type 
between genotype-origin groups. There were significant differences between the 6 and 16 
week time-points with an increase in B cells for the GKI-origin cells and T cells for both 
groups at the 16 week time-point (green asterisks). Graphs are represented as mean 
percentages where n = 9 at the 6 week time-point and n = 7 at the 16 week time-point. Error 
bars denote SD and significance was assigned where p < 0.05 (*), p < 0.01 (**), p < 0.001 
(***).  
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donor cells, in which only major myeloid and lymphoid cell markers were included. The 
placement of gates for analysis and the univariate analysis used in the FlowJo software 
may also have contributed to that shortfall. 
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Figure 6.17: Total donor peripheral blood leukocytes of primary chimeric mice 
This graph represents the cell type analysis of total peripheral blood leukocytes of 
donor-origin at six and 16 weeks after irradiation and fetal liver transplant. From six 
weeks to 16 weeks, both WT-origin and GKI-origin groups show an increased bias 
towards lymphoid lineage cells which is suggestive of increased limits in self-renewal 
capacity of HSCs as the new immune system establishes itself. 
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6.3.3 Secondary chimera results 
The secondary chimera experiment was carried out using bone marrow cells from 
primary chimeric mice as donor cells along with BM cells from congenic PTPRCA mice 
as competitor cells. These were transplanted into irradiated congenic PTPRCA mice. As 
the result of the secondary engraftment was unknown before commencement of the 
experiment, competitor cells were used in the transplant to ensure successful cellular 
engraftment, immune regeneration and survival of the recipient mice (Duran-Struuck 
and Dysko, 2009). While the primary chimera can provide information on the integrity 
of the progenitor pool and the functionality of HSC, serial transplantation into 
secondary recipients can help identify potential defects in HSC self-renewal capacity 
and their potential for expansion (Gudmundsson et al., 2012).  
 
 
6.3.3.1 Weight change data 
Mice were monitored throughout the period of the experiment as described for the 
primary chimera study. While both mouse groups receiving the DPP9S729A/S729A-origin 
and DPP9wt/wt-origin primary chimeric mouse BM cells showed a similar pattern of 
weight loss and gain throughout 13 weeks of weight monitoring (Figure 6.18A), there 
was a noticeable difference in start weight between the two groups with heavier 
recipient mice inoculated with GKI-origin BM cells. Unfortunately, these mice were 
used for the study in the cage groups provided by the supplier and this discrepancy 
was not detected until the study was underway.  
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Despite the difference in mean start weight, both the mouse groups receiving the 
DPP9S729A/S729A-origin and DPP9wt/wt-origin primary chimeric mouse BM cells showed no 
significant difference in mean percentage weight change for the study period (Figure 
6.18B). As with the primary chimera, this was indicative of a successful immune 
reconstitution in  
the secondary recipient mice. Return to start weight after initial weight loss was 
achieved in a much shorter time frame (around 2 weeks post irradiation) than for the 
primary chimeric mice (4 -5 weeks post irradiation). This is consistent with the sub-
lethal irradiation dose administered to the secondary mice whereas the primary mice 
received a higher lethal myelo-ablative treatment.  
Figure 6.18: Weight monitoring post-irradiation of secondary chimeric mice 
Irradiated mice inoculated with DPP9S729A/S729A or DPP9wt/wt bone marrow cells along 
with PTPRCA WT BM cells were monitored for weight loss as a gross indicator of 
dysfunctional or failed immune regeneration. Both GKI and WT cell-origin groups 
displayed an initial weight loss for several days before gradual weight increase back to 
the original start weight at around 2 weeks post-irradiation. Graphs are represented as 
(A) the mean actual weights per mouse group and (B) the mean percentage weight 
change per group where 0 (red dotted line) represents the start weight just prior to 
irradiation. Each mean value consists of weights measurements of 9 mice for the WT-
origin group and 10 mice for the GKI-origin group. 
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6.3.3.2 Immune regeneration of secondary chimeric mice 
Fetal liver cells have been shown to possess greater repopulation potential than adult 
bone marrow cells (Rebel et al., 1996, Harrison et al., 1997, Taylor et al., 2002). While 
the commitment of HSCs to either the myeloid or lymphoid lineages is stricter in bone 
marrow transplants, the general framework of regeneration with regard to the 
reappearance of cell types is conserved between fetal liver and adult bone marrow 
(Takeuchi and Miyajima, 2004, Duran-Struuck and Dysko, 2009). As previously 
mentioned, for this experiment, both sub-lethal irradiation and the addition of extra 
bone marrow cells from WT PTPRCA mice were used to ensure successful engraftment. 
 
6.3.3.2.1 Donor cell survival and degree of chimerism in secondary chimeric mice 
This study was carried out as a competitive strategy for transplanting adult donor bone 
marrow cells along with congenic mouse BM cells where the ratio of donor to 
competitor was 40: 60 respectively (Figure 6.7). As both the competitor cells in the 
original graft and the recipient mice carried the CD 45.1 allele, then it was not possible 
for this strategy to differentiate between residual recipient cells after irradiation and 
competitor cells. Donor cells, however, all carry the CD 45.2 allele and can be clearly 
differentiated from the competitor and residual recipient cells.  
At both 6 and 16 weeks post-irradiation, the ratio of donor cells to competitor cells for 
WT-origin groups is roughly 20:80 where the 80 % includes residual recipient cells that 
survived irradiation (Figure 6.19). This shows a dominance of competitor and residual 
recipient cells over donor cells, which may be due to increased numbers of residual 
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recipient cells remaining after sub-lethal irradiation. Such a process would result in 
only partial myelo-ablation of the recipient mice. Alternatively, that 20:80 ratio may 
suggest an enhanced regenerative ability in the competitor cells over the donor cells, 
which would result in their more effective engraftment. As both donor and competitor 
are of WT-origin, this alternative explanation is less likely to be the case. There are, 
however, studies which have shown that the CD 45.1 and CD 45.2 alleles demonstrate 
mild alloreactivity between them (Chen et al., 1998, Xu et al., 2004) and variations in 
the immune cell subpopulations (Basu et al., 2013) in bone marrow chimeras and this 
action may affect donor versus competitor cell ratios.  
Interestingly, for the GKI-origin groups for both time-points, the ratio of donor to 
competitor (+ residual recipient) cells more closely aligns to the original inoculum ratio 
(Figure 6.19). This provides evidence for the residual recipient cells contributing 
around 5% of the total peripheral blood leukocyte numbers which is well within the 
normal range for murine BM transplants. This also suggests that the GKI-origin donor 
cells are not impaired in their ability to engraft compared to the WT-origin donor cells 
and may even display and enhanced engraftment ability. 
For all cell-origin groups, the ratios between donor and competitor cells did not alter 
from 6 to 16 weeks post-irradiation. With the reduced repopulation potential of BM 
compared to fetal liver along with less enhancement of marrow chimerism in early 
transplantation after sub-lethal irradiation (Andrade et al., 2011), the donor cells may 
take longer to establish a dominant chimera than for the primary chimera. Or possibly, 
the ratios may remain at this level of mixed chimerism in the long term. As no later  
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Figure 6.19: Proportion of donor and residual recipient cells of secondary chimeric mice 
Irradiated mice were inoculated with DPP9S729A/S729A or DPP9wt/wt adult bone marrow cells 
along with PTPRCA adult BM cells in the ratio of 60 (donor):40 (competitor). They were 
assessed for the percentage of donor and competitor cell-origin leukocytes at six and 16 
weeks after irradiation of the recipient mice. The WT-origin group displayed a bias towards 
competitor cells over donor cells for both time-points whereas the GKI-origin group 
roughly maintained the original ratio of donor to competitor cells for both time-points. All 
groups displayed a shortfall below 100 % (red dotted line) which represented outlier 
competitor cells and residual recipient cells gated out during analysis. Graphs are 
represented as mean percentages where n = 9 for the WT-origin group and n = 10 for the 
GKI-origin group for both time-points.  
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time-points were taken, the answer to this question will need to be elucidated by 
future experiments. 
 
6.3.3.2.2 Identification of myeloid and lymphoid cell types in secondary chimeric 
mice 
The addition of competitor cells to the original BM cell inocula resulted in the creation 
of viable secondary chimeric mice but with a reduced donor cell level. Despite this, 
analysis of peripheral blood leukocytes of donor cell origin in these chimeric mice 
showed the presence of myeloid and lymphoid lineage cells consistent with successful 
engraftment.  
In a similar pattern to the primary chimera, myeloid cell percentages showed a 
significant reduction from 6 weeks to 16 weeks post-irradiation with no differences 
observed between WT-origin and GKI-origin groups for either individual time-point 
(Figure 6.20). The percentages at 6 weeks were lower in the secondary chimera 
compared to the primary which is consistent with a reduction in the inflammatory 
response that would have been caused by the sub-lethal irradiation dose applied to 
recipient mice in that instance. Although the myeloid cell percentages decreased for 
both genotype groups by 16 weeks, the change was less pronounced than in the 
primary chimera suggesting that resolution of the inflammation caused by irradiation 
was slower in the secondary chimera. 
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As with the primary chimera, around 60% of myeloid cells for both genotype groups 
were shown to be neutrophils at the 6 week time-point (Figure 6.20). At 16 weeks, 
however, the proportion of myeloid cells identified as neutrophils reduced to around 
50% for both genotype groups and this difference was significant for GKI-origin 
samples (green asterisks). This data is consistent with a reduction of the irradiation-
induced inflammatory response and suggests that the myeloid cell compartment may 
be normalising from a neutrophil-biased state to encompass other granulocyte cell 
types. 
The main lymphoid lineage cell subsets (Figure 6.21) were all present and showed very 
little variability across all genotype-origin groups and time-points. No statistically 
significant differences were seen. NK cells were present in the secondary chimera at 
similar levels to the primary chimera and did not change between 6 weeks and 16 
weeks. B cell percentages were also stable between the two time-points with no 
differences existing for different genotype-origin groups. As with the primary chimera, 
the B cell percentages were consistent with those normally observed in peripheral 
blood (Chen and Harrison, 2002). 
T cells did not show any differences between WT-origin and GKI-origin groups which 
matched the primary chimera results. In contrast to the primary chimera, however, 
there was also no difference between the time-point data for the groups. All groups 
had mean percentages of approximately 11% with very little variation in standard 
deviation. As mentioned previously, T cells are the most resistant to radiation and a 
sub-lethal dose would leave many viable T cells to bolster the early time-point 
     Chapter 6: The role of DPP9 enzymatic activity in immune regeneration and function 
209 
 
 
Figure 6.20 Percentage of myeloid cell types in peripheral blood of secondary 
chimeric mice 
Mice from the secondary chimera were assessed by flow cytometry of peripheral 
blood for the percentage of total myeloid and neutrophil leukocytes at six and 16 
weeks after irradiation. There were no differences observed between GKI-origin 
groups compared to WT-origin groups. There were significant differences between 
the 6 and 16 week time-points (green asterisks) for myeloid cells and GKI-origin 
neutrophils. Graphs are represented as mean percentages where    n = 9 for the WT-
origin group and n = 10 for the GKI-origin group for both time-points. Error bars 
denote SD and significance was assigned where p < 0.05 (*), p < 0.01 (**), p < 0.001 
(***). 
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percentages. This could result in a reduced ratio of donor cell chimerism in the T cell 
compartment for the secondary chimera. However, this is unlikely since the overall 
levels are comparable for both chimeras and are close to the normal expected level of 
20% for peripheral blood. With its stable T cell numbers, the secondary chimeric mice 
should be able to generate an effective T cell response against pathogens and cancers. 
This could be investigated in future experiments. 
Unlike the primary chimera, the overall peripheral blood leukocytes of both myeloid 
and lymphoid lineages (Figure 6.22) showed little variation between the 6 and 16 week 
time-points with a strong bias towards the lymphoid lineages. This suggests a more 
limited self-renewal capacity of the HSCs and is consistent with the reduced flexibility 
of progenitor cell commitment in bone marrow transplants over fetal liver transplants. 
However, the pattern is the same for both WT-origin and GKI-origin groups which 
implies that this effect is not related to the absence of DPP9 enzymatic activity in the 
regenerating immune system. 
 
6.3.4 Immune challenge with Influenza 
DPP9-origin chimeric mice have not previously been subjected to an immune 
challenge. The aim of this challenge was to assess whether the reconstituted immune 
systems of the chimeric mice were capable of normal immune function. For these 
studies, it was decided to infect the mice from both the primary and secondary 
chimera experiments with influenza virus. [PR8], which was used for the immune 
challenge, represents the A/Puerto Rico/8/1934 (H1N1) strain, an influenza A virus of 
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Figure 6.21: Percentage of lymphoid cell types in peripheral blood of secondary chimeric 
mice 
Mice from the secondary chimera were assessed by flow cytometry of peripheral blood for 
the percentage of lymphoid lineage leukocytes at six and 16 weeks after irradiation. There 
were no significant differences observed for any cell type between genotype-origin groups 
at either time-point.  Graphs are represented as mean percentages where    n = 9 for the 
WT-origin group and   n = 10 for the GKI-origin group for both time-points. Error bars 
denote SD. 
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Figure 6.22: Total donor peripheral blood leukocytes of secondary chimeric mice 
This graph represents the cell type analysis of total peripheral blood leukocytes of 
donor-origin at six and 16 weeks after irradiation and adult bone marrow cell 
transplant. From six weeks to 16 weeks, both WT-origin and GKI-origin groups show 
very little change between lymphoid and myeloid lineage cell proportions. The cell 
percentages added up to slightly more than 100% (designated by the red line) for the 
16 week time-point as a result of the univariate analysis used by the FlowJo software 
to preserve the relative relationship between groups. 
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H1N1 subtype. While host resistance to influenza is a complex multigenic trait, 
C57BL/6 mice are susceptible to infection with this virus and the clinical signs, such as 
weight loss and lethargy, make tracking the progress of the disease possible (Bouvier 
and Lowen, 2010). 
At 30 weeks post-irradiation, the primary chimeric mice were inoculated intra-nasally 
with influenza virus and monitored for weight loss. By this time, the reconstitution of 
the mouse immune systems would be expected to be complete and peripheral blood 
donor cells should be long-term HSCs. The pattern of weight loss was identical for both 
genotype-origin groups with a maximum mean loss of approximately 25% of original 
body weight before signs of weight recovery around 13 days after infection (Figure 
6.23). This suggests that the regenerated immune system in each group was equally 
functional and able to cope with the immune challenge. 
The experiment was repeated with the secondary chimeric mice which were produced 
by irradiation of recipient mice and transplantation of adult bone marrow cells for 
immune regeneration. As the infection weight loss results for the primary chimeric 
mice were quite severe, it was decided to reduce the virus infection dose to 25 pfu to 
ensure mouse survival. 
Of note for this experiment is the mean start weight discrepancy between the two 
genotype-origin groups, with the GKI-origin group displaying a statistically significantly 
higher mean start weight than the WT-origin groups (as mentioned in Section 6.3.3.1). 
Despite this, there was no difference in the percentage weight change between the 
two groups for the first 5 days post-infection, with both groups showing a 5% loss 
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Figure 6.23: Weight monitoring of primary chimeric mice after influenza infection 
Mice from the primary chimera experiment were inoculated intra-nasally with 50 pfu 
of [PR8] influenza virus at 30 weeks after irradiation and fetal liver cell transplant. 
There were no significant differences for either mean weight change or percentage 
weight change between WT-origin or GKI-origin groups.  Graphs represent group 
means where n = 7 for the WT-origin group and n = 5 for the GKI-origin group. Error 
bars denote SEM. 
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 (Figure 6.24). The WT-origin group continued to lose weight until day 10 in a similar 
fashion to the primary chimeric mice. The weight loss for the WT-origin secondary 
chimeric mice was not as high (maximum loss around 20%) as for the primary chimeric 
mice and recovery began several days earlier. This is consistent with a lower starting 
dose of influenza in the secondary chimeric mice and, hence, a lower viral load.  
Interestingly, from day 6 onwards, there was a divergence of the two groups, with the 
GKI-origin mice maintaining a relatively steady weight for the duration of the 
experiment (Figure 6.24). Theoretically, the higher start weight of the GKI-origin group 
may have increased their resistance to the influenza infection. However, the identical 
percentage weight change of the two groups for the first five days of infection tends to 
suggest this is not the reason for the difference.  
Another possibility for consideration is an advantage in the GKI-origin secondary 
chimeric mice which increased their resistance to the immune challenge of influenza  
Figure 6.24: Weight monitoring of secondary chimeric mice after influenza infection 
Mice from the secondary chimera experiment were inoculated intra-nasally with 25 pfu of [PR8] 
influenza virus at 25 weeks after irradiation and adult bone marrow cell transplant. While there 
were no significant differences for percentage weight change between WT-origin or GKI-origin 
groups for the first 5 days post infection, the two groups differed from day 6 onwards. The GKI-
origin groups maintained a stable weight while the WT-group followed a more typical loss-and-
recovery pattern. Graphs represent group means where n = 9 for the WT-origin group and n = 9 
for the GKI-origin group. Error bars denote SEM. 
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infection. Future experiments will need to be undertaken to investigate whether this is 
the case. Either way, neither the primary nor the secondary chimeric mice of GKI-origin 
show any disadvantage in carrying the DPP9-GKI mutant allele and, thus, the absence 
of DPP9 enzymatic activity in immune cells does not impair immune function. 
 
6.4 Discussion 
 
The murine immune system is essential to protect the mouse from the many toxic and 
pathogenic elements to which it is exposed in the environment. To this end, normal 
function is required of both the perennially-present innate immune responses and the 
activated adaptive immune system. DPP9 has been shown to have roles in the mouse 
in both the innate and adaptive immune system (Lankas et al., 2005, Reinhold et al., 
2009, Tang et al., 2009, Yu et al., 2009, Geiss-Friedlander et al., 2009, Chowdhury et 
al., 2013). By creating chimeric mice using normal tissue and tissue lacking DPP9 
enzymatic activity from both fetal and adult mice, this chapter aims to explore the 
possible functions of DPP9 in mouse immune regeneration and hematopoiesis. 
The first consideration before undertaking this experiment was whether the fetal liver 
cells of DPP9-WT and DPP9-GKI genotype origin showed any differences which may 
affect the experimental outcome and result in incorrect conclusions being drawn 
regarding the negative or positive impact of DPP9 enzymatic activity. However, both 
cell inoculum groups showed the same proportions of erythroid and non-erythroid 
lineage HSCs. This provided a common starting point for creation of the chimeric mice 
and assessment and quantification of HSC numbers and functionality. 
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Weight tracking is an important monitoring tool to assess the impact of irradiation on 
the recipient mice and indicate potential graft failure after fetal liver or adult bone 
marrow transplant. The use of percentage weight change data normalises the weights 
from each group to overcome mouse-to-mouse variation and provide a common start 
point. The primary chimeric mice showed no differences in the weight loss-and-gain 
pattern after irradiation between the two genotype-origin groups. While there was a 
difference in the start weight of the two groups for the secondary chimera, the 
percentage weight change showed no difference between the groups in their recovery 
from irradiation over the period of the experiment. These data confirm the success of 
the grafts of both the fetal liver cell and adult bone marrow cell chimeras. 
Although there were no differences between WT-origin and GKI-origin groups in 
weight change data, the time taken to regain the initial lost body weight after 
irradiation was different between the primary and secondary chimeric mice. The 
primary chimeric mice took 5 weeks to reach the original start weight, while the 
secondary mice achieved the same in just over a week. This difference is most likely 
due to the dose of initial irradiation and the use of supplementary cells to boost 
immune regeneration. The primary chimeric mice were subjected to a lethal myelo-
ablative dose of irradiation and inoculated with only donor cells. As these were fetal 
liver cells, which possess an enhanced ability to initiate immune regeneration, the 
engraftment was successful but the time to reach the original start weight was 
delayed. For the secondary chimeric mice, however, irradiation was at a sub-lethal 
dose and the inoculum was supplemented with PTPRCA competitor cells which assured 
mouse survival and also greatly reduced the time taken to regain body weight to the 
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original start weight in both groups. Despite this disparity between the primary and 
secondary chimera in the time taken to attain original start weight, the overall pattern 
of weight gain throughout the experimental period was the same for all groups. 
Another indicator of successful engraftment in recipient mice is the percentage of 
chimerism in peripheral blood, in this study shown by the donor cells present 
identified with the CD 45.2 allelic marker and flow cytometric analysis. The degree of 
chimerism of the primary mice was very high at both the six and 16 week time-points 
with only small percentages of residual recipient cells present after irradiation. This 
was consistent with the lethal irradiation regime employed and suggested that, as well 
as the success of engraftment, there was no impairment in the DPP9-GKI HSCs ability 
to engraft. 
For the secondary chimeric mice, the percentage chimerism is harder to interpret. 
There is no difference between the early and late time points for each matching origin 
group but a noticeable difference between the WT-origin and GKI-origin 
competitor:donor ratios for each time-point. The WT-origin group has a higher 
proportion of competitor cells (which comprise residual recipient cells plus introduced 
competitor cells) over donor cells, when compared with the original inoculum. This 
predominance of competitor cells may arise from the contribution of increased levels 
of residual recipient cells surviving after sub-lethal irradiation or an enhanced 
regenerative ability of the competitor cells over the donor cells. A separate point to 
consider is that some studies have shown alloreactivity and variable cell 
subpopulations in bone marrow chimeras when using congenic CD 45.1 and CD 45.2 
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mice, and this may affect competitor:donor cell ratios (Chen et al., 1998, Xu et al., 
2004, Basu et al., 2013).  
However, the GKI-origin group shows a competitor:donor ratio for both time-points 
much more closely matched to the original inoculum ratio. As both the WT-origin and 
GKI-origin chimeric groups were inoculated with the same competitor cells, received 
the same irradiation dose and, therefore, most likely had the same proportion of 
residual recipient cells, it is more likely that the sole differing variable of cell-origin 
genotype is influencing this result. If so, then the GKI-origin donor cells may possess an 
enhanced engraftment ability in the secondary chimera. This would need to be shown 
by repeating the experiment. Now that successful engraftment and survival of the 
secondary chimeric mice has been shown, a future secondary chimera could be carried 
out with lethal irradiation and/or a non-competitive strategy using only donor cells for 
transplant, thereby removing the confounding effects of competitor and residual 
recipient cells. 
Having confirmed effective engraftment of donor cells by mouse husbandry methods 
and degree of donor chimerism, it is then necessary to determine the contribution of 
the different hematopoietic cell lineages to the development and repopulation of the 
reconstituting immune system. By six weeks post-irradiation, the peripheral blood cells 
that arise from the original donor cells can be the progeny of short-term HSCs or long-
lived progenitor cells (Duran-Struuck and Dysko, 2009, Mayle et al., 2013). Most HSCs 
that repopulate the ablated immune system are short-lived and the length of time 
they function has shown to be proportional to donor species lifespan (Morrison and 
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Weissman, 1994). By 16 weeks, however, all donor cells present are long-term HSCs 
capable of self-renewal and are the progeny of short-term HSCs. Hence, it is possible to 
determine if the self-renewal capacity of the donor HSCs is stable or transient and 
whether the transition from short term to long term immune regeneration has 
occurred. The cell types chosen as a broad indicator of lineage development were 
general myeloid cells and neutrophils as representative of the myeloid lineage and NK 
cells, B cells and T cells as representative of the lymphoid lineage. Analysis of these few 
cell types was sufficient to show hematopoietic and immune regeneration after 
irradiation. In-depth analysis of cell subpopulations would be necessary for complete 
analysis of immune regeneration but was beyond the scope of the present study. 
At 6 and 16 weeks post-irradiation, in both the primary and secondary chimeric mice, 
all myeloid and lymphoid cell types considered in this study were present for both 
genotype-origin groups. This confirms that the progenitor cell pool was intact and both 
the primary and secondary HSCs showed no defect in self-renewal or proliferation 
capability.  
No differences in myeloid lineage cells were seen between genotype-origin groups in 
either time-point or chimera. However, a significant reduction in myeloid cells was 
seen between the 6 and 16 week time-points for both genotype-origin groups in both 
chimeras. This result was supportive of the resolution of irradiation-induced 
inflammation at the later time-point. It was also consistent with reduced myeloid cell 
output as HSCs are reprogrammed after six weeks to an adult gene expression pattern 
(Bowie et al., 2007).  
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Neutrophils represented around 60% of the total myeloid cells in both the WT-origin 
and GKI-origin groups in the primary and secondary chimeric mice at the 6 week time-
point. While this proportion remained the same at the 16 week time-point for the 
primary chimeric and WT-origin secondary chimeric mice, the proportion of 
neutrophils decreased significantly in the secondary GKI-origin mice suggesting an 
increase in other granulocytes and, hence, normalisation of the myeloid cell 
compartment. Whether this is indicative of a hematopoietic reconstitution advantage 
is unclear and would require further investigation. 
The cells of lymphoid lineage targetted for analysis in this study were NK cells, B cells 
and T cells. NK cells are reported to regain normal cell numbers and function within a 
month of engraftment (Awwad, 1990, Auletta and Lazarus, 2005, Sungur and Murphy, 
2014) and both the primary and secondary chimeric mice for both genotype-origin 
groups and time-points showed stable NK cell numbers consistent with this 
observation. This early establishment of NK cells would be important for protection of 
mice against infection with pathogens. 
B cells were also present in comparable stable levels in both the primary and 
secondary chimeras with the only observed difference being at the 6 week time-point 
in the primary chimera. There was a significant reduction in the B cells numbers in the 
GKI-origin group compared to the WT-origin group, which normalised at 16 weeks. The 
reason for this difference is difficult to explain but, as it was only slight and not present 
at 16 weeks, it may have been due to mouse-to-mouse variations in analysis or a slight 
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delay in B cell re-establishment for this group. Repeating the primary chimera with a 
more detailed focus on B cell subsets may explain this in the future. 
T cell reconstitution was the same for all genotype-origin groups for each time-point in 
the primary and secondary chimeras. While the secondary chimera also showed no 
difference between time-points, the primary chimeric mice, for both WT-origin and 
GKI-origin groups, showed a highly significant increase in T cells at 16 weeks compared 
to six weeks. The low 6 week T cell levels is consistent with the lethally irradiated 
primary chimeric mice being more severely depleted of residual recipient T cells than 
the secondary chimeric mice. Although the numbers have greatly increased at 16 
weeks, they are still not at normal levels for mouse peripheral blood (Chen and 
Harrison, 2002), unlike the secondary chimeric mice that appear to have early full 
reconstitution of the T cell compartment. As was the case for the B cells, future 
investigation of T cell subsets during immune regeneration may shed light on the 
mechanisms in play. While this needs further investigation, the fact that it was 
consistent across both genotype-origin groups suggests that it is unrelated to the 
presence or absence of DPP9 activity. 
The overall proportion of myeloid to lymphoid lineage cells in donor-derived 
peripheral blood leukocytes can provide further information about the regenerated 
immune system of chimeric mice (Kent et al., 2009).  When the reconstituted immune 
system shifts from short term to long term regeneration, the self-renewal capacity of 
HSCs becomes more limited, as progenitor cells are produced with defined lineage 
potential. This is usually displayed by a trend towards a greater lymphoid-biased 
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output of peripheral blood leukocytes. This trend is evident in both the primary and 
secondary chimeric mice (Figure 6.17 and 6.22), where the change from the 6 to 16 
week time-point for all groups is an increased bias towards lymphoid cells over 
myeloid cells. 
The final assessment of immune regeneration and function in this study was the 
infection of primary and secondary chimeric mice with influenza virus to determine 
potential functional differences caused by the presence of DPP9-enzyme-activity-
deficient immune cells. The primary chimeric mice displayed identical weight loss and 
recovery patterns for both the WT-origin and the GKI-origin groups suggesting an 
equivalent level of functionality of the regenerated immune systems of both groups 
when presented with an immune challenge. As both the primary and secondary 
chimeras resulted in successful engraftment and regeneration of viable immune 
systems in the recipient mice, it was surprising to see a very notable difference in the 
body weight data for the GKI-origin secondary chimeric mice after immune challenge. 
Although the difference in starting body weight between the secondary chimera 
groups was significant, it did not appear to present the GKI-origin mice any advantage 
in the initial five days after infection. Both groups followed a similar weight loss 
pattern over this period but showed divergent path from day 6.  
With a reduced inoculation dose and lower viral load for the secondary chimeric mice, 
it would be expected that both groups would recover quickly. The WT-origin mice did 
show a lower percentage weight loss and an earlier upturn to weight gain than either 
of the primary chimeric groups. The secondary GKI-origin chimeric mice, however, 
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maintained a stable weight from day 6 onwards for the duration of the experiment. 
This data indicates that the secondary GKI-origin chimeric mice had an increased 
resistance to an immune challenge. Whether this was specific for influenza infection 
alone as the immune challenge or the result was influenced by the increased start 
weight of groups, and whether similar observations might be made in other infections, 
will need to be determined by future experiments.  
Considering the combined immune challenge results, nonetheless, it is apparent that 
there is no weakening of immune function shown by either the primary or secondary 
chimeric mice of GKI-origin over the WT-origin mice. In fact, the result of the 
secondary immune challenge experiment tends to suggest there may be an advantage 
in the absence of DPP9 enzymatic activity in immune cells, certainly in relation to 
immune function. 
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7 General Discussion 
 
7.1 Introduction 
This study aimed to increase our understanding of the role of DPP9 in biological 
systems. This goal was achieved through the use of a mouse model of targetted 
inactivation of DPP9 enzyme activity to generate physiologically relevant in vivo data. 
This study utilised a broad strategy of histological, immuno-histochemical and 
molecular biological techniques which resulted in novel findings in both neonatal and 
adult mice. The major findings of this study were: 
 
 the absence of DPP9 enzymatic activity in the mouse results in a lethal neonatal 
phenotype 
 the DPP9-GKI mouse displays evidence for dysregulation in autophagy, which 
may contribute to the lethal phenotype 
 adult heterozygous DPP9-GKI mice display reduced skin collagen levels 
compared to their WT littermates 
 DPP9-enzyme-activity-deficient secondary chimeric mice, in which the 
hematopoietic tissue and immunological system derive from a different mouse 
than other somatic cells, may have an enhanced ability to recover from an 
immune challenge with influenza virus. 
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7.2 DPP9 in the neonatal mouse 
 
7.2.1 Lethality in the neonatal mouse 
Much of the early work in this thesis revolved around determining that inactivation of 
DPP9 resulted in lethality in the mouse and confirming that death occurred in the early 
neonatal stage (Chapter 3). After confirming that DPP9 was indeed inactivated, the 
focus of this study then turned to elucidating the specific cause(s) of lethality. 
Recently, much information regarding the roles of DPP9 in vitro is emerging (Zhang et 
al., 2013, Waumans et al., 2015, Wilson et al., 2016, Okondo et al., 2016, Justa-Schuch 
et al., 2016). However, in vivo data, especially in neonatal mice, is extremely limited. 
The current study resulted in a broad investigation of potential lethal effects of DPP9 
enzyme inactivation starting with the most obvious causes such as defects in mouse 
gross morphological and/or histological development and aberrant structure and 
function or failure of organs. Also considered were behavioural differences in the 
DPP9-GKI neonates that may have caused exclusion of the pup from proper care and 
suckling by the mother. 
While the characterisation of adult mice was focussed on aspects of DPP9 biology that 
are not suspected to be involved in neonate lethality, it is possible that, by elucidating 
roles of DPP9 in the adult mouse, we can gain further clues into the cause of lethality 
at that particular developmental stage. For example, the finding that adult 
heterozygous DPP9-GKI mouse skin shows reduced levels of collagen may indicate 
reduced levels in the neonatal mouse. If true, this could have implications for organ 
function. It has been shown that cardiovascular abnormalities often lead to neonate-
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lethal phenotypes (Turgeon and Meloche, 2009) as dramatic changes occur in the 
circulatory system immediately after birth. Working with our collaborator, close 
inspection of the internal valve structure of the neonates showed a possible aortic 
valve defect in the DPP9-GKI neonatal mice (Chapter 4). Normal valve function could 
be affected by reduced collagen levels, if present. While the gross morphological and 
histological make-up of organs may appear normal, the strength, and hence 
functionality of organ structures, may be impaired. Collagenolytic activity is necessary 
for skeletal and extra-skeletal connective tissue modelling and reduced collagen 
turnover and/or low collagen levels in neonates has been shown to affect normal 
function and result in many defects including dwarfism, osteopenia, arthritis, heart 
valve dysfunction and connective tissue disease (Holmbeck et al., Joyce et al., 2009). 
Also, many disorders exist, in both humans and mice, that are related to collagen 
depletion in connective tissues (Royce and Steinmann, 2002, Turgeon and Meloche, 
2009).  Thus, it would be beneficial to measure collagen content in neonate organs and 
other adult organs besides skin in the future. While the impact of reduced collagen in 
skin may not be detrimental to long term survival, reduced collagen in other organs 
may have a greater impact, especially at the early neonate stage. 
The lack of a selective DPP9 inhibitor is an ongoing roadblock to understanding this 
protease. Inhibitors have been developed that are selective for DPP8 and DPP9 over 
DPP4 and FAP (Lankas et al., 2005, Wu et al., 2009, Jiaang et al., 2005, Van der Veken 
et al., 2008, Van Goethem et al., 2011) but none are selective for DPP9 alone. If an 
effective DPP9-specific inhibitor is found, then several future experiments could be 
undertaken that may contribute to our understanding of DPP9 function in vivo at the 
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neonatal stage. One such study could be to administer inhibitor from birth into WT 
neonatal mice to establish if the lethality experienced by the DPP9-GKI homozygous 
mice can be induced. Alternatively, DPP9 inhibitor could be administered at later pre-
weaning time-points to determine if the lack and/or reduced level of DPP9 enzymatic 
activity affects survival after the early neonatal starvation period once milk 
metabolism is established. This result, in conjunction with findings from our lab’s study 
into the influences of DPP9 expression on neonatal metabolic genes (Chen et al., 
2016), may enable better definition of the metabolic time-point when DPP9 enzymatic 
activity is critical for survival. 
 
7.2.2 Autophagy in the neonatal mouse 
Dysregulation in autophagy was shown in DPP9-GKI neonate mouse tissues (Chapter 4) 
with up-regulation in some organs and down-regulation in others relative to DPP9-WT 
tissues. Enzyme activity of DPP8/ 9 has been shown to be present in all organs that 
displayed autophagy dysregulation in the neonate mouse, that is, heart muscle, lung, 
gut,  brain and liver (Yu et al., 2009) and, like LC3, are found in both nucleus and 
cytoplasm. DPP9 nuclear localisation was evident, although unpublished at the time of 
this work, both in vivo in immune-histochemical DPP9 tissue staining (Figure 3.2 B) and 
in vitro in WT and DPP9-GKI MEFs (Figure 3.4 C and D). DPP9 is known to exist in two 
isoforms (Ajami et al., 2004), short and long, that are found predominantly in the 
cytoplasm and nucleus respectively, and it has been shown that the long isoform of 
DPP9 may be involved in the regulation of the activity or stability of nuclear 
transcription factors (Justa-Schuch et al., 2014). Many autophagy genes, including LC3, 
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are regulated at the transcriptional level with autophagy in the cytosol inducing their 
activation via nuclear-cytosolic shuttling (Fullgrabe et al., 2014). The occurrence, in 
normal tissue, of the autophagy marker LC3 in the same cellular locations as both 
DPP9 isoforms may be coincidental. It does, however, raise the question as to whether 
the absence of DPP9 activity in the DPP9-GKI mouse may directly influence autophagic 
processes. Further staining of neonate tissues using both DPP9 and autophagy protein 
antibodies concurrently with more advanced microscopy may show whether an exact 
co-localisation exists. 
The organs in which LC3B was most up-regulated without DPP9 activity were heart 
muscle, lung and gut. All of these organs are subject to enormous functional 
adjustments in the early neonate period and autophagic processes are maximised to 
provide resources for drastic metabolic changes (Mizushima et al., 2004, Turgeon and 
Meloche, 2009). The high levels of autophagy displayed by these organs in the DPP9-
GKI mouse may have been induced to overcome a shortfall in resources at this time-
point caused by an unidentified metabolic dysfunction. However, it is known that high 
levels of autophagy can lead to an overload of cellular components and an 
accumulation of debris that disrupts cellular function (Sivridis et al., 2010). Thus, rather 
than an attempt to alleviate the metabolic shortfall, the increased autophagy, in this 
case, may actually be exaggerating the problem. This could suggest that the presence 
of DPP9 may be a limiting factor in preventing excessive increases in autophagy. 
Similarly, brain and liver, which displayed down-regulation of autophagy in DPP9-GKI 
mice, may be unable to induce the necessary level of autophagy for normal 
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requirements due to the same dysfunction, depending on the metabolic pathways 
affected. Both brain and liver show high levels of DPP9 in early neonate mice (Gall et 
al., 2013) and autophagy is normally upregulated in these organs in order to maintain 
an adequate amino acid pool to be used as an energy source (Kuma et al., 2004).  
While the number of autophagosomes in neurons is not increased during the neonate 
starvation period (Mizushima et al., 2004), autophagy can be induced in cortical 
neurons, Purkinje cells (Alirezaei et al., 2010) and neurons of the hypothalamus 
(Kaushik et al.) in a fasting state. Due to technical limitations of our study, comparison 
of the level of autophagy between the DPP9-GKI and WT neonatal mouse brains was 
difficult to evaluate as only the diencephalon was consistently present across all 
samples. Future investigations to identify the exact regions of the brain and specific 
cell types that display up- and down-regulation of autophagy in the early neonatal 
stage need to be undertaken. 
Autophagy in the liver is known to aid in the prevention of hepatocellular 
degeneration, remove lipid droplets, suppress tumour formation and play a part in 
gluconeogenesis (Mizushima and Komatsu, 2011). In the neonatal mouse, where 
efficient function of the liver is extremely important, any down-regulation in 
autophagy may impair its ability to produce ketones. This could result in an indirect 
effect on the brain due to an autophagy dysregulation in liver. The link between liver 
and brain is still unclear, but it is known that autophagy-deficient mice show the 
formation of ubiquitin-inclusions in the liver and brain and the protein, 
p62/A170/SQSTM1 links autophagy with inclusion formation (Waguri and Komatsu). 
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Therefore, it is possible that the reduced LC3B staining in DPP9-GKI mouse liver and 
brain are linked by metabolic interactions between the two organs. A future study 
could be undertaken using conditional Atg-7 deficient mice to study autophagy in a 
tissue-specific manner in both liver and brain. The addition of immunohistochemical 
double-staining to show the presence of both autophagy proteins and DPP9 in those 
mice may provide further insights into the potential involvement of DPP9 in 
autophagic processes. 
Obvious dysregulation in autophagy, as displayed by up- and down-regulation in 
organs, provides clues about affected organ function. However, those tissues that 
displayed no apparent difference in the positivity of overall tissue immunoreactivity, 
but rather localisation variations of LC3B staining, can also hint to the influence of the 
absence of DPP9 enzyme activity on autophagy. Both the liver and adrenal gland DPP9-
GKI samples showed unusual immunoreactivity localisation compared to the WT tissue 
with little or no difference in overall tissue reactivity.  
In the adrenal gland, the presence of many secretory granules in the DPP9-GKI adrenal 
gland may be indicative of either increased production or dysfunctional release of 
catecholamines from the granules in these animals. Increased production of 
catecholamines could arise as a physiological stress response in the DPP9-GKI mice due 
to whatever event(s) are causing their impending death. Alternatively, reduced 
catecholamine release could contribute to lethality. It is known that, immediately after 
birth, catecholamine release sharply increases due to labour-induced hypoxia when 
the umbilical cord is severed. The increase in catecholamines decreases the insulin/ 
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glucagon ratio in the neonate, resulting in the induction of metabolic changes essential 
to survival during the early starvation period until milk metabolism can contribute to 
energy production (Medina et al., 1992).  
One major process that can be impaired by dysfunction of catecholamine release is 
long-chain fatty acid (LCFA) uptake. If there are insufficient LCFAs available for β-
oxidation and ketogenesis during the neonate starvation period, this will result in 
reduced energy supplies for all organs, especially the brain which uses ketones as the 
main energy source. In the mouse, the main ketogenic organ during this time is the 
liver (Medina et al., 1992). Our group has recently reported mRNA expression data 
from DPP9-GKI mouse liver that points to disrupted LCFA uptake in the neonates and a 
lowered ketogenesis (Chen et al., 2016). As with the suggestion of reduced autophagy 
in the DPP9-GKI mouse brain due to ketone deficiency discussed above, this data 
supports a metabolic link between the liver and the brain. 
Perhaps the increased autophagy seen in the heart muscle, lung and gut and the 
decreased autophagy in the brain and liver in the DPP9-GKI neonates is an attempt to 
overcome catecholamine dysregulation during this critical phase. Future investigation 
of catecholamine levels in neonate organs and whether DPP9 co-localises and/or 
interacts with known autophagy proteins may answer this question.   
While the early neonatal time-point has been proven to result in a lethal phenotype 
for the DPP9-enzyme-activity-deficient mice, once the cause of death is discovered it 
may be possible to bypass this lethality. As most heterozygous mice survive to weaning 
and beyond, this suggests that it is possible to survive with a lowered level of DPP9 
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enzymatic activity. However, if survival was achieved at this time-point with a 
complete deficiency of DPP9 activity, later developmental or metabolic time-points 
may exist where lethality is again the outcome. To date, no single factor has shown 
potential for causing the death of the early neonates. It is most likely that the cause of 
lethality is interplay between several different physiological and/or metabolic effects, 
including those that we have identified. 
 
 
7.3 DPP9 in the adult mouse 
 
The adult heterozygous DPP9-GKI mice appear to show no signs of disadvantage in 
daily life or overall survival compared to their WT littermates. However, there is a 
significant effect on survival to weaning in immature heterozygous mice (Gall et al., 
2013). Perhaps DPP9 enzymatic activity is not completely redundant after weaning in 
the adult mouse. The study of adult DPP9-GKI heterozygous mice was therefore driven 
by what differences may exist in mice with depleted DPP9 enzyme levels as compared 
to WT mice with full DPP9 enzymatic function. The lack of availability of a DPP9-
selective inhibitor meant that DPP9 enzyme activity levels in heterozygous mice could 
not be measured, so whether the heterozygous mouse tissues contain 50% of the 
levels of DPP9 of WT mice is not known. Hence, the production of DPP9-GKI chimeric 
mice had an important role in overcoming this limitation. 
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7.3.1 Collagen in the adult mouse 
The adult DPP9-GKI mice display no overt structural or functional skin defects. DPP9 is 
detectable in abundance in embryonic and neonate WT mouse skin, but in lower levels 
in adult skin (Yu et al., 2009). The inhibition of DPP9 in epithelial cell lines in vitro 
decreases cell mobility and adhesion (Zhang et al., 2015a), which suggests a potential 
skin repair role, however wound healing after full thickness wounding was not 
impaired (Chapter 5). This is contrary to other DPP4 protein family members that have 
known roles in granulation tissue formation and wound healing (Garin-Chesa et al., 
1990, Kohl et al., 1991, Thielitz et al., 2008, Schürmann et al., 2012, Sinagra et al., 
2015).  
The proper function and integrity of skin plays in integral role in providing a protective 
barrier against physical and biological onslaughts, such as wounds, dehydration, 
thermal regulation and immunological assaults. Mouse epidermis, while consisting 
mainly of keratinocytes, also has densely packed hair follicles. Stem cells reside in the 
follicular bulge and dermal papilla. These stem cells restore epidermal integrity after 
wounding (Kimlin and Virador, 2013). The underlying dermis is rich in extracellular 
matrix and contains fibroblasts and many populations of myeloid and lymphoid 
immune cells (Pasparakis et al., 2014). The fibrous components of the dermis include 
collagen and elastin fibres.  
The finding that DPP9-GKI heterozygous mouse skin in the steady state has reduced 
collagen content as compared to the skin of WT littermates is novel. While it appears 
to have no survival impact on the mice, it does raise questions as to the potential 
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interaction between DPP9 and collagen deposition and maintenance. It has previously 
been shown that DPP9 influences cell behaviour, including cell–extracellular matrix 
interactions (Yu et al., 2006a) in vitro and other DPPs are known to interact with 
collagen (Waumans et al., 2015). However, no known data exists showing a link 
between collagen deposition and DPP9 enzymatic activity in vivo. While an in vitro 
study of keloid-derived skin fibroblasts showed that inhibition of DPP8/9 could 
suppress secretion of procollagen type 1 (Thielitz et al., 2008), there is no known direct 
link between collagen and DPP9 in vitro. 
Whether reduced collagen levels occur in both neonatal and adult DPP9-enzyme-
activity-deficient mice needs to be established as there is insufficient data at this point 
to use the adult skin finding to extrapolate conclusions in the neonate mouse skin 
without further experimental work. The lower collagen levels may arise in early 
developmental stages or arise subsequently after a prolonged period of depleted DPP9 
enzymatic activity in the DPP9-GKI heterozygous mice that has affected new collagen 
deposition. It would also be of interest to determine whether the collagen fibrils in 
DPP9-GKI tissues are ordered or disordered. Disordered collagen fibrils confer less 
strength on the host tissue, since the mechanical behaviour of the connective tissue of 
skin is primarily determined by collagen organisation and composition (Xu et al., 2008, 
Bancelin et al., 2015, Smithers et al., 2016). 
Once again, the availability of a DPP9-specific inhibitor could be useful for testing these 
theories. By administering an inhibitor long-term, it may be possible to show a gradual 
decline in collagen. Nevertheless, further studies are required to elucidate the timing 
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of collagen decline and whether fibril disorganisation exists, to attempt to determine 
the mechanistic link between DPP9 enzymatic activity and collagen in the skin.  
 
7.3.2 Immune regeneration and immunity in the adult mouse 
The in vivo expression of DPP9 in immunological tissues and cells is well documented, 
however the role of DPP9 in immune regeneration and immune cell repopulation has 
not been investigated. Protection from exposure to environmental toxins and 
pathogens is essential for mouse survival and involves a functional innate and adaptive 
immune system. The findings in this thesis in respect to donor engraftment and 
subsequent immune responses in chimeric mice created using DPP9 enzyme activity 
deficient stem cells (Chapter 6) are novel and have broadened knowledge of DPP9 
enzymatic activity in immune function.  
Recently, interest in DPP9 as a potential therapeutic target has increased due to the 
implications of a possible role in tumour growth and metastasis (Zhang et al., 2013). 
DPP9 is abundant in human tumour cell lines and may play a part in tumour growth 
(Spagnuolo et al., 2013). For future targetting of DPP9, it is important to expand in vivo 
data regarding immunity in order to assess and avoid possible off-target effects of 
therapy. 
This study has shown that the lack of DPP9 enzymatic activity in HSCs does not impair 
either their ability to engraft in irradiated mice or to repopulate all major immune cell 
types in the regenerated immune system in both a primary and secondary chimera. 
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These novel findings have confirmed that DPP9 enzyme activity is not necessary for 
stable HSC self-renewal and proliferation. 
These findings may suggest that DPP9 plays no role in immune regeneration at all but 
the subsequent challenge of the regenerated immune systems by influenza infection 
showed surprising and novel results implicating DPP9 enzyme activity in immune 
function. The rapid weight improvement of the DPP9-GKI-origin secondary chimeric 
mice compared to their WT-origin counterparts suggests an enhanced ability to 
recover from immune challenge when DPP9 enzymatic activity is absent. This is the 
first time that DPP9 has been examined in the context of infection with a virus or 
indeed any pathogenic organism. The result might be specific to influenza infection as 
opposed to other types of virus or immune challenge. This question needs to be 
addressed by a repeat of this experiment with influenza and then with other types of 
immune challenge.  
Another approach to testing the impact or absence of DPP9 on immune status or 
function could be via the use of transgenic mice. Deleting DPP9 enzymatic activity from 
the immune system in this study was achieved by subjecting mice to immuno-ablative 
irradiation and regenerating a DPP9-enzyme-activity-deficient immune system. This 
method, while commonly used, is technically challenging and involves long-term 
experiments. If a conditional DPP9 knockout became available it could be crossed with 
existing Cre-Vav1 mice to cause conditional hematopoietic cell depletion of DPP9. Or, 
the DPP9 conditional could be crossed with other immune depleted mice, such as RAG 
knockouts, to produce partial loss of DPP9 in the context of immune ablation. 
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Induction of DPP9 deficiency could perhaps be targetted to specific immune cells, 
allowing in-depth analysis of immune and/or hematopoietic cell lineages. Alternatively, 
induction of DPP9 deficiency could be targetted to connective tissue cells to examine 
the role of DPP9 in supportive stromal cells. Such approaches have important 
implications for the potential therapeutic targetting of DPP9. 
7.4 Concluding remarks 
 
Unravelling the in vivo activity of a protease is a complex undertaking as proteases 
usually act as part of an interaction between many other proteins and pathways 
(Eckhard et al., 2016). It was, therefore, of great interest and significance in this study 
to determine the novel finding that DPP9 enzymatic activity is necessary for neonatal 
survival. The absence of gross morphological or histological defects in the neonates or 
reduced survival ability in the DPP9-GKI heterozygous and DPP9-enzyme-activity-
deficient chimeric adults, suggests that the function of DPP9 enzymatic activity 
appears to be critical to a set time-point. The potential heart valve defects, observed 
dysregulation in autophagy and suggested disruption of normal catecholamine release 
and LCFA metabolism raised in this thesis hint at possible causes for lethality in the 
DPP9-GKI mice. These points, and the timing of death, allude to a metabolically crucial 
function of DPP9 enzymatic activity during the early neonatal starvation period. This 
critical function most likely influences more than one of the processes that are 
essential for the transition from maternal dependence of the neonate to independent 
metabolic autonomy. Future studies will be needed to elucidate the reason that the 
neonates die.  
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The characterisation of the adult DPP9-GKI heterozygous mice and creation of DPP9-
GKI chimeric mice also provided novel findings of reduced skin collagen levels and 
enhanced immune function respectively. Once past the critical neonatal period, the 
DPP9-GKI heterozygous mice are no longer subject to reduced survival ability. 
However, it is evident from these results that DPP9 continues to be important in the 
biological processes of the mouse in ways that cannot be overcome by protease 
redundancy. The presence of DPP9 in the nucleus and previous studies in our lab and 
by others, have shown a role for DPP9 in regulatory processes. If DPP9 does have a 
regulatory role, then DPP9 enzymatic function would impact on many biological 
processes within the mouse. This suggestion needs examination by future studies.  
By using in vivo techniques, this study has aimed at expanding the current published 
works of in vitro DPP9 function by providing physiologically relevant results. It has 
resulted in novel findings that have enhanced both the knowledge of DPP9 enzyme 
function and the overall biological roles of DPP9. 
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